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ABSTRACT 
       Immunotherapy has been revitalized with the advent of immune checkpoint blockade 
treatments, and neo-antigens are the targets of immune system in cancer patients who 
respond to the treatments. The cancer vaccine field is focused on using neo-antigens from 
unique point mutations of genomic sequence in the cancer patient for making 
personalized cancer vaccines. However, we choose a different path to find frameshift 
neo-antigens at the mRNA level and develop broadly effective cancer vaccines based on 
frameshift antigens. 
     In this dissertation, I have summarized and characterized all the potential frameshift 
antigens from microsatellite regions in human, dog and mouse. A list of frameshift 
antigens was validated by PCR in tumor samples and the mutation rate was calculated for 
one candidate – SEC62. I develop a method to screen the antibody response against 
frameshift antigens in human and dog cancer patients by using frameshift peptide arrays. 
Frameshift antigens selected by positive antibody response in cancer patients or by MHC 
predictions show protection in different mouse tumor models. A dog version of the 
cancer vaccine based on frameshift antigens was developed and tested in a small safety 
trial. The results demonstrate that the vaccine is safe and it can induce strong B and T cell 
immune responses. Further, I built the human exon junction frameshift database which 
includes all possible frameshift antigens from mis-splicing events in exon junctions, and I 
develop a method to find potential frameshift antigens from large cancer 
immunosignature dataset with these databases. In addition, I test the idea of ‘early cancer 
diagnosis, early treatment’ in a transgenic mouse cancer model. The results show that 
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early treatment gives significantly better protection than late treatment and the correct 
time point for treatment is crucial to give the best clinical benefit. A model for early 
treatment is developed with these results. 
       Frameshift neo-antigens from microsatellite regions and mis-splicing events are 
abundant at mRNA level and they are better antigens than neo-antigens from point 
mutations in the genomic sequences of cancer patients in terms of high immunogenicity, 
low probability to cause autoimmune diseases and low cost to develop a broadly effective 
vaccine. This dissertation demonstrates the feasibility of using frameshift antigens for 
cancer vaccine development. 
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CHAPTER 1  
Introduction 
1.1 Cancer Statistics 
Cancer has been a major public health concern around the world for decades and it is also 
the second leading cause of death in US after heart disease. It is predicted that in 2017 
there will be 1,688,780 new cancer cases and 600,920 cancer deaths in the United States. 
Even with the tremendous improvement of technology in cancer diagnosis and treatment, 
overall cancer incidence has increased from 1975 to 2013 while mortality rate has only 
dropped slightly in the same period. The probability of developing invasive cancer in 
men’s lifetime is 40.8%, for women the number is slightly lower: 37.5% [1].  These 
numbers indicate that cancer is not only affecting a group or a portion of the people, it 
has a great impact over every one of us. 
With billions of dollars invested in the cancer research and trillions of dollars paid by 
patients in cancer health care, cancer incidence or mortality rate has not been 
dramatically reduced. The reason behind this disappointing situation is probably due to 
the complexity of this disease, and it is also possible that cancer research has been led in 
a wrong direction.  
Cancer is a group of abnormal cells with uncontrolled growth and the potential to invade 
or spread to other parts of the body. Since cancer cells can originate from almost 
anywhere in the body, cancer is a collection of diseases. There are over 100 human 
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cancer types and it is believed that each cancer type has its unique origination and path to 
develop into a tumor. Even for the same cancer type, each patient has been shown to have 
unique mutations and may need to be treated uniquely (personal medicine). These 
complexities and difficulties make it so hard and so expensive to treat cancer effectively. 
However, there are still six major hallmarks of cancer which are shared across multiple 
kinds of cancer types and summarized by Hanahan and Weinberg: in order to have 
uncontrolled cancer cell growth, these cancer cells need the ability to sustain proliferative 
signaling, resist cell death signaling, evade growth suppressors and enable replicative 
immortality; to invade and spread to other locations of the body, they need to induce 
angiogenesis and activate metastasis signaling [2].  
For a long period, people attributed cancer to inherited genetic mutations or 
environmental factors like diet, obesity, tobacco or other carcinogens. But recently a 
group of scientists in John Hopkins University calculated the correlation between lifetime 
risk of cancers in 17 tissues worldwide and the lifetime number of stem cell divisions in 
those tissues, they found that these two numbers are well correlated (median CORR=0.8) 
and they concluded that random DNA replication errors are responsible for two-thirds of 
human cancer mutations. While environmental factors are still very crucial for a subset of 
cancers like esophagus cancer, lung cancer, stomach cancer and cervical cancer. 
Surprisingly, inherited genetic factors have minimal effects in cancer development of the 
human population [3]. This conclusion makes the cancer research situation even worse 
since random DNA replication errors are very difficult to predict and target. The 
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implication is we will need to design unique drugs/vaccines for each patient - known as 
precision medicine. 
Despite that we are facing so many difficulties with cancer disease, a lot of new 
treatments have emerged as people are learning from the battle against cancer. Within 
those cancer treatments, immunotherapy has been the most popular and successful in 
recent years.  
1.2 Current Cancer Immunotherapy and Limitations 
The immune system is our weapon to defend the body against all “foreign” invaders 
including foreign microbes and abnormal cells in our body. The idea of cancer 
immunotherapy is to utilize the immune system to treat cancer - it can be either activating 
or suppressing the immune system of cancer patients.  
The logic behind cancer immunotherapy is based on the “foreign” invader characteristics 
of cancer. Any protein which has not been exposed to the immune system can induce an 
immune response against that protein. Cancer cells need to go through several rounds of 
mutations to become invasive and the immunogenic mutated proteins related to tumor 
formation are tumor specific antigens, while at the same time, cancer cells are also 
producing many errors in proteins unrelated to cancer progression during uncontrolled 
growth.  These are passenger neo-antigens. And the third group of tumor antigens is 
tumor associated antigens which are over-expressed wildtype proteins. These “foreign” 
antigens can induce specific anti-tumor immune responses and these specific immune 
responses are the key for immunotherapy.  
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There are many types of cancer immunotherapy, and they can be classified into four 
categories based on the mechanisms of therapy: Cellular Immunotherapy; Antibody 
Therapy and Cytokine Therapy; Immunotherapy targeting innate immune responses; 
Cancer Vaccines. Within these four categories, most immunotherapy treatments are 
specific treatments which target one specific type of cancer or even one cancer patient for 
a personalized cancer vaccine, while other immunotherapy methods are non-specific. 
These are used to boost the immune system generally and can be used broadly in 
different types of cancer.  
Dendritic cell therapy and Adoptive T-cell transfer therapy are the two most extensively 
studied cellular therapies. Sipuleucel-T (Provenge) is one kind of dendritic cell therapy, 
and it was approved by FDA for treating castrate-resistant prostate cancer in 2010.   The 
treatment method includes three steps: extraction of PBMC (primarily dendritic cells) 
from patient by leukaphoresis; incubation of dendritic cells with a prostate cancer specific 
antigen PAP (antigen prostatic acid phosphatase) and immune stimulating factor GM-
CSF (granulocyte-macrophage colony stimulating factor); activated dendritic cells are 
then reinfused into the patient. This treatment has been shown to increase patient survival 
rate modestly on average but significantly for a minority [4]. Another limitation for this 
cell-based vaccine is the high cost.  The company Dendreon filed for bankruptcy in 2014 
due to lack of profit.   
Chimeric Antigen Receptor (CAR) T cell therapy is an adoptive T-cell transfer therapy 
using engineered T-cell receptors. CAR usually consists of three parts: an artificial 
antibody to bind a common cancer antigen on tumor cells; part of a receptor for 
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activating cells and multiple activation and co-stimulatory endo-domains to overcome 
immune tolerance and immune suppression in tumor microenvironment. Carl June’s 
group reported using CAR T cells expressing the anti-CD19 domain and a costimulatory 
domain from CD137 and the T cell receptor ζ domain to treat three advanced chronic 
lymphocytic leukemia (CLL) patients successfully.   Two of three patients had complete 
remission and on average one CAR T cell eradicated at least a thousand CLL cells [5]. 
However, CAR T therapy also has severe limitations.  The CAR-T design needs an 
antibody domain to bind common tumor antigens. Usually the common tumor antigen is 
a tumor associated antigen and it is widely expressed in normal tissues, so unexpected 
autoimmune disease is a danger in such treatments. For example, in a trial conducted by 
NCI researchers, nine cancer patients were treated using anti-MAGE-A3 CAR T cells. 
Two patients died from comas because another MAGE-A family protein with high 
similarity to MAGE-A3 has low expression in brain tissue as well [6].  
Antibody Therapy has been the most successful immunotherapy for last few decades and 
the FDA has approved over a hundred monoclonal antibodies for cancer therapeutic 
treatments [7]. The principle for antibody therapy is relatively simple.  Antibodies can be 
designed to target every hallmark of cancer like angiogenesis/tumor specific 
antigens/tumor associated antigens/immune suppression etc. Some of these antibodies are 
targeting tumor antigens for a specific type of cancer and thus can only be used for one 
cancer type or subtype. We can call them specific treatments. While other antibodies are 
targeting tumor angiogenesis or immune suppression and can be used widely in multiple 
cancer types.  These are non-specific treatments. As specific mAb treatment examples, 
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Herceptin and Perjeta are two monoclonal antibodies targeting HER2 product, which is a 
tumor associated antigen that is overexpressed in 20%-30% of breast cancer tumors [8]. 
These two antibodies are specifically designed for the treatment of HER2-positive breast 
cancer. CD20 is another good example of this category. CD20 is a B-cell antigen and it is 
a good target for treating B cell lymphomas and leukemia.  There are over one dozen 
mAbs targeting CD20 which have been approved by FDA (rituximab, obinutuzumab, 
tositumomab etc.) or are still under development in clinical trials. 
The beauty of non-specific treatments is that instead of searching for specific antigens in 
cancer patients, we can simply block the cancer progression or immune suppression 
pathways. One good example is Avastin, which targets the vascular endothelia growth 
factor A (VEGF-A).  VEGF-A is an important growth factor for blood vessels and thus a 
key element in tumor angiogenesis.  Avastin has been approved to treat multiple types of 
cancer including colorectal cancer, lung cancer, breast cancer, renal cancer and brain 
cancer. However, Avastin is not perfect as well and there are many limitations.   Many 
health services have restricted the using of Avastin due to the minimal benefit but large 
expenses for cancer patients [9].  
Blocking immune suppression is another non-specific method to treat cancer, and with 
this method, the most popular group of mAbs - immune checkpoint inhibitors, has been 
developed recently. Immune checkpoints are regulating molecules which can activate or 
suppress the immune system. Immunosuppression has been a key obstacle for successful 
immunotherapy in late stage cancer patients. 
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Based on the immunoediting theory [10], cancer cells can escape from the immune 
system after the elimination and equilibrium phase.  In the escape phase, cancer cells can 
get rid of highly immunogenic tumor antigens, down-regulate immune recognition 
molecules like MHC class I or co-stimulatory molecules, increase the expression of 
immunosuppression molecules like PD-L1 (Programmed death-ligand 1), galectins, IDO 
(Indoleamine-2,3-dioxygenase) etc. At the same time, MDSCs (myeloid-derived 
suppressor cell), M2 macrophages and DCs in tumor microenvironment can express 
immunosuppressive cytokines like IL-10 and TGF-β.   They can also induce the 
generation of regulatory T cells. T regulatory cells then express inhibitory receptors such 
as PD-1, CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4), Tim-3 and LAG3 to 
suppress anti-tumor response further [11]. Therefore, it is necessary to overcome the 
tumor immunosuppression for the anti-tumor T cells to kill the tumor. PD-1/PD-L1 and 
CTLA-4 are three hot candidates in this field.  Ipilimumab which targets CTLA-4 was 
approved by FDA in 2011 for late-stage melanoma treatment.  PD-1 inhibitor Nivolumab 
was approved in 2014 for treating melanoma, lung cancer, kidney cancer and Hodgkin’s 
lymphoma.  PD-L1 inhibitor Atezolizumab was granted accelerated approval for treating 
bladder cancer. Many other similar mAbs targeting PD-1/PD-L1 and CTLA-4 are still 
under development and some are recently approved (Durvalumab is approved on May 1 
2017 and Avelumab is approved on May 9 2017) [114,115], as well as other 
immunosuppressive targets [114].  
The immune checkpoint inhibitors are very promising drugs but still have at least two 
limitations: the objective response rate for these mAbs in different cancer types is not 
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high and the number usually varies from 10%~40% [12-14]; the cost is over $100K for 
one course of treatment. These two limitations may impede the use of ICI in developing 
countries.  
1.3 Personalized cancer vaccines and neo-antigens  
The latest immunotherapy method is cancer vaccine. Vaccines for infectious diseases 
have proved their great values and these vaccines have eliminated or controlled multiple 
infectious diseases. Nowadays vaccines are administered to children as standard care in 
most countries. The world would be much better if we could develop cancer vaccines as 
well using the same principles. However, the cancer vaccine field has faced many clinical 
failures during the last few decades. Big pharmaceutical companies and biotech 
companies used to focus on developing cancer vaccines with tumor associated antigens 
(TAAs) or tumor germline antigens.  These vaccines usually did not pass efficacy trials. 
Meanwhile, two preventative cancer vaccines which target HBV (Hepatitis B Virus) and 
HPV (Human papillomavirus) are approved for preventing virus induced cancers (Hep B) 
or STD (HPV). However, the HPV vaccine is expected to prevent cancers. And only 2 
therapeutic cancer vaccines are approved in people: Sipuleucel-T (dendritic cell based 
cellular vaccine) which was mentioned previously and one oncolytic virus (T-VEC) 
therapy for treating patients with metastatic melanoma which could not be surgically 
removed. The mechanism behind T-VEC is that this virus could only replicate in cancer 
cells but not in healthy cells due to disrupted stress response system in cancer [15]. There 
is one therapeutic vaccine (Oncept) approved for melanoma in dogs [116]. 
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There are two reasons for the disappointing cancer vaccine trials: overwhelming 
immunosuppression in tumor microenvironment needs to be overcome; tumor associated 
antigens are bad antigens as they are not very immunogenic and can cause self-tolerance. 
It was also suggested that late stage cancer is too difficult to overcome. 
However, with the combination of immune checkpoint inhibitors and next generation 
sequencing technology, this area has attracted huge interests again. The tumor 
immunosuppression can be overcome by using checkpoint inhibitors as adjuvants, and 
the trials of using tumor associated antigens (MUC1, HER2) in combination with 
immune checkpoint inhibitors are being tested again. 
Meanwhile, analysis of the results from the immune checkpoint inhibitor trials pointed to 
neo-antigens as the key element for effective ICI response. One report demonstrated that 
in melanoma patients with anti-CTLA-4 antibody therapy, long-term clinical benefit was 
associated with mutational load and specific neoepitopes were associated with long-term 
benefit [16].  In another case report of a 56-year-old male with melanoma who had been 
treated anti-CTLA4 antibodies, specific T cells targeting two neo-antigens with point 
mutations were detected [17]. A recent report further showed that immunogenic neo-
antigens were better biomarkers for predicting patients with objective response in ICI 
trials [18]. All this evidence supports that neo-antigens are better choices for cancer 
vaccine development over TAAs. But one important disadvantage for this approach is 
that there are no common neo-antigens between cancer patients from the exome 
sequencing results [19]. To design cancer vaccines for patients, the individual cancer 
patient must be sequenced to identify specific genomic mutations that might be 
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immunogenic.  It has been estimated that only a few percent of these mutations will be 
immunogenic [116].  
In summary, the development of personalized cancer vaccine includes 7 steps: isolate 
DNA/RNA from tumor tissue; Construct DNA and cDNA libraries; whole exome 
sequencing and RNA sequencing; identify mutations in sequence results; select best 
epitopes by MHC prediction or other algorithms; formulate vaccines using peptides, 
DNA vectors or other delivery methods; add adjuvants like immune checkpoint inhibitors 
or other immune adjuvants [20].   
Even with the complexity of the personalized vaccine approach, big pharmaceutical and 
biotech companies are strongly interested in this area. Advaxis, Moderna, Merck, Amgen, 
Gritstone Oncology etc. decided to invest hundreds of millions of dollars into this 
concept. Even with the same idea, each company provides their own platform to 
construct or deliver the vaccine to boost the immune response. Here I have summarized 
different techniques and potential advantages or disadvantages for each strategy in Table 
1-1. In summary, there are five available strategies now: traditional peptide vaccine; 
mRNA vaccine in nanoparticles; oncolytic virus vaccine; DNA vaccine; bacteria based 
vaccine like listeria vaccine [21-24].  
Preliminary results for two personalized cancer vaccines have been reported so far and 
both vaccines were tested in melanoma patients. One group immunized 6 late stage 
melanoma patients with 13-20 long overlapping peptides (15-30 aa) from mutated 
sequences.  All 6 patients showed positive T cell immune responses against vaccines and 
4 patients had no recurrence within 25 months after vaccination.  2 patients with 
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recurrence were treated with ICI and the tumor regressed afterwards [25]. The second 
group used RNA vaccination instead of peptides with the same concept.  Patients had 
positive T cell immune responses against vaccination and they experienced significantly 
less recurrence after vaccination. One patient was not responsive to vaccination due to 
lack of β2-microglobulin in the cancer cells [26]. Both personalized cancer vaccines 
showed a cautious promising preliminary result with neo-antigens. 
Table 1-1 Personalized Cancer Vaccine Strategies 
 
Company Name Technology Advantage and Disadvantages Reference
Advaxis
ADXS-NEO based 
technology: use attenuated 
Listeria monocytogenes 
transformed with specific 
plasmids encapsulating many 
patient's immunogenic 
neoepitopes
Can induce T-cell responses 
against weak antigens; can cover 
hundreds of neo epitopes; 
potential antigen competetion 
problem
[21]
Caperna/Modern
a
mRNA personalized cancer 
vaccine with Merck's anti-
PD-1 mAb Keytruda
mRNA vaccine is believed to 
work effectively at very low dose 
and induce immune response very 
fast; mRNA vaccine cost is high 
and not stable
[22]
Inovio and 
AstraZeneca
SynCon DNA vaccine with 
IL-12 encoded and 
checkpoint inhibitors, 
electroporation delivery
DNA vaccine manufacture cost is 
low and vaccine is stable, can 
induce strong T cell response
[23]
PsiOxus and 
BMS
Oncolytic virus vaccine 
Enadenotucirev with anti-
PD1 mAb Nivolumab
One oncolytic virus therapy T-
VEC has been approved in 2015, 
can induce strong immune 
response 
[24]
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Personalized cancer vaccines are very promising, but they also have limitations. Since the 
vaccine market is aimed, at least initially, at late stage cancer patients, the timescale of 
making such a vaccine is crucial. Currently, companies need 6-12 weeks to generate the 
vaccine (15-18 weeks from resection to vaccine delivery in two previous reports) and 
they are aiming at the reducing the manufacture time to 1 month.  But some argue that 
even 6 weeks is optimistic [27]. Meanwhile, this approach relies on the immunogenic 
genomic point mutations.  Peptides from point mutations are not very immunogenic due 
to being single amino acid changes and strict antigen selection algorithms need to be 
applied. Current MHC prediction methods are not accurate and this makes the antigen 
selection step very difficult. Meanwhile, the tumor needs to have enough mutations for 
selecting immunogenic neo-antigens.  It is estimated that only ~13% of point mutations 
would bind MHC I and far less could be validated by mass spectrometry [28].  Melanoma 
or lung cancer patients have thousands of point mutations in their tumors, but patients 
with pancreatic cancer or neuroblastoma may not have enough mutations for making such 
a vaccine. The last disadvantage of personalized cancer vaccine is still the cost-benefit 
problem.  The immune checkpoint inhibitor treatment alone can cost over $100K for a 
course of treatment. When combined with genomic sequencing and vaccine design, the 
price will be even more (most estimates are ~$50K). This would mean that this approach 
would not be widely available to those with cancer.  
It is widely agreed that the combination of neo-antigen cancer vaccines with checkpoint 
inhibitors is the best strategy to treat cancer. But instead of making the complexed 
personalized cancer vaccine, to develop a cancer vaccine with low cost and high 
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efficiency is more promising and urgent for the public. The key element in making such a 
cancer vaccine is to find common, tumor specific, neo-antigen and we need to find a new 
path for searching for specific for neo-antigens.   To date, all the research effort has been 
focused on finding neo-antigens produced by genomic mutations. It is known that in 
every step of the biological process from DNA replication to gene transcription to mRNA 
splicing to protein synthesis to protein assembly, cells are making a lot of random errors. 
The natural error rate of these biological processes is astounding, so the cells have 
evolved numerous quality control system at every biological process: proofreading of 
exonuclease, DNA repair system, nonsense mediated decay at mRNA, proteasome to 
remove aberrant proteins and beyond all these correcting mechanisms, cells have 
apoptosis signaling pathway to kill themselves in an emergent situation. Even with so 
many correction mechanisms to reduce the errors, random errors are still inevitable.  The 
random errors in DNA replication have already been shown to be the most important 
factor in tumor formation [3]. And at each step of information transfer far more new 
errors are introduced into the system due to the errors of enzymes or radiation, free 
radicals or other unknown reasons, the error rate increases exponentially from the initial 
step to the final step. Based on this theory, it will be much easier to find tumor neo-
antigens in mRNAs or in proteins, which are downstream of the DNA replication, yet 
very little effort has been put into these two categories. While the search of neo-antigens 
in proteins was difficult before, it will be a very promising direction for finding neo-
antigens as the MALDI technology improves. mRNA is relatively easier and more 
straightforward to analyze. My thesis is focused on uncovering one type of tumor neo-
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antigens in mRNA: the frameshift mutations in coding mono-repeat microsatellite regions 
and mis-splicing events.  
 
1.4 Coding Mono-repeat Microsatellite Regions and Microsatellite Instability in 
Cancers 
Microsatellite DNA is a large family of repetitive DNA sequences consisting of DNA 
motifs with 1-5 base pairs. It is also known as simple sequence repeats (SSRs). 
Microsatellites are primarily used as a genetic marker for kinship analysis and genetic 
relatedness between subspecies [29]. Microsatellite instability (MSI) has also been found 
to play an important role in neurological diseases [118] and cancer.  
Microsatellite mutations are different compared to point mutations used in personalized 
cancer vaccines.   Point mutations (PMs) change only one nucleotide, missense PM 
changes one amino acid and neutral PM do not change the amino acid sequence, while 
microsatellite mutations result in the gain or loss of repeat units. If the repeat unit consists 
of 3 nucleotides, the mutations will cause amplification or contraction of certain amino 
acids, but when the repeat unit is 1/2/4/5 nucleotides, the mutations can cause frameshift 
mutations.  Translation will be shifted in frame to produce frameshift peptides. The 
mutation mechanisms can also be totally different from point mutations.  Replication 
slippage of the DNA polymerase in the lagging strand during DNA replication can be an 
important mechanism in long microsatellite mutations [30].  
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There are over 20 unstable microsatellite repeats which can cause neurological diseases. 
Most of microsatellite repeats are tri-nucleotide repeats (CAG, CTG, CGG etc.), and they 
are located in the coding region or 5’UTR and 3’UTR of different genes.  The pathogenic 
mechanisms can be protein loss-of-function, gain-of-function or RNA gain-of-function, 
with the mechanism of some diseases still unknown. The most famous example is the 
expansion of trinucleotide (CAG)n, which will generate insoluble poly Q aggregates and 
cause neurological disorders [31].  
Unlike microsatellite instability in neurological diseases, microsatellite instability in 
cancer is related to the impairments of the mismatch repair (MMR) system. DNA 
mismatch repair is a system to recognize and repair errors in DNA replication and 
recombination.  DNA polymerase has an internal error rate of 10-4 – 10-5 at the nucleotide 
insertion step.  With the help of the proofreading exonuclease the error rate can be 
reduced to ~10-7.  Escaped mistakes will then be corrected by the mismatch repair 
system, which will further reduce the error rate by 50 to 1000-fold [32]. So, it is apparent 
that the mismatch repair system is essential for maintaining DNA integrity during 
replication, and any mutation-induced inactivation or epigenetic silencing of the system 
will cause microsatellite instability [33], which is common in various types of cancer 
including stomach cancer, esophageal cancer, head and neck squamous cell carcinoma, 
non-small cell lung cancer, colorectal cancer and melanoma etc.   
Another important feature in cancer microsatellite instability is that mono-nucleotide 
microsatellite mutations are detected much more frequently. One report has analyzed 
microsatellite patterns in exome and whole-genome sequencing data of 147 colorectal 
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cancer samples and 130 endometrial cancer samples from TCGA (The Cancer Genome 
Atlas). Out of total 10K microsatellite instability (MSI) events in colorectal genome 
sequences, di-nucleotide and tri-nucleotide mutations only account for 7.6% of the total 
mutations, while 92.4% MSI events are mono-nucleotide mutations. A strong bias pattern 
of mononucleotide mutations also exists in the genomic sequences.  Based on their 
findings, one nucleotide and two nucleotides deletions events have much higher 
frequencies than one nucleotide insertions in both colorectal cancer and endometrial 
cancer. Microsatellite frameshift mutations do not solely exist in MSI positive cancer 
patients.   For example, TGFBR2 gene has a 10A homopolymer and the mutation rate of 
two nucleotide deletion was over 50% in MSI-positive samples, but one nucleotide 
deletion mutation was detected in MSI-negative sample with lower mutation rate (~10%) 
[24].   This indicates that microsatellite mutations in genomic sequences exist in MSI 
negative or even in the normal population but with much lower mutation rate. Another 
genomic sequencing report had similar findings.  They detected over 2,000 MSI events in 
one MSS (microsatellite stable) cancer patient, which was much less mutations compared 
to the numbers in MSI cancer patients but still a considerable amount of mutations [25]. 
MSI events are also much more enriched in 5’UTR, 3’UTR, non-coding sequences than 
in coding regions, which may be related to high selection pressure of mutations in coding 
regions. Another interesting finding is that most of the MS frameshift mutated genes are 
under-expressed (loss of function) with only a very small portion of frameshift mutated 
genes over-expressed.  These over-expression genes may offer a selective advantage in 
cancer development [34].   
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Microsatellite Instability is also an important biomarker for predicting survival in MSI 
cancers. Higher MSI burden is significantly associated with better survival of cancer 
patients. The pattern of microsatellite instability distributions in different genes can be 
used as a classifier to separate different types of MSI cancers [35]. 
With the development of immune checkpoint inhibitor (ICI) therapy, MSI can be an 
important biomarker to predict clinical benefit after ICI treatment. It has been shown that 
the number of neo-antigens is associated with clinical benefit in ICI treatment [16].   
Since MSI cancer patients have large numbers of frameshift neo-antigens from the 
microsatellite regions, obviously MSI status should correlate with clinical benefit of ICI 
treatment as well. A clinical trial has confirmed this hypothesis, MSI status can be used 
as a predictive marker for response to PD-1 (pembrolizumab) blockade treatment in stage 
IV cancer patients.  In the trial, 40% of MMR-deficient colorectal cancer patients (N=10) 
and 71% of MMR-deficient non-colorectal cancer patients (N=7) had object response, 
while 0% of MMR-proficient patients (N=18) had object response [36]. Recently the 
FDA, in a milestone decision, approved the use of Merck’s PD-1/PD-L1 inhibitor 
Keytruda for MSI-H patients with unresectable or metastatic solid tumors regardless of 
cancer types.    
Besides in human malignancies, Microsatellite Instability is also detected in benign 
diseases especially in benign lung diseases. D Spandidos detected 23% of chronic 
obstructive pulmonary disease (COPD) samples were positive in at least one 
microsatellite marker [37].  Microsatellite instability was also detected in asthma, 
sarcoidosis, idiopathic pulmonary fibrosis [38]. Usually patients with these lung diseases 
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will have higher probability of developing into malignant tumor, these findings may 
indicate that microsatellite instability can be a marker for precursor cancer or 
microsatellite instability can exist in different kinds of diseases which we have never 
thought of.  
1.5 Microsatellite Frameshift neo-antigens as cancer vaccine source 
Till now, microsatellite instability research has been focused on finding mutations in 
genomic sequences.  People have found that microsatellite regions are very unstable and 
microsatellite mutations in genomic sequences can still be frequently detected in various 
MSI tumors, MSS tumors and even in benign lung diseases. However, if we consider the 
fact that the DNA polymerase error rate is around 10-10 to 10-8 per generation [39], while 
the RNA polymerase error rate is 10,000-fold higher and it is around 10-6 to 10-5 [40], 
each mRNA molecule is then translated into 2000-4000 protein molecules [41] and the 
error rate is amplified over another 1000-fold. It is obvious that microsatellite mutations 
should be more enriched in mRNA and proteins than in DNA sequences, and it is very 
likely that common microsatellite frameshift neo-antigens can be found from mRNA 
sequences.  
Table 1-2. Advantages of RNA-based Frameshift Antigens over DNA –based 
Personalized Cancer Antigens 
 
Antigen 
Source 
Antigen 
Abundance 
Antigen 
Type 
Immunogenicity 
& 
Autoimmunity 
Cost 
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I have mentioned that Biotech and Pharmaceutical companies have decided to pursue the 
hardest way to find neo-antigens: massive genome sequencings for point mutations. The 
advantages of using frameshift mutations in microsatellite regions have been summarized 
in Table 1-2.  There are 3 major advantages: 1. Microsatellite frameshift antigens from 
mRNA regions are more abundant due to the high mutation rate; 2. Frameshift antigens 
usually consist of peptides from several amino acids to hundreds of amino acids, which 
are likely to have high immunogenicity and low chance of causing autoimmunity; 3. The 
cost of making a vaccine from microsatellite frameshift antigens is much lower without 
the need of sequencing and analyzing the whole genome of the patient.  
 
1.6 Frameshift antigens from mis-splicing events 
Microsatellite regions are one type of error-prone DNA sequences where frameshift 
mutations may frequently occur at the mRNA level during transcription.  But it is not the 
Personalized 
Cancer Neo-
antigens 
DNA 10-10 to 10-8 
Point 
Mutations 
Low 
May cause 
autoimmunity 
over 
$100K 
Microsatellite 
Frameshift Neo-
antigens 
mRNA 
10-6 to 10-5 
10,000-fold 
enrichment 
Frameshift 
Antigens 
High 
Low chance of 
causing 
autoimmunity 
~$200 
depend 
on 
delivery 
system 
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only source. As mentioned before, random errors in the transcription and splicing process 
are more abundant than genomic mutations, microsatellite FS mutations are from the 
transcription process and another type of FS mutations can be caused by random errors in 
the splicing which are mis-splicing FS mutations.  
There are 8.8 exons per human gene and alternate splicing increases the diversity of 
proteins [119]. It is reported that 95% of multi-exon genes in human are alternatively 
spliced [120] and it is difficult for spliceosome to accurately splice every time with such 
complexity. Mis-splicing events generate unexpected proteins and in most cases quality 
control machineries in the cell can handle these aberrant proteins. However, mis-splicing 
events are commonly detected in multiple diseases.  One study estimated that over 60% 
of human disease-causing mutations alter the splicing process instead of changing the 
coding sequences [121]. For example, amyotrophic lateral sclerosis (ALS) and retinitis 
pigmentosa are caused by mutations of important genes in the splicing process [122]. 
Mis-splicing events are widely detected in cancer cell lines and in human tumor EST 
(Expressed Sequence Tag) libraries [123-125]. However, little attention has been paid to 
investigate the frameshift variants from mis-splicing events and the applications of these 
frameshift peptides. Previous graduate students in our group have analyzed mis-splicing 
frameshift mutations which are enriched in tumor EST libraries and results indicate that 
there are over 400 frameshift peptides from mis-splicing within the same gene (majority) 
or across different genes (gene fusions), tens of mis-splicing events were validated in the 
tumor cDNA samples or cancer cell line cDNA samples. Several mis-splicing FS 
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peptides are also detected in the mouse tumors and they could offer protection from 
tumor challenge in both mouse breast cancer and melanoma models [126,127].   
These preliminary results proved the feasibility of using mis-splicing frameshift antigens 
for cancer vaccine development. However, tumor EST libraries only provide limited data 
for detecting all possible mis-splicing events in cancer patients. The development of 
high-throughput peptide array technology makes the unbiased screening of all mis-
splicing frameshift peptides possible and we are currently working with Roche 
Nimblegen for this goal. I have built a human exon junction FS peptide database which 
covers all potential mis-splicing frameshift peptides. In this thesis, I have described the 
characteristics of this database and its potential applications in Chapter 6.       
 
 
My thesis includes three parts: the first part is focused on building databases for MS 
frameshift antigens in different species, demonstrating the biological principles of using 
MS frameshift antigens for cancer vaccine development, developing algorithms to select 
MS FS antigens and test in mouse models; the second part involves developing a dog 
prophylactic cancer vaccine and a small dog safety trial with our vaccine; the third part 
expands our antigen searching to all possible FS antigens in human genes and explore the 
potential of “early diagnosis, early treatment” in mouse transgenic tumor model with 
immune checkpoint inhibitors.   
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CHAPTER 2 
Characterization of FS Peptides from MS Regions and Its Advantages to be Used as 
Cancer Neo-antigens 
 
2.1 Abstract 
With emerging evidence supporting that cancer neo-antigens are the key elements for 
successful immune checkpoint inhibitor treatment [16, 42], the idea of developing a 
cancer vaccine with neo-antigens thrives again after decades. Currently the most popular 
neo-antigen source is the personalized genomic point mutations which has the limitations 
of high cost and low efficiency.  A recent report indicated that FS antigens from 
insertions and deletions (INDELs) of microsatellite regions (MS) and mis-splicing events 
were much more abundant at mRNA level than in DNA, and frameshift (FS) peptides 
from these mutations offered protection in different mouse tumor models (in review). 
However, thousands of MS regions exist in the human coding sequences and these 
potential FS peptides have not been investigated systematically.  Here I provided a 
comprehensive analysis of predicted FS peptides from mono-repeat MS regions. We 
constructed a predicted MS FS peptides database for human, dog and mouse. There are 
over 7,000 MS FS peptides with a minimum peptide length of 8aa in the human coding 
sequences. In addition, we summarized the characteristics of MS distribution and natural 
selection pressures over MS regions and FS peptides. Long FS peptides were highly 
enriched in MS FS mutations and a group of extremely long FS peptides (>200 amino 
acids) showed unique amino acid composition and codon usage patterns. In addition, 
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human MS FS peptides were predicted to be better cancer neo-antigens than point 
mutations with much higher MHC I and MHC II binding affinity. These data provided a 
rich resource for cancer vaccine development with MS FS peptides.  
 
2.2 Introduction 
Cancer vaccines have suffered several decades of failures in clinical trials using tumor 
associated self-antigens. Neo-antigen is the remaining choice for developing preventive 
or therapeutic cancer vaccines. With the appearance of immune checkpoint inhibitors 
(ICI) and their great success in cancer clinical trials and in practice, the whole cancer 
vaccine field is revitalized. Objective Response rate for anti-CTLA4 and anti-PDL1 
treatments is around 10%~40% in clinical trials and the rate is higher when used in 
combinations [12-14]. More importantly, mutation load is reported to be closely 
associated with the clinical benefit of ICI treatments [16, 42] and T cells are directed to 
target neo-antigens in ICI treatments [43]. So, it would be ideal if cancer vaccines 
composed of neo-antigens and ICI treatments can also be used in combination therapy. 
However, with the analysis massive genomic sequencing data, it is clear that common 
neo-antigens do not exist at the genomic level.  One report demonstrated that there is no 
CD4/CD8 neo-antigen epitope which has frequency higher than 0.2% in a cohort of 
20,000 human tumor samples [44]. While it is nearly impossible for finding common 
neo-antigens based on genomic sequencing results, our lab showed that FS mutations 
from MS regions and mis-splicing events are much more abundant at the mRNA level 
than DNA level, and FS peptides from these mutations can offer protection in multiple 
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mouse tumor models (in review and unpublished data). Therefore, we have constructed 
databases which include all possible FS peptides from mono-repeat MS regions in 
human, dog and mouse, and we provided a comprehensive analysis of these MS regions 
and FS peptides in this chapter. 
MS regions are known to be very unstable even at the genomic level and MS instability is 
associated with multiple neurological diseases [31], 18 types of cancer diseases [35], and 
also in multiple benign lung diseases [38]. MS regions have high mutation rates due to 
the slippage of DNA polymerase in DNA replication. One specific gene ACTBP2 with an 
MS repeat length of 15A, was reported to have a mutation rate as high as 7*10-3 per locus 
per generation in humans [45]. Similar to the findings of a high correlation between the 
mutation load and ICI treatment clinical benefit, high MS mutation burden in certain 
cancers is also reported to be associated with longer survival of cancer patients compared 
to low MS mutation burden [35]. MSI-H cancer patients were reported to benefit from 
PD-1 blockade treatments [36] and the FDA granted accelerated approval for using MSI 
as biomarker for PD-1/PD-L1 inhibitor treatments. These data indicate that an anti-MS 
FS peptide immune response is an important factor of anti-tumor activity in MSI-H 
patients.  
Past research on MS FS mutations has been focused on characterizing a small number of 
genomic mutations in MSI-H cancers patients [33, 46-48], and the evolution patterns of 
MS regions across species [49, 50].  No report has characterized the FS peptide 
sequences from potential MS FS mutations. MS regions have long been used as a genetic 
marker but not as a focus as a potential cancer neo-antigen source. With the growing 
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interest in cancer neo-antigen discovery, it is important to analyze these potential FS 
antigens from MS regions. In this chapter, I have provided a comprehensive analysis of 
the potential MS FS antigens in human, dog and mouse. In addition, specific patterns of 
these MS regions and FS antigens are also summarized and the data provides important 
information for cancer vaccine development.  
 
2.3 Results 
2.3.1 Distribution of mono-repeat MS in coding regions of human, dog and mouse 
Mono-repeat MS regions are more prevalent in non-coding regions but they are also in 
coding regions.  Only MS FS mutations in coding regions will be translated into FS 
peptide sequences and used as potential neo-antigens. Mono-repeat MS regions with a 
minimum repeat length of 7 and predicted one nucleotide insertion/deletion FS peptides 
were included in the analysis of this report.   
One example of a MS containing gene is human RNPC3.  The mRNA and peptide 
sequence is shown in Fig 2-1. This gene has 12 continuous adenine repeats and a 
predicted 1A insertion generates insertion FS peptide (KV) with 2 amino acids, while 1A 
deletion generates deletion FS peptide (GLMTLSKMIKKK …) with 17 amino acids. 
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Figure 2-1 Mono-repeat MS region of human RNPC3 gene.  Human RNPC3 gene 
(NM_017619.3) has 12A homopolymer, predicted one nucleotide insertion and deletion 
events can generate predicted insertion FS peptide (KV) and deletion FS peptide 
(GLMTLSKMIKKK...).   
 
To analyze all possible MS regions and potential FS peptides, human and mouse coding 
sequences were acquired from the Consensus Coding Sequence database [51].  Dog 
coding sequences were acquired from NCBI RefSeq database [52].  
In total, there are 8,617 human mono-repeat MSs in coding regions, 10,182 in dog and 
4,837 in mouse. The distribution of human mono-repeat MS regions in Fig 2-2 shows that 
the number of MSs increases exponentially as MS length decreases.  Nearly 80% of all 
the MSs have only 7 mono-repeats. Adenine (A) homopolymer is the dominant MS type 
and accounts for 58% of all the MSs while T and C homopolymers are in the middle 
range with 16% to 18% of all MSs, and G homopolymer has the least number of 
candidates with 8% of the total MSs. Mouse MS distribution has a similar MS type and 
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MS length distribution as in human (Fig2-3B), while dog has more G MS regions (13%) 
and C MS regions (30%). In addition, A and T MS regions are the dominant MS type in 
long MS regions (10 repeats or above), which is same as in short MS regions, while C 
repeats are the dominant MS type in dog long MS regions (11 to 15 repeats) (Fig2-3D). 
With the differences in distribution of MS regions, it would be interesting to know 
whether these MS regions and FS peptides are under natural selection pressure.   
A 
 
B 
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Figure 2-2 Distribution of MS Regions in Human coding regions. A. Number of MSs 
by mono-repeat length and type. B. Percentage of MSs by mono-repeat length and type. 
 
 
 
 
 
 
 
 
            MS Type 
MS LEN 
A T G C SUM 
7 43.42% 12.86% 7.22% 16.17% 79.68% 
8 10.99% 2.30% 0.80% 1.77% 15.86% 
9 2.58% 0.54% 0.08% 0.12% 3.32% 
10 0.71% 0.12% 0.00% 0.01% 0.83% 
11 0.21% 0.01% 0.00% 0.01% 0.23% 
12 0.02% 0.00% 0.00% 0.01% 0.03% 
13 0.01% 0.02% 0.00% 0.00% 0.03% 
SUM 57.94% 15.86% 8.10% 18.10% 100.00% 
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B 
 MS Type 
MS Len 
A T G C SUM 
7 42.46% 16.21% 6.57% 14.74% 79.99% 
8 10.83% 2.79% 0.50% 1.32% 15.44% 
9 2.92% 0.41% 0.10% 0.17% 3.60% 
10 0.52% 0.08% 0.00% 0.02% 0.62% 
11 0.10% 0.02% 0.00% 0.00% 0.12% 
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12 0.02% 0.00% 0.02% 0.00% 0.04% 
13 0.02% 0.08% 0.00% 0.00% 0.10% 
14 0.00% 0.04% 0.00% 0.02% 0.06% 
18 0.00% 0.02% 0.00% 0.00% 0.02% 
SUM 56.87% 19.66% 7.19% 16.27% 100.00% 
 
C 
 
D 
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MS Length\MS 
Type 
A T G C SUM 
7 32.10% 9.82% 9.84% 23.29% 75.04% 
8 8.33% 1.86% 1.98% 5.25% 17.42% 
9 2.52% 0.50% 0.47% 0.92% 4.42% 
10 0.54% 0.12% 0.23% 0.36% 1.25% 
11 0.19% 0.08% 0.08% 0.31% 0.66% 
12 0.06% 0.04% 0.11% 0.11% 0.31% 
13 0.11% 0.01% 0.02% 0.10% 0.24% 
14 0.06% 0.01% 0.04% 0.08% 0.19% 
15 0.04% 0.01% 0.02% 0.08% 0.15% 
16 0.06% 0.02% 0.01% 0.03% 0.12% 
17 0.03% 0.01% 0.02% 0.04% 0.10% 
18 0.02% 0.01% 0.00% 0.00% 0.03% 
19 0.01% 0.00% 0.00% 0.00% 0.01% 
22 0.00% 0.02% 0.00% 0.01% 0.03% 
24 0.00% 0.02% 0.00% 0.00% 0.02% 
25 0.00% 0.01% 0.00% 0.00% 0.01% 
28 0.01% 0.00% 0.00% 0.00% 0.01% 
SUM 44.07% 12.53% 12.82% 30.58% 100.00% 
Figure 2-3 Distribution of Mono-repeat MSs in Dog and Mouse coding sequences. 
A-B, Number of MSs and percentage distribution by mono-repeat length and type in 
Mouse coding sequences. C-D, Number of MSs and percentage distribution by mono-
repeat length and type in Dog coding sequences. 
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2.3.2 MS type has a significant impact on selection pressure  
MS regions were reported to be highly unstable only at the genomic level in small 
populations like MSI-H cancer patients, who have mutations in the mismatch repair 
systems. MS regions could be under selection pressure constantly even in the normal 
population or they might not be randomly distributed. At least two factors could be 
related to selection pressure: MS type and MS length. Adenine (A) and Thymine (T) 
mono-repeats are generally thought to be more mutagenic with only two hydrogen bonds, 
while Guanine (G) and Cytosine (C) mono-repeats are more stable with three hydrogen 
bonds. In addition, long MSs are known to have much higher mutation rate than short 
MSs [45].  
Selection pressure was calculated with the ratio of actual MS numbers to predicted MS 
numbers (no selection pressure would be randomly distributed) in the human coding 
sequences. A high ratio indicates low selection pressure while low ration means high 
selection pressure. The results showed that all four MS types were under selection 
pressure to some degree, but A and T MS regions had much lower selection pressure with 
75.8% and 66.1% of actual MS numbers compared to predicted MS numbers. On the 
contrary, G and C MS regions only had 4.2% and 11.8% of actual MSs compared to 
predicted numbers.  G/C MS regions had significantly lower ratio (higher selection 
pressure) than A/T MS regions (Fig2-4). 
Another important factor was repeat length.  It turned out that selection pressure went 
much higher when repeat length increased from 7 (52.6%) to 11 (29.9%), but it was not 
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statistically significant. Selection pressure over A repeats did not change when repeat 
length increased from 7 to 11 (79.6% and 81.2% correspondingly). However, selection 
pressure did increase a lot for T repeats (83.5% to 32.9%), G repeats (13.3% to 0%) and 
C repeats (33.9% to 5.6%).  
In addition to the characteristics of MS regions, we analyzed the distribution and patterns 
of MS FS peptides predicted from the MS regions. 
A                                                                      B 
         
C 
MS 
Type 
Actual# Expected# ratio MS 
Type 
Actual# Expected#  ratio 
7A 3750 4710 79.62% 10G 
 
85 0.00% 
7T 1111 1331 83.50% 10C 1 70 1.43% 
7G 624 4706 13.26% 11A 18 22 81.18% 
7C 1397 4111 33.98% 11T 1 3 32.87% 
Ac
tu
al
/E
xp
ec
te
d
7 8 9 10 11 A T G C
34 
 
8A 949 1234 76.92% 11G 
 
22 0.00% 
8T 199 291 68.40% 11C 1 18 5.58% 
8G 69 1232 5.60% 12A 2 6 34.44% 
8C 153 1056 14.49% 12T 
 
1 0.00% 
9A 223 323 69.01% 12G 
 
6 0.00% 
9T 47 64 73.88% 12C 1 5 21.74% 
9G 7 323 2.17% 13A 1 2 65.73% 
9C 10 271 3.69% 13T 2 0 N/A 
10A 61 85 72.07% 13G 
 
2 0.00% 
10T 10 14 71.88% 13C 
 
1 0.00% 
 
Figure 2-4 Selection pressure in Human MS regions. Expected MSs were calculated 
by the frequency of A, T, G, C in human coding sequences. A-B. percentage of actual 
MS number over predicted MS number was used to measure the selection pressure of 
MSs, x axis were MS length and type. C. Detail table of the actual MS numbers and 
expected MS numbers for different MS types and lengths. 
 
2.3.3 Distribution of and selection pressure on Predicted MS FS Peptides  
Coding FS peptides from MS regions are important for making cancer vaccines, since FS 
peptides are generally thought not to be functional proteins and we would expect them 
not to be long peptides if stop codons (TGA, TAA, TAG) are distributed randomly. In the 
meantime, relatively long FS peptides have the advantage of containing multiple high 
affinity MHC class I and II epitopes.  
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The human coding FS peptide sequences were used in our analysis. In the distribution of 
FS peptide length, the number of FS candidates decreased exponentially as FS peptide 
length increases (Fig2-5). Most FS peptides had less than 50 amino acids. But there were 
still over 300 FS candidates which had over 100 amino acids, with the longest FS peptide 
over 400 amino acids.  
Long FS peptides could be under selection pressure considering they were more 
immunogenic and may have deleterious functions when expressed. The expected FS 
peptide length was calculated with a random distribution of stop codons in mRNA 
sequences and the selection pressure was quantified with the ratio of actual FS peptide 
length distribution over predicted distribution. 
Results indicated that short FS peptides (<50 amino acids) are under selection pressure. 
There were 60% of the expected 20-mer FS peptides in the real human MS FS peptides. 
While long FS peptides (100 amino acids or longer) were more highly enriched in these 
MS FS peptides than expected. There are over 4-fold of actual FS peptides with 100 aa or 
longer than expected and the fold change increased as FS peptide length increases. The 
number of FS peptides with 50 aa or longer was about equivalent between actual and 
predicted number (Fig2-5B).  
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Figure 2-5 Distribution of Human MS FS peptide length. A. Distribution of human 
MS FS peptide length. B-C Selection pressure over the FS peptide length. Expected FS 
peptide length was calculated with random distribution of stop codons and selection 
pressure was quantified with ratio of actual FS peptide length distribution over predicted 
distribution. 
 
At the genomic level, one nucleotide insertion and deletion events are biased. One 
nucleotide deletion is the dominant mutation in MSI cancer patients [34]. Therefore, it is 
also interesting to see that whether there is a bias in the peptide length of insertion and 
deletion peptides. FS peptides from one nucleotide deletion events are significantly 
Frameshift Peptide Length
0 100 200 300 400
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longer than one nucleotide insertion events by a few more amino acids (Figure 2-6). A 
small group of FS peptides from one nucleotide insertion events had extremely long 
peptide lengths with 300 amino acids or more, while there was no FS peptide with 300 aa 
in one nucleotide deletion events.  
As mentioned previously, long FS peptides were more highly enriched in MS regions 
than expected and it would be interesting to know whether these FS peptides had specific 
characteristics.    
 
A                                                                       B 
 
Figure 2-6 Insertion and Deletion FS Peptide Length Bias. A-B Comparison of 
peptide length of insertion and deletion events, a group of extremely long FS length is 
marked with red circle. Non-paired student’s t-test is used to compare two groups.        
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2.3.4 Long FS peptides are a unique group of peptide sequences 
Long FS peptides from MS regions with 200 aa or longer should not exist in human 
sequences based on probability calculations. However, this group was enriched in both 
human and dog microsatellite regions. One possibility would be that these long FS 
peptides were functional proteins as WT protein sequences. To test this idea and compare 
these FS peptides to the WT proteome, codon usage and amino acid compositions were 
compared among these three groups: long FS, short FS and WT peptide sequences.  
Results of codon usage analysis showed that human WT codon usage and dog WT codon 
usage were almost identical with correlation of 0.995. Human and dog short FS peptides 
shared a similar pattern of codon usage compared to WT codon usage 
(correlation=0.92~0.93). Both human and dog long FS peptides had quite different codon 
usage patterns from short FS peptides (correlation 0.85~0.78) or the wildtype proteome 
sequences (correlation 0.88~0.89) (Fig2-7). Interestingly, human long FS peptides codon 
usage had very high similarity to dog short FS peptides (correlation 0.94) and very low 
similarity to dog long FS peptides (correlation 0.69).   
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A 
 
B. Codon usage correlation between 6 groups 
 
 
Figure 2-7 Codon usage bias between long FS peptide versus short FS peptides. A-B, 
64 dog long FS peptides with 300 aa or longer and 53 human long FS peptides with 
200aa or longer were included in “long FS” group, FS peptides with 20 aa or shorter were 
 
Human 
Reference 
Human 
Short FS 
Human 
Long FS 
Dog 
Reference 
Dog Short 
FS 
Human 
Reference 
1.000     
Human 
Short FS 
0.931 1.000    
Human 
Long FS 
0.884 0.847 1.000   
Dog 
Reference 
0.995 0.937 0.852 1.000  
Dog 
Short FS 
0.938 0.915 0.942 0.922 1.000 
Dog Long 
FS 
0.866 0.911 0.688 0.897 0.783 
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included in “short FS” group, human and dog wildtype proteome sequences were used as 
“WT”. Heat map of codon usage distribution was shown in A and correlation table of 
codon usage between different groups was shown in B. 
 
Amino acid compositions were compared by the same method. The amino acid 
composition of human and dog WT sequences were very similar as well 
(correlation=0.981). WT protein amino acid composition was not randomly distributed 
(correlation to random was 0.7~0.79). However, the aa composition of FS peptides 
should be more randomly distributed if they were not under selection, and in fact whole 
human/dog MS FS database and short human/dog FS peptides had very high correlation 
to the random distribution (correlation ~0.9), which indicates that they were likely not 
under selection. However, both human and dog long FS peptides had unique amino acid 
compositions which were very different from other groups (correlation to WT (0.5~0.6), 
random distribution (0.6~0.7) or short FS sequences (~0.6)) (Fig2-8). Despite that 
different codons were used between human and dog long FS peptides (Fig2-7), they were 
highly conserved in amino acid composition (correlation=0.98). Alanine, Glycine, 
Proline, Arginine and Histidine were enriched in long FS peptides, while other amino 
acids were less abundant in these long FS peptides than short FS peptides or WT 
sequences.  
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Figure 2-8 Amino acid composition bias between long FS peptides and short FS 
peptides. Expected: aa composition by random; Dog/Human WT: WT proteome aa 
composition; Dog/Human FS: whole MS FS database aa composition. A. Two-way 
hierarchical clustering of amino acid composition in human and dog peptide sequences, 
expected number is calculated based on number of codons for each amino acid. B. 
Correlation matrix of amino acid composition between different groups.  
 
Expected Dog WT Dog FS Dog Short FS Dog Long FS Human WT Human FS Human Short FS Human Long FS
Expected 1.000
Dog WT 0.792 1.000
Dog Frameshift 0.885 0.749 1.000
Dog Short FS 0.890 0.789 0.955 1.000
Dog Long FS 0.652 0.530 0.807 0.668 1.000
Human WT 0.713 0.981 0.663 0.743 0.398 1.000
Human Frameshift 0.901 0.785 0.985 0.989 0.722 0.720 1.000
Human Short FS 0.865 0.795 0.912 0.989 0.573 0.767 0.968 1.000
Human Long FS 0.728 0.631 0.865 0.740 0.986 0.502 0.796 0.659 1.000
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The unique characteristics of long FS peptides indicated they could have unknown 
functions. The simplest way to answer this question would be to see whether these FS 
peptides were used as functional proteins in another species. Out of a total of 53 FS 
peptides with 200 amino acids or longer in human, 40% of these candidates (total 21) 
have conserved peptide sequences in the wild type protein sequences of other species. 
While the percentage went down to 9% for mid-length FS peptides (31-50 aa) and 3% to 
short FS peptides (17-30 aa). However, when the percentage was normalized to FS 
peptide length, the rate was about the same between long FS peptides and short FS 
peptides, while mid-length FS peptides had higher chance of being found in WT 
proteomes of other species (Fig2-9). These results demonstrated that long FS peptides 
were not preferably used as functional proteins in other species, which was consistent 
with previous results that long human and dog FS peptides did not share the same codon 
usage or amino acid composition with WT sequences (Fig2-8). This group of 53 long FS 
peptides containing genes were not enriched in a specific biological process or molecular 
function based on ontology analysis, but most of these long FS containing genes had 
repetitive functional domains.  These proteins included 12 DNA-binding proteins like 
zinc finger proteins and forkhead box proteins, and transmembrane proteins or other 
proteins.  
In addition to these interesting characteristics, it was important to know why FS antigens 
would be better than the commonly used point mutations based neo-antigens. 
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A                                                                      B 
 
Figure 2-9 Long Human FS peptides were not preferably existed in wildtype protein 
sequences of other species. A. Human FS peptides were blasted against NCBI Refseq 
protein sequences of other species, percentage of FS peptides which had homolog 
wildtype sequences in another species was calculated. 53 long FS peptides (200 aa or 
longer), 1332 mid-length FS peptides (31aa~50aa) and 2133 short FS peptides 
(17aa~30aa) were used in the analysis. B. Percentage of FS peptides in WT sequences of 
another species was normalized to 100 amino acids of FS peptide length. E-value cutoff 
is 0.01.    
 
2.3.5 Advantages of using MS FS peptides over point mutations as neo-antigens 
Patient-specific point mutations at the genomic level are the focus for use in personalized 
cancer vaccines. However, there are three potential advantages of using MS FS peptides 
instead of point mutated peptides: high immunogenicity; low chance of causing 
autoimmunity and low cost of making a vaccine from these FS peptides.  
To compare the immunogenicity of FS peptides and peptides from point mutations, both 
MHC Class I and Class II predictions were performed between MS FS peptides and point 
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mutated peptides. 1,242 point mutated peptides and corresponding wild type peptide 
sequences were acquired from a previous published cancer genome sequencing report 
[53]. The same number of MS FS peptides with the same peptide length as the point 
mutations were randomly selected from human MS FS peptides. Results showed that MS 
FS peptides had significantly more MHC II prediction hits (high immunogenicity) with a 
prediction rank percentile of 10 or lower when compared to their WT counterparts or 
point mutation peptides, while overall the point mutation peptides had almost the 
identical MHC II prediction hits compared to wildtype sequences. Very similar results 
were observed in MHC I predictions. The best prediction score for each peptide was used 
in the analysis. The MS FS peptides had significantly lower percentile rank (high 
immunogenicity) than paired wildtype sequences or point mutation peptides, while there 
was still no difference between point mutations peptides and paired wildtype sequences. 
These results indicated that MS FS peptides were much more immunogenic on average 
than genomic point mutated peptides. 
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Figure 2-10 MHC Class I and II prediction for MS FS peptides and point mutation 
peptides. FS: MS FS peptide, FS_WT: FS peptide paired WT peptide, PM_Mut: point 
mutated peptide, PM_WT: point mutation paired WT peptide. Reference human HLA 
types are used. A. 1,242-point mutation peptides were somatic cancer genome missense 
point mutations,20 aa peptides were generated from the point mutation site, same number 
of 20-aa MS FS peptides and paired WT peptides were used for comparison, y axis was 
number of hits with percentile rank < 10 in MHC II prediction; B. 1,259 10-aa peptides 
were generated using the same method as in A for MHC I prediction, y axis was the best 
prediction percentile rank for each peptide, reference human HLA types are used. 
 
Another advantage of MS FS peptides is that many MS regions are conserved across 
human, dog and mouse. It is easy, therefore, to transform vaccine candidates in mouse 
into dog or human trials directly. Humans and dogs share 1,124 homolog MS candidates, 
dog and mouse share 345 homolog MS candidates, and 269 MS candidates can be found 
in all three species. Vaccines developed with these 269 MS candidates can be tested in all 
three species without needing to change the components (Figure 2-11).  This criterion is 
used in antigen selection for the dog cancer vaccine which will mentioned in Chapter 5.   
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In addition, FS peptides have a low chance of causing autoimmune diseases when 
compared to point mutations. Point mutated peptides only have 1 amino acid change and 
immune responses against these peptides can potentially spread to target the wildtype 
peptide sequence and cause autoimmune diseases, while FS peptides do not have this 
disadvantage. The cost of making a personalized cancer vaccine from point mutations 
was tremendous with genome/exome sequencing, antigen selection and vaccine 
development. While MS FS mutations at the mRNA level were abundant as reported and 
these predicted peptide sequences may make producing a personal vaccine much less 
expensive.  
Table 2-1 Advantages of Microsatellite Frameshift Antigens over Personalized 
Cancer Antigens 
 
Antigen 
Source 
Antigen 
Abundance 
Antigen 
Type 
Immunogenicity 
& 
Autoimmunity 
Cost 
Personalized Cancer 
Neo-antigens 
DNA 10-10 to 10-8 Point 
Mutations 
Low 
May cause 
autoimmunity 
over $100K 
Microsatellite 
Frameshift Neo-
antigens 
mRNA At least 
10-6 to 10-5 
Frameshift 
Antigens 
High 
No 
autoimmunity 
issues 
~$200 
depend on 
delivery 
system 
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Figure 2-11. Microsatellite Homologs across human, dog and mouse. Homolog genes 
with same MS region were included in the analysis. 
 
2.4 Discussion 
Cancer neo-antigens are the key element for cancer vaccine development.  Neo-antigens 
from patient specific genomic point mutations, the focus of current efforts, have severe 
limitations in high cost and a long production cycle. Here we have provided a 
comprehensive analysis of the mono-repeat MSs and predicted FS peptides from these 
MS regions.  We have constructed an MS FS peptide sequences database for human, dog 
and mouse. Analysis showed that MS type was related to selection pressure and long FS 
peptides were highly enriched in human MS regions.  A group of long FS peptides had 
unique codon usage and amino acid composition which could be related to repetitive 
domains of the proteins. We further demonstrated that MS FS peptides had higher MHC I 
and MHC II binding affinity compared to point mutations and low chance of causing 
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autoimmunity. These data support that at least FS derived from RNA-MS FS antigens 
could be a rich resource of potential cancer neo-antigens for cancer vaccine development. 
In the MS regions analysis, selection pressure was much higher on the G/C repeats than 
the A/T repeats, which could be related to the stable triple hydrogen bond in G/C pairs 
compared to the double hydrogen bond in A/T repeats. The selection pressure on the MS 
length only went slightly higher as the MS length increased but the difference was not 
statistically significant. This suggests that MS regions could be relatively stable at the 
genomic level when the mismatch repair system was functioning properly. This is 
consistent with the findings that MSI-H cancer patients only accounted for a small 
percentage of all the cancer patient population. However, MS mutations at the mRNA 
level were much more abundant as reported.  
Long frameshift peptides are a unique set of peptide sequences.  They are specifically 
enriched in the microsatellite FS peptides while short frameshift peptides are under 
negative selection pressure. These long FS peptides have unique amino acid composition 
and codon usage patterns which is quite different from wildtype sequences and short 
frameshift peptide sequences. Five amino acids (Glycine, Arginine, Alanine, Histidine 
and Proline) are highly enriched in these long frameshift peptides. Two amino acids 
(Arginine, Histidine) are positively charged with the other three neutral amino acids.  The 
positive charge of these long frameshift peptides may offer selective advantages. We first 
thought that these long frameshift peptides might be functional protein variants of the 
wildtype proteins.  It turned out these three groups have about the same chance of being 
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in WT proteomes of other species, which indicates these long frameshift peptides are 
probably not known functional proteins.  
With thousands of potential MS candidates available, we could not use all of them at 
once for vaccine development.  The algorithms to select personalized MS FS antigens 
and broadly effective MS FS antigens remains to be investigated. B cell immune response 
and T cell immune response screening of these potential MS FS antigens may uncover 
some of these commonly reactive antigens in cancer patients.  
In conclusion, thousands of MS FS peptides have the potential of being used as cancer 
neo-antigens. With the advantages of high immunogenicity, low chance of causing 
autoimmunity and low cost, the idea of developing prophylactic and therapeutic cancer 
vaccines with these predicted MS FS antigens can be helpful in reducing the cancer 
incidence and mortality rate in developing countries.    
 
2.5 Materials and Methods 
2.5.1 FS peptide database 
Human and mouse mRNA sequences were acquired from the NCBI CCDS database [51], 
dog mRNA sequences from the NCBI RefSeq database [52]. Mono-repeat MS regions 
with a minimum of 7 nucleotides were predicted in coding sequences.   One nucleotide 
predicted insertion and deletion peptides were predicted after the MS regions. 
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2.5.2 Selection pressure calculation 
The expected number of MSs for a specific length and type in coding sequences was 
calculated by the following equation: 
  
The expected number of a certain FS peptide length was calculated by the frequency of 
non-stop codons (61/64) and FS peptide length: 
  
2.5.3 Codon usage analysis 
Human and dog reference codon usage numbers were acquired from the codon usage 
database [54]. FS peptide codon usage was analyzed with the original mRNA sequences 
and a codon usage heatmap was generated using JMP Pro 13 (SAS, NC).    
2.5.4 Amino acid composition and peptide analysis 
Amino acid composition was calculated by counting the number of each amino acid in 
the FS peptide and WT peptide sequences using Excel. Expected frequency of amino 
acids was calculated by the percentage of codons for each amino acid. Two-way 
hierarchical clustering with the Ward method was performed using JMP Pro 13. To find 
conserved FS peptide sequences which were used in wildtype proteins of other species, 
human and dog FS peptides were blasted against whole RefSeq protein database [55]. 
Blast hits were counted with the cutoff e-value of 0.01, then blast hits were normalized to 
the original FS peptide length.  
( , , , ) ( , , , )Microsatellite LengthExpected Number A T G C total mRNA nucleotides Frequency A T G C     
61( ) *( )
64
Peptide LengthExpected Number Peptide Length total microsatellite number     
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2.5.5 MHC Prediction analysis 
Human MHC II Reference sets [56] and MHC I Reference sets [57] were acquired from 
IEDB. The Consensus prediction method [58-60] was used for MHC I and II prediction. 
For MHC Class I prediction, the best prediction score for each peptide was used. In MHC 
Class II prediction, the number of predicted hits with percentile rank less than 10 were 
counted for each peptide. Point mutated peptides in cancer patients and corresponding 
WT peptides were analyzed from previous published cancer genome sequencing results 
[53]. 1,242-point mutation peptides were somatic cancer genome missense point 
mutations, 20 aa peptides were generated from the point mutation site (10 aa before the 
mutation site and 9 aa after).  The same number of 20-aa MS FS peptides and paired WT 
peptides were used for comparison. 1,259 10-aa point mutated peptides (5 aa before the 
mutation site and 4 aa after) and WT peptides were generated using the same method for 
MHC I prediction. 
  
 
 
 
 
 
 
 
                                                  
52 
 
CHAPTER 3 
Microsatellite Frameshift Peptides are More Abundant at the mRNA Level and 
Offer Protection in the 4T1 Mouse Tumor Model 
 
3.1 Abstract 
   Microsatellite instability (MSI) is well characterized as a phenotype for certain cancer 
types (colon cancer, stomach cancer etc.) due to the impaired DNA mismatch repair 
machinery [33, 61, 62]. But for most other cancer types, microsatellite mutations are 
rarely detected at the genomic level [63] and believed not relevant to cancer progression. 
However, microsatellite frameshift mutations at the RNA level have not been thoroughly 
investigated, largely because it is difficult to pick out partial single nucleotide 
insertion/deletion from the background noise in RNA sequencing technology. Here, we 
detected mono-repeat microsatellite frameshift mutations in tumor cDNA samples and 
show that mutations at the mRNA level are much more abundant than at the DNA level. 
Microsatellite frameshift mutation rates were strongly related to microsatellite repeat 
length. Frameshift peptides for one specific microsatellite candidate, SEC62, could be 
detected in both the human HEK293 cell line and mouse 4T1 cancer cell line with a GFP 
reporter system. We also developed a method to select the best 9 mouse MS FS peptides 
and this pool showed protection in the 4T1 mouse breast cancer model.  Both T and B 
cell responses were correlated to the tumor protection. Our results demonstrated that 
instead of using MS as a biomarker, a large group of microsatellite frameshift peptides 
are also a potential cancer vaccine source.  
53 
 
3.2 Introduction 
   Microsatellite Instability (MSI) is caused by impaired DNA mismatch repair (MMR). 
The phenotype is characterized by hypermutability in microsatellite regions of MSI-H 
cancer patients. Microsatellite Instability is not very common in the general cancer 
population.  In an exome sequencing study of 18 microsatellite instability cancer types, 
15 cancer types had less than 5% of the patients with the MSI-H signature, while only 
endometrial cancer, colon cancer and stomach cancer have around 20%-30% MSI-H 
cancer patients [35].  
   Microsatellite instability is usually used as biomarker for cancer subtypes [48, 64]. 
Recently, it was reported that high microsatellite mutation load is beneficial to cancer 
patients compared to microsatellite stable cancer patients. High MSI burden is correlated 
with significantly better survival of cancer patients [35, 65], and microsatellite instability 
shows promise in checkpoint blockade immunotherapy [66-68]. These results indicate 
that the immune system can target these microsatellite mutations derived frameshift 
antigens and killing the tumor cells.  
Both antibody responses and T cell responses against microsatellite frameshift antigens 
were detected in MSI-H cancer patients [69-71]. T cell responses against microsatellite 
frameshift peptides in microsatellite stable (MSS) cancer patients was much lower 
compared to MSI-H patients but still detectable. More interestingly, 2%~15% of the 
healthy controls also had antibody response against frameshift peptides [70], which was 
also lower than the percentage in the MSI-H patients. These data suggest that 
microsatellite mutations are expressed and presented in the healthy population with lower 
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level as well. Apparently, these mutations are more prevalent at the protein level than 
people have thought. 
     The mutation rate at the mRNA level is 10,000-fold higher than it is at the DNA level 
[40] and each mRNA molecule is translated into 2,000 – 4,000 proteins [41]. It is 
apparent that microsatellite frameshift mutations should be much more prevalent at the 
mRNA level or protein level in cancer patients. And when the fact of high mutation rate 
at mRNA level is combined with the evidence that the immune response against these 
MS frameshift peptides is beneficial to MSI cancer patients [5-11], these microsatellite 
frameshift peptides could be ideal cancer vaccine antigen sources. However, the 
application of these frameshift peptides as cancer vaccine has not been studied. 
     Here we have examined microsatellite frameshift mutations at the mRNA level and 
DNA level using dog tumor cDNA samples and 4 human breast cancer cell lines. We 
found that frameshift mutations are much more abundant at the mRNA level than the 
DNA level. Furthermore, we have constructed a plasmid with an 11A MS region and a 
GFP reporter.  The mutation rate for this 11A MS in human HEK293 cell line is as high 
as 25.5%. In addition, a pool of 9 MS FS candidates was tested in the mouse 4T1 breast 
cancer model and the vaccine showed protection. Together these results proved that MS 
FS peptides at the mRNA level could be unrecognized source of cancer vaccine 
components. 
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3.3 Results 
3.3.1 Microsatellite variants are much more abundant at the mRNA level than 
mutations at the genomic level 
   Microsatellite sequences are usually repeated sequences of 1-6 base pair units.  Mono-
repeat microsatellite mutations are the most abundant category in MSI-H cancer patients 
[35]. Here we only used mono-repeat microsatellite sequences in coding regions with 
microsatellite repeat length larger or equal to 7 repeats. One example of such a repeat 
(dog gene Sec62, XM_846664.4) is presented in Figure 3-1.  Wild type Sec62 gene has 
11 consecutive Adenine and a one nucleotide insertion or deletion can shift the reading 
frame, thus making insertion frameshift peptide RWGKGRA and deletion frameshift 
peptide MGKRKSLK….    
   To measure microsatellite mutations at the mRNA level, 20 dog microsatellite 
candidates with variable MS repeat length were sequenced in dog tumor cDNA samples 
from 4 major dog cancer types (Fibrosarcoma, Mast Cell Tumor, Osteosarcoma and 
Hemangiosarcoma). Sequencing results showed that the microsatellite regions rarely 
mutate at mRNA level when repeat length ranged from 7 to 9 with the exception that 
there was one nucleotide insertion mutation in the 9G MS region of B3GAT gene. As the 
mono repeat length increased to 10 or longer, most microsatellite regions had either 
insertions or deletions in the cDNA sequences.  10A in EIF2B3 and 11A in MS038 had 
both one nucleotide insertions and deletions. When the MS repeat length was not very 
large (11 repeats or less), mutations are detected in the cDNA sequences but rarely in 
genomic DNA sequences. One example was dog gene Sec62   We sequenced both 
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genomic sequences and cDNA sequences for the candidate in tumor cDNA samples and 
the corresponding DNA samples from same tissue. Mutations at cDNA level were much 
more abundant (1A insertions and deletions) than at the genomic level.  There was a very 
small percentage of one nucleotide insertions in the genomic sequences which could 
rarely be seen (Fig3-1B&C). But as the repeat length increased to 15, as in MS305 with 
15T microsatellite region, a significant amount of insertion and deletion mutations were 
detected at genomic sequences as well (Fig3-1D). 
 
Figure 3-1 Example of mono repeat microsatellite in coding sequences. Dog Sec62 
gene (XM_846664.4) include 11 adenine repeat, one nucleotide insertion and deletion 
frameshift peptides are marked as red. 
 
A similar approach to detect microsatellite mutations at the mRNA level and in genomic 
sequences was applied to human microsatellite candidates. Genomic DNA and cDNA of 
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four human breast cancer cell lines (HTB26, CRL2315, CRL2326 and CRL1504) were 
used in the sequencing. When microsatellite repeats were of length 10 or less, 
microsatellite mutations could be detected in cDNA sequences (one nucleotide insertion 
in MS443 and MS75, one nucleotide deletion in MS807) but rarely in genomic 
sequences. While for microsatellite candidates with 11 repeats, one nucleotide deletion 
events could also be easily detected in genomic sequences of candidates MS866, MS20 
and MS87 (Fig3-3). Interestingly, only one nucleotide deletion was detected in the 
genomic sequences but not one nucleotide insertion, which was consistent with findings 
that one nucleotide deletion was the dominant mutation type of microsatellites in MSI-H 
cancer genome sequencing results [34]. 
A                                                      B 
 
Genomic Sequences:  Sec62, 11A, No mutation 
 
C 
cDNA Sequences:    Sec62, 11A, 1A Ins / Del 
 
 
Candidate MS Type Mutation at cDNA
MS136 7A No
MS459 7A No
MS683 7T No
MS383 8A No
SWAP70 8A No
MS880 8A No
MS507 8C No
MS497 8G No
HNRNPH1 8T No
MS226 9A No
ARV1 9A No
OPHN1 9A No
MS265 9G Yes (1G Ins)
ZC3HAV1 9T Yes (1T Ins/Del)
MS514 10A Yes (1A Ins)
MS383 10A Yes (1A Del)
CEP290 10A Yes (1A Ins)
EIF2B3 10A Yes (1A Ins/Del)
MS038 11A Yes (1A Ins/Del)
EFHC2 11A Yes (1A Ins)
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D Genomic Sequence for MS305, 15T 
 
Figure 3-2. Microsatellite frameshift mutations at Dog tumor cDNA samples. A. 
Summary sequencing results of 20 microsatellite candidates in 3 dog cancer types (MCT, 
OSA, HAS); B&C. Genomic sequence and cDNA sequence of dog Sec62 gene in 5 dog 
tumor samples (MCT, OSA, HAS). D. Genomic sequence of dog candidate MS305 with 
15T microsatellite region in dog tumor DNA samples. 
A 
 
B. Human Sec62 9A NM_003262.3, Genomic DNA 
 
Candidate MS Type Mutations
MS93 8T No mutation at cDNA&DNA level
MS24 9A No mutation at cDNA&DNA level
MS990 9T No mutation at cDNA&DNA level
MS443 9C 1C Insertion at cDNA level
MS687 9G No mutation at cDNA&DNA level
MS75 9A 1A Insertion at cDNA level
MS806 10T 1T Deletion at cDNA level
MS866 11A 1A Deletion at DNA level
MS20 11A 1A Deletion at DNA level
MS87 11A 1A Deletion at DNA level
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C. Human Sec62 9A cDNA, 1A Insertion 
 
D. Human MS866 11A, genomic sequence 
 
Figure 3-3. Microsatellite frameshift mutations at Human breast cancer cell lines. A. 
Summary results of 10 microsatellite candidates sequenced in HTB26, CRL2315, 
CRL2326 and CRL1504 breast cancer cell lines. B&C. Genomic sequence and cDNA 
sequences of human Sec62 gene. D. Genomic sequence for human MS866 candidate with 
11A MS region. 
 
3.3.2 Translation of microsatellite frameshift mutation can be detected in both the 
human HEK293 cell line and the mouse 4T1 breast cancer cell line 
Frameshift mutations in microsatellite regions usually cause premature termination 
codons (PTCs) and they are believed to be degraded by nonsense-mediated mRNA decay 
system (NMD pathway). However, some truncated frameshift proteins can escape the 
NMD system or bypass the NMD system if PTCs are located within 50-55 nucleotides of 
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the last exon junction [72].  Frameshift proteins for these microsatellite regions can be 
detected. Another report estimated the overall NMD effect on INDELs was only 14% 
[18], suggesting that NMD would not prevent the translation of MS FS peptides.   
To test whether frameshift proteins are translated, we used a different approach by 
constructing a plasmid which contained the coding sequences of Sec62 with 11A MS 
region followed by GFP in the +1 reading frame (an insertion frameshift mutation will 
induce GFP expression). Sec62 with 12A region and GFP in the WT frame were used as 
positive controls to calculate the mutation rate. The 11A microsatellite region was 
disrupted in Sec62-NM (No Microsatellite) construct and used as negative control. 
A. 
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B. 
      
GFP Positive Control        Sec62-12A                Sec62-11A              Sec62-NM 
                                       Positive Control                                          Negative Control   
C. 
  
Figure 3-4.  Detection of frameshift protein in HEK293 cell line. A. Construct of 
plasmids, GFP is in +1 reading frame of Sec62-11A construct and WT frame of Sec62-
12A construct. B. HEK293 cell line was transfected with plasmids, GFP fluorescence in 
Sec62-11A plasmid represented frameshift insertion events. C. Mutation events were 
counted in FACs, Sec62-12A was used as positive control. 
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When the human HEK293 cell line was transfected with Sec62-11A, GFP fluorescence 
from one nucleotide insertion events was detected as shown in Figure 3-4B. One 
nucleotide deletion events were rarely detected with only 0.45% of all cells were GFP 
positive (Figure S3-4). However, if the 11A microsatellite region was disrupted (Sec62-
NM, used as negative control), the fluorescence disappeared completely, which indicated 
that intact 11A microsatellite region was essential for the INDELs. To measure the 
mutation rate, 80,000 cells from each group were collected after transfection and counted 
by flow cytometry.  50.10% of cells were fluorescence positive in Sec62-12A as positive 
control, while 12.77% of cells were fluorescence positive in Sec62-11A. The mutation 
rate based on this experiment is 25.5% for 11A microsatellite region, which was about 
the same level of mutation rate as measured by estimate from the cDNA sequence traces 
shown in Figure 3-2C.  The same experiment was repeated in the mouse breast cancer 
cell line 4T1 (data in Figure S3-1, S3-2).  1A insertion and 1A deletion were both 
detected in the 4T1 cell line. However, the mutation rate was much lower in the 4T1 cell 
line than the HEK293 cell line due to a low transfection rate. Then same experiment was 
repeated in other mouse and human cancel cell lines like MCF7 and HCC1143.  
However, mutations could not be detected due to extremely low transfection rate since 
GFP was rarely detected even in positive controls (Figure S3-3).   
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3.3.3 Frameshift peptides derived from microsatellite mutations show protection in 
the mouse 4T1 cancer injection model  
Frameshift mutations at microsatellite regions could be detected at the cDNA level based 
as shown above. However, to test whether frameshift peptides are a good cancer vaccine 
source, we need to test whether these FSPs protect mice from developing tumors.   
Thousands of FSPs from mouse microsatellite regions are potential vaccine candidates. 
To select the best vaccine candidates, we designed a method to screen the microsatellite 
frameshift candidates (Fig3-5). As we demonstrated above, microsatellite repeat length is 
correlated with frameshift mutation rate.  Microsatellites with repeat length of 10 or 
above usually had high frameshift mutation rate at the cDNA level as shown in previous 
data. MHC I&II predictions for BALB/c mouse were used to select candidates with the 
best MHC I&II epitopes. The top 9 candidates were selected with this method with their 
detailed information was summarized in Table 3-1.  
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Figure 3-5. Method of selecting best microsatellite frameshift peptides. Minimum 
microsatellite repeat length was 10, frameshift peptide was longer than 10 amino acids 
and less than 100 amino acids, combination of MHC I&II prediction scores were used to 
select the best 9 candidates. 
Table 3-1. Information of 9 Microsatellite Frameshift Peptides 
 
These 9 microsatellite frameshift peptides were pooled to immunize naive BALB/c mice 
and the mice then challenged with 5,000 4T1 mouse breast cancer cells [73]. 4T1 mouse 
breast tumor model is a well characterized transplantable mouse breast tumor model 
which can metastasize spontaneously. The immunization regime included two rounds of 
genetic immunizations (GI1, GI2) with a gene gun and then one dose of KLH conjugated 
peptide boost (PB). Empty plasmid and KLH only were used in genetic immunization 
and peptide boost correspondingly for the control group (Fig3-6A).  
Gene Name mRNA Accession MS Type Frameshift Peptide
GM5464 NM_001034881.3 14_T VTAGYQEEEMEASACGAKGPGLAPWP
PSWLALQDSLLCVVVALADLRRKSCC
SLC35F5 NM_028787.4 10_T LLCVVFGKFVIPRSTFRHTGCHSEYFVF
NFWTFYFNPCSCISE
FAM71A NM_001109759.1 10_A RQKKIRPPKKKRSIQGQRQKPPRDHRC
ECDQLFCFFWWGGNP
CCDC112 NM_001160399.1 11_A RVYSKLENQKAAKEGGNTQVKRKGGH
RASAFSKQSRR
NEMF NM_025441.3 11_A KAKEQAAAEAAEEQAAACRCGSQPVS
LCQCQKIL
ANKRD45 NM_028664.1 18_T FGVNGARRNSRIGEFRKVTIFLTARV
RFC3 NM_027009.2 10_A LKSAPLQATTTLKLIPVMRGTATEL
CALR4 NM_001033226.4 13_T FFSLSLSFLHRWMDKTVGTI
CHD2 NM_001081345.2 10_A VLPNLPSQSSTF
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Tumor volume was measured over time after tumor injection. As shown in Fig3-6B, 
tumor volume was significantly lower in the vaccine group compared to the control group 
from day 11 after the tumor injection and the tumor progression was successfully 
suppressed. Tumor weights were measured at the termination time point. The vaccine 
group had significantly lower tumor weight than the control group as well. These results 
indicated that this 9 microsatellite frameshift peptides pool delayed tumor growth 
significantly in this mouse breast tumor model. 
 
A. 
 
B.                                                                                    C 
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Figure 3-6 Nine Microsatellite frameshift peptides pool vaccination offer protection 
in mouse 4T1 injection model. A. immunization regime, GI1: 1st genetic immunization, 
GI2: 2nd genetic immunization, PB: peptide boost. B. tumor volume of 9MS pool 
vaccination group versus control group, each group had 10 mice. C. tumor weight 
comparison of vaccine group versus control group at termination point.  
 
3.3.4 T Cell and B Cell Immune Responses Were Related to the Tumor Protection 
T cells are known to be important in anti-tumor immune responses. To test whether the 
T-cell immune response was related to the tumor protection in this mouse model, 10 mice 
in the vaccine group were separated into two groups, 5 mice with lowest tumor volume 
were assigned into Low Tumor Volume (LTV) Group and 5 mice with highest tumor 
volume were assigned into High Tumor Volume (HTV) Group. Spleen cells were 
collected at termination point and pooled in the corresponding groups. IFN-gamma 
releasing T cells were counted after spleen cells were stimulated with immunized 
peptides pool. Results showed that the LTV group had many more spots than the HTV 
group. The control group had very few IFN releasing T cells. These data indicate that the 
T-cell response was directly correlated to tumor progression.  
A.                                                        B. 
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Figure 3-7. T cell immune response was related to tumor protection level. A. 10 mice 
in vaccination group were separated in LTV (low tumor volume) and HTV (high tumor 
volume group). B. IFN γ releasing ELISPOT was used to measure T cell immune 
response in LTV, HTV and control group. X axis represents the partial frameshift 
peptides which were used in the immunization, each frameshift antigen was divided into 
17-mer non-overlapped frameshift peptides, CCDC112-1 represented the first peptide 
from CCDC112 frameshift antigen shown in Table 3-1 .   
 
To test whether the B cell immune response was also related to tumor protection, serum 
samples after peptide boost were collected and the antibody response against each 
immunized frameshift peptide was measured by ELISA. Within the vaccine group, 4 
mice had significantly higher antibody responses than the rest of the 6 mice and they 
were assigned to High Antibody Response (HAR) group. The other 6 mice were assigned 
to Low Antibody Response (LAR) group (Fig3-8A). Then we compared tumor volume 
between HAR group and LAR group at the termination point.  Results show that HAR 
group had lower tumor volume than the LAR group (Fig3-8B).  The p-value for one tail 
non-paired T-test was 0.052.  
The CCDC112 frameshift peptide shows positive response in both the T-cell response 
and B-cell response.  The T/B immune response against different portions of CCDC112 
was correlated to tumor protection. Therefore, the CCDC112 frameshift peptides from 
the vaccine pool could have played an important role in the tumor protection. In addition, 
the ANKRD45 frameshift peptide in the T cell response and FAM71A frameshift peptide 
in B cell response were also correlated to tumor protection. 
In summary, both T cell and B cell immune response assay showed that positive immune 
response was important in tumor protection. 
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A. 
 
B. 
 
Figure 3-8. High antibody response (HAR) group had lower but not significant 
tumor volume than Low antibody response (LAR) group. A. Antibody response was 
measured in ELISA at 1:200 dilution, 4 mice in vaccine group were assigned to HAR and 
6 mice were assigned to LAR, antibody response in HAR was significantly higher than 
LAR. B. Tumor volume of HAR and LAR group at termination point, HAR group had 
lower tumor volume but not statistically significant than LAR group, p-value=0.052 with 
one tail non-paired t test. 
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3.4 Discussion 
In this study, we showed that frameshift mutations in mono-repeat microsatellite regions 
could be detected in tumor cDNA samples and the mutations at the mRNA level were 
much more abundant than at the DNA level. Furthermore, we showed in one example of 
Sec62-11A-GFP (GFP in +1 frame), the insertion frameshift protein was successfully 
translated and the mutation rate for this 11A was up to 25.5%. Furthermore, we selected 
the 9 best mouse microsatellite frameshift peptides based on MS repeat length, frameshift 
peptide length and MHC prediction scores to test as a vaccine.  These 9 FSPs were 
pooled and vaccinated in BALB/c mice.   This vaccine delayed tumor growth 
significantly in the mouse 4T1 breast cancer injection model.   The tumor protection was 
also closely related to T cell and B cell immune responses. Our findings prove that 
microsatellite frameshift peptides can offer protection in the mouse tumor model, and 
these FSPs could be a potential antigen source in human cancer vaccine development. 
Microsatellite frameshift mutations were usually used as biomarkers of microsatellite 
instability in MMR deficient cancer patients. Microsatellite regions were very unstable at 
the genomic level and MSI was found in benign lung diseases as well [35, 38]. Other 
reports have provided evidence as well.  For example, microsatellite frameshift mutation 
in the 10A MS region in TGFBR2gene was detected at a lower level at MSI-Negative 
cancer patients [34]. And microsatellite instability events were also found in 
Microsatellite Stable (MSS) cancer patients at a lower level (1,500 1bp instability events 
vs 6,000 in MSI patient) [35].  
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The sequencing results of 20 dog MS candidates and 10 human MS candidates showed 
that MS frameshift mutations at the mRNA level could be easily detected when the MS 
repeat length is 10 or above, and the frameshift mutations were also detected at the 
genomic level when MS repeat length was even longer (repeat length is 15 in dog tumor 
samples and 11 in human breast cancer cell lines). Others report similar findings that long 
microsatellites are extremely mutagenic.  For example, one report showed that the gene 
ACTBP2, with a microsatellite length of 15, was reported to have a mutation rate as high 
as 7*10-3 per locus per generation in humans [45]. Interestingly, genomic mutations of 
microsatellite regions in human cancer cell lines were biased to one nucleotide deletions, 
which was consistent with cancer genome sequencing results from other reports [34]. 
However, more insertions than deletions were in the cDNA sequencing results, which 
might be related to the characteristics of DNA polymerase and RNA polymerase. In 
addition, some MS candidates showed both insertion and deletion events while other 
candidates only had one type of mutation, which could be caused by the detection limit of 
the PCR experiment.  Frameshift mutations of most MS candidates at the genomic level 
included both insertion and deletion events with different frequency (APPENDIX A 
Table A.1). 
The expression of most microsatellite frameshift peptides is usually suppressed [72] with 
only a small percentage over-expressed [34]. The Sec62-11A-GFP (+1 frame) construct 
showed that the mutation rate was as high as 25.5% by counting the GFP+ cells. This 
evidence proved that the NMD system was not very efficient in cell lines at least. 
However, the limitation of the design for determining this number may not represent the 
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real mutation rate in vivo, since the whole GFP sequence was inserted after the 11A 
region instead of the wildtype Sec62 sequence. A small portion of frameshift proteins 
will transform GFP-negative cells to GFP-positive cells and 25.5% is the maximum 
mutation rate possible. The real mutation rate in vivo remains to be investigated.  
To select the best MS FS candidates, MHC I&II predictions were used in combination 
with MS repeat length and FS peptide length. The MHC II prediction was included 
because recent cancer therapy reports showed that the MHC II could be more important 
[74]. Many other criteria like gene/protein function, other characteristics of FSPs were 
not included in our analysis and might provide important information in selecting FS 
antigens. 
In conclusion, we demonstrated that microsatellite frameshift mutations were more 
prevalent at mRNA level and they could offer tumor protection in 4T1 mouse breast 
cancer injection model. Instead of using microsatellite frameshift mutations as 
biomarkers, we proved that MS frameshift peptides could also be great antigen source. 
Thousands of microsatellite regions are available in the human coding sequences, and 
this huge list of potential MS frameshift peptides may boost the cancer vaccine 
development.  
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3.5 Materials and Methods 
3.5.1 cDNA and DNA samples 
   Dog tumor RNA snap samples were collected by Dr. Douglas Thamm at Colorado 
State University. Allprep DNA/RNA mini kit (Qiagen, CA) was used to extract genomic 
DNA and RNA from tumor samples. Tumor samples from Fibrosarcoma, Mast Cell 
Tumor, Osteosarcoma and Hemangiosarcoma were used. Each candidate was sequenced 
in 3 dog tumor samples. 
Human cDNA samples and DNA samples were extracted from 4 human breast cancer 
cell lines: HTB26, CRL2315, CRL2326 and CRL1504. PureLink genomic DNA mini kit 
and PureLink RNA mini kit (Thermo Fisher Scientific, MA) were used to extract DNA 
and RNA. Primers for these 31 candidates are listed in the table S3-1, Phusion High-
Fidelity PCR Kit (New England Biolabs, WA) was used for PCR experiments and the 
standard protocol in the manual was used. 
3.5.2 Peptides Selection 
    BALB/c mouse MHC alleles H2-Kd, Dd, Ld for MHC I prediction and H2-IAd, H2-
IEd for MHC II prediction were used for analysis. The MHC Consensus prediction 
method [59, 60] was used for MHC I and II prediction and the prediction was performed 
with IEDB analysis resource. Peptide sequences were predicted frameshift variant 
peptides from corresponding microsatellite regions. The minimum microsatellite repeat 
length was 10 and minimum FS peptide length was 10 amino acids. Candidates with best 
combined MHC I/II prediction scores were selected (sorted by rank). Peptides were 
synthesized by Sigma. 
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3.5.3 Mouse Vaccination 
    20 naïve Balb/c mice were ordered from Jackson Laboratory (Bar Harbor, ME). 
Genetic immunization was conducted with the Helios Gene Gun System (Life Science 
Research, CA) using published protocols [75-78].  The protocols for making gene 
vaccine bullets was described elsewhere [79]. The first genetic immunization was at 
week 7, each mouse was immunized with two types of bullets and each bullet included 
100ng plasmid, 0.25µg LTA-LTB mix adjuvant and 2.5µg CpG. 4 weeks later, mice were 
vaccinated with the second genetic immunization with 1 µg plasmid and equal amount of 
LTA-LTB, CpG as in the first immunization. The control group was immunized with 
empty plasmid and the same dosage of adjuvants. Peptides were conjugated with KLH 
using Imject Maleimid-Activated mcKLH Spin Kit (Thermo Fisher Scientific, MA) using 
the standard protocol. In the peptide boost, mice in the vaccine group were immunized 
with 15 µg KLH-conjugated peptide pool and 15 µg CpG, and the control group was 
immunized with 15 µg KLH only and same dosage of CpG. 
3.5.4 ELISA 
Mouse serum was collected after peptide boost and the antibody response was measured 
by ELISA. Briefly, 96-well plates (Thermo Fisher Scientific, MA) were coated with 50ul 
10 µg/ml peptide overnight at 4 ºC, then it was blocked with 3% BSA/PBST for 1hr at 37 
ºC. After incubation with sera for 1hr at 37 ºC, the wells were probed with HRP Anti-
mouse goat IgG for 1hr at 37 ºC, then the plate was developed using TMB substrate 
solution and terminated with 0.5N HCl. Plates were assessed using SpectraMax 190 
Molecular Devices at OD 450nm. 
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3.5.5 ELISPOT 
Mouse spleen cells were collected at the termination point.  Spleen cells were pooled into 
three groups: low-tumor volume group (5 mice with lowest tumor volume), high-tumor 
volume group (5 mice with highest tumor volume) and control group. ELISPOT assay 
was used to calculate the frequency of T cells releasing interferon γ. BD Mouse IFN-
gamma ELISPOT set (BD Bioscience, CA) was used and standard protocol of the manual 
was applied. Splenocytes (106 cells per well) were incubated for 48 hours with the 
vaccinate frameshift peptides (20 µg/ml). Concanavalin A (2 µg/ml) was used as a 
positive control. After the assay was completed, the plate was scanned and positive spots 
were counted. 
3.5.6 Cell lines transfection 
Cell lines (HEK293, 4T1, MCF7, HCC1143) were purchased from ATCC and cultured 
with standard protocols. Lipofectamine 2000 Transfection Reagent (Thermo Fisher 
Scientific, MA) was used to transfect plasmids into cell lines for overnight.  Cells were 
then prepared in FACS buffer and quantified with flow cytometry.   
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Supplemental Data 
 
 
Figure S3-1. Frameshift mutations of Sec62-11A in 4T1 mouse breast cancer cell 
line.  
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Figure S3-2 Insertion mutations were detected in Mouse 4T1 cell line.  
M2 represents GFP positive population, 0.32% of cells with SEC62-11A construct were 
GFP positive and only 0.09% of cells in negative control were GFP positive. 
 
 
Figure S3-3 Insertion mutations were not detected in MCF7 and HCC1143 cell lines 
due to low transfection efficiency. There were very few GFP positive cells even in 
SEC62-12A positive controls from MCF7 and HCC1143 cell lines.  
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Figure S3-4 Deletion mutations were very rare in HEK293 cells in SEC62 11A 
microsatellite region. Sec62-10A construct was built for detecting 1A deletion events, 
only 0.45% of cells had deletion mutations and were GFP positive. 
 
Table S3-1 PCR Primers for MS Candidates 
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Candidate ID Forward Primer Reverse Primer
345777443 CGGTGTCACTGCTCTTGG GTAAGAGGTGAGAAGCCG
345777443 GTTACGGGCCGGTGTCAC CCCTTTTTGCTGTGTGGC
345778567 TTGGAGAAAGGCAGGCAG TCCGAGAACTCCGAGATC
345778567 CAGCCGCAGAGAAAGGAG CTGCTCCGAGAACTCCGA
345780774 AGACAGGTGCCCGAGTTG ACCACAACTCCGAGGCCT
345781087 CAGGAATTAGTGCTAGTTGC AGACCAAATTGAGTGTGCC
345782500 AGTGAGCATCTATGTTGTG GGGTCGAACGTGTGTCTC
345783265 GCCTCCTCTTCACACACC GCCACACTGAGACACCAC
345789305 CAACCTCCTGGACTACAAG TGAACACGTACACCAACTG
345790242 GATGAACAACAGTGGCCTGA TGCACTAGTTTCAGGAGATTC
345794507 GATGTCACCCCTCTGCTCT GGATGACCCCTTTGGACA
345794507 GACTTGCTTCGTGGTACTC CATGTCAGCCTCGCTCTC
345796041 AGGAGAGAAGGCAGGAAG AGCTTTTTCCTTGTTATGTG
345796516 CAGTCAGTGTGGTGGGTG GGGAGGAAAGAGTTGGTC
345796542 AAGGGAGTCTGTGGTTGA CAAAGAGGGAAGAGAGTGG
345796987 TCCCTCTTCCTCCACCTC ATCTCCCCCTCTTCTTCAG
345797136 TGCTGATGGGGTATTGAAG TGGTCGGGAAGGTTAGTG
345801690 TTGTTTTGTGATGGAGGC TCTTATAGGATGACTTGTTGG
345802155 GCCTTCAGCCTTGTTGCG GCCGCCACCGTCGCTGCC
345803383 TAGATCTTAGTGACTGTGTTGAC TGGAAGTGTTTGGGATTAG
345807358 CGGAGGAGCAGTACAAAGTG CGGTGGCTGGTCTTGTAC
359322296 AGAGCGCAGAAAGTTCCA CGGAGGCTCTCAGAGGTA
359323976 GCGTTGCGGGCCCCCTCC CGCTGCTCTGCTCTGCTC
ms050 CCTGAGAACACAAACATTGAT TACCAGCACAACACCTCCA
MS053 TGGAGCAGCAGAAAAGGC GTCACGGATGAAGAGGACTT
MS20 GAGCAAGATTCATCAGATAC TCTATCATCATTGTTCATCAG
MS20_cDNA TCCCATGTTCTCCTGCCC TGGGAGAGTCGGCCTGTC
MS226dogc ACCTTCGAGCGTCTCCTAGA CCTTGAACTCTGGGAAGACG
MS24 TCTTGGGTCTCTTGTTCTTCAG TTTTCTTGTCTCATGTGCTGTC
MS24_cDNA TTGGAGGAAGAGCTTAGG CACTAAGGAAATCAAAGGC
MS246dogc TCGCAAAATTTCCAAAAAGG ACAAACTGCATCCTGGGAGT
MS266dogc GACCTGCGCGACTCCTTT GGCGAAGGTAAGGGTGAGG
MS292 AGATGAGGAGGTCGCTGAGA CTGGTGGGTCTCTTGAGGAT
MS305dogc CATGCTCAACCTCCTGGACT AAGAGCTCACCGAAGAACGA
ms355 ACTGGGGGAACTGATTCACA CAAGTAGTCCGCTCGGGTCT
MS361 CGACAAAGTGGTGAAGAAGG ATCAGGGCTGCAAAAACATT
MS434 CCCTACCCTGTCCCCTGT GAAAAAGGGGTCTCGGTCTC
MS434C GAGGCCACCCTGCTCTTG GAGGGACCCCTTCCTCCT
MS443 CCACCCCTGAGATTCTGTCT GGCTCACCATGACAGCATAA
MS443C CCTTCAACCAGAGCTCCCTA GACAGGATGGCAAGGATGAT
MS459 GATCGAATGCTGCCAGAACT TTGGGCCTGAAGATCAGACT
MS470 AAGGACACAGTGACACAGAGG GTGCTGATATGGTGAGGAAG
MS497 TGCGTGGAAGACAAGGAC GACATAATTCTTAGTGGGGTAC
MS500Cdogc GGTCCTCGGGGTCTGTCC CTCTCGTAGGGGAGGGATG
MS500dogc AGACCCGGCTCACTGATACA GAGCACGGGAGAATCAGAAA
MS514dogc GTGTGGGTCTTGAACCGAAG TCCAGCTGCTTATTTTCTTCG
MS683 GCCACCTTCCTTGAAGACAC TCATGACCATCTGTGCCTTC
MS687 GATTTCCACTGGGTGAATGG AGGTGGGAGGGAAAGTGTTC
MS75 TGCCATACCTGTTTTTCCC AGTTATCTCAGGTAGGTGTTGC
MS75_cDNA AAAGGAAAAGCTGAAAGTGGAA GCAACAGCAAGGAGAAGAATAC
MS773 CCAAATAGGAGCCTGCTGTC TCTCCTTCAGAGCCTCGTTC
MS806 GGAAGGTGGCAGAAACAGAG TCTTCATGCTGGGGATAAGG
MS806C GGCTTCACAATTCAGGAAGG AATACAAGCTCATCCGGGACT
MS866 GCGCCTACAGTGCCTACTCT AGAGCCTGATAGGGTGTTGC
MS866C TCCAGCTGGTGGTGTCTGTA AGGAGGATGACTGCACCAAA
MS87 GTGCGCCTACAGTGCCTAC CCTCAAACACTGCATGAAGC
MS87_cDNA TCAAGTTGGCTGCTAGAGTC GTTGGCCAGGAGGATGAC
MS880 GGGCCATCCAGTATATTCCA CGTACAATACACCTGTGGGC
MS93 TGCACAGCACAGAGGTCCT CAGCAAACAGGAATGGGC
MS93_cDNA CCAACTGGTGCTGCAAGG TGGGAGAGTCGGCCTGTC
MS990 CAAATCAGGCCTCACTGTCA TCTGACGACTCAAGCTGTGG
MS990C TGCTCATCAGCACTGTAGGC GCTCCCCACAAAACAATGTC
MS991 GGGGAAGAAGGATGAGGAAC TTAATTCTCCCACGGCAAAG
MS991C GTTGGGGACACTTGCTCAGT TCCGTGTCTGTTTCCTCCTT
79 
 
CHAPTER 4 
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening 
 
4.1 Abstract 
Neo-antigens are important for an anti-tumor immune response based on recent clinical 
studies of immune checkpoint inhibitors (ICI). Besides point mutations at the DNA level, 
we reported recently that frameshift peptides (FSPs) from insertions or deletions 
(INDELs) of microsatellite regions (MSs) and exon mis-splicing FS mutations were 
detected in the mRNA but not in the corresponding DNA (in submission).   These FSPs 
offered protection in mouse tumor models. FSPs shown to be better neo antigens than 
point mutations in the sense of high immunogenicity and low probability of causing 
autoimmunity. However, there was not a general method available to select the best FSPs 
from thousands of potential candidates. Here we provided a platform of using frameshift 
peptide arrays for cancer neo-antigen screening which quantifies the anti-FSP humoral 
immune response in cancer patients. The results of screening 9 types of dog cancer serum 
indicated that cancer serum samples had significantly higher antibody responses against 
FSPs than normal samples.   Common reactive FSPs and cancer specific immune 
responses were both detected. In addition, non-reactive FSPs and the corresponding 
reactive FSPs were selected from the screening. The mouse homolog FSP sequences 
were used for testing in mouse tumor models. Non-reactive FSPs did not offer protection 
in mouse melanoma and breast cancer models while reactive FSP offered protection in 
both models.  The tumor protection was linearly correlated to Ab response to the FSP. 
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These data provide a rationale for using frameshift peptide array as the platform for 
cancer neo-antigen screening. 
4.2 Introduction 
Neoantigens have been shown to be the primary targets of effective, anti-tumor T cells 
during ICI therapy [128,129]. The combination of neo-antigen vaccination with 
immunotherapy has been hypothesized to boost the anti-tumor immune response and 
further improve the treatment benefit and the number of patients responding to treatment 
over ICI alone. Research efforts were directed to searching for genomic mutations and 
massive genome sequencing technology was used for finding personalized point 
mutations [130]. Two initial studies of personalized melanoma cancer vaccines showed 
that this approach induced strong immune responses and reduced recurrence significantly 
[131,132]. Meanwhile, we have proposed an alternative approach for neo-antigen based 
vaccine development. Frameshift mutations based cancer neo-antigens can be better than 
point mutations. Frameshift mutations from microsatellite regions and mis-splicing 
events [80] are much more abundant at the mRNA level as shown in previous chapters 
and they are easily missed in genome sequencing. The feasibility of using FSPs for 
cancer vaccine development was validated using the mouse 4T1 breast cancer model.  
However, with thousands of frameshift candidates available, a general method for 
frameshift antigen screening is necessary. Here we were test whether a frameshift peptide 
array platform is effective or not in neo-antigen screening. 
Frameshift mutations are usually generated from transcription through microsatellites and 
mis-splicing of RNA INDELs. High levels of microsatellite frameshift mutations at the 
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DNA level are observed in mismatch repair deficient cancer patients (MSI), but 
frameshift mutations at mRNA level are rarely investigated. Frameshift mutations are 
much more abundant at the mRNA level due to the 10,000-fold higher error rate from in 
RNA compared to DNA. Chapter 3 showed evidence that FSPs from microsatellite 
regions and mis-splicing events [80] worked independently and they offered tumor 
protection in injectable and transgenic mouse tumor models. 
Here we tested the idea of using a dog frameshift peptide array for neo-antigen screening. 
Mono-repeat microsatellite regions and INDELs were predicted from the dog coding 
DNA sequences, while mis-splicing INDELs were found from human tumor EST 
libraries [81] and dog homolog sequences were used in the FS array. We constructed a 
frameshift peptide array with 830 20-mer peptides representing 377 frameshift antigens. 
116 dog cancer serum samples from 9 major dog cancer types and 52 dog healthy serum 
samples were screened for positive cancer neo-antigens. Common reactive FSPs and non-
reactive FSPs were then tested in the mouse melanoma and breast cancer models.    
4.3 Results 
4.3.1 Dog Frameshift Peptide Array Platform 
830 peptides from 377 predicted frameshift antigens were synthesized commercially and 
printed on NSB9 amine surface slides. The space between each peptide on the NSB9 
surface is 3nm and the NSB9 slide is specifically designed for detecting high affinity 
antibody-peptide binding, as opposed to the immunosignature arrays [133]. Each 
frameshift antigen was represented with 1~4 17-mer non-overlapping frameshift peptides, 
depending on the frameshift peptide length, with a three-amino acid linker (GSC) at C-
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terminus. 328 of these 377 antigens were predicted INDEL frameshift peptides from 
mono-repeat microsatellite regions (minimum repeat length was 7).  The rest of the 49 
frameshift antigens were from mis-splicing events. Mis-splicing frameshift antigens were 
discovered in human tumor EST libraries and the dog homolog peptide sequences were 
then used for the frameshift peptide array. 
Each NSB9 amine slide included 24 peptide arrays.  The principle of this frameshift 
peptide array was like a conventional ELISA but with much higher sensitivity. Cancer 
patient sera was incubated with the frameshift peptide array overnight and fluorescence 
labeled secondary antibody was then applied. The slide was scanned afterwards and the 
anti-frameshift peptide response was transformed to fluorescence intensity (Fig4-1).  
To test this platform, we screened dog cancer serum samples and normal samples on this 
array. 
 
Figure 4-1. The process of measuring anti-FS immune response on frameshift 
peptide array. Cancer patient serum was incubated overnight with frameshift peptide 
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array, fluorescence labeled secondary antibody was then used for transforming antibody-
FSP binding signal to fluorescence, each slide contains 24 arrays. 
 
4.3.2 Screening dog cancer serum samples with frameshift peptide arrays 
9 types dog cancer serum with a total of 116 samples were screened with the dog 
frameshift peptide array. These 9 types of cancer included carcinoma, fibrosarcoma, 
hemangiosarcoma, lymphoma, mast cell tumor, osteosarcoma, histiocytic sarcoma, 
synovial cell sarcoma and malignant histiocytosis. 52 healthy dog serum samples were 
used as control. The sample description is summarized in table S4-1.  
Fluorescence intensity for each array (sample) was normalized to median florescence of 
the array. A cutoff value (Cutoff = Average (Normal) + 2*STD (Normal)) was set for 
each peptide.  Samples with normalized values which were larger than the cutoff were 
counted as positive for this peptide and samples with lower value were negative. The 
distribution of positive samples for each peptide was shown in Figure 4-2.  There were 
fewer positive samples in the normal group generally and these samples were distributed 
relatively evenly. Overall the cancer samples had a significantly higher positive rate than 
normal samples (p-value <0.0001).  About half of the peptides had a similar positive rate 
between cancer group and normal group, while there was small group of FSPs (122 
FSPs) which were highly positive in the cancer group and they had over 10% positive 
rate in the cancer group.  A small group of highly positive rate peptides is listed in Table 
S4-2.  Most of the listed FSPs were from the MS regions with positive rate as high as 
15%~19%. Interestingly, 65 FSPs had no reactivity in the cancer group at all, while these 
non-reactive FSPs had the same reactivity in normal group as other FSPs. These non-
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reactive peptides and common reactive peptides were then tested with mouse tumor 
models. 
Since 9 types of cancer serum were tested with the array, one interesting question would 
be whether cancer type-specific and common anti-FS reactivity could be observed. 
A 
 
B 
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Figure 4-2 Dog cancer serum samples had higher positive rate than normal samples. 
A. Overall distribution of FSP positive samples in cancer group and normal group. 
Reactivity was sorted by descending order of cancer group, each red dot represented one 
positive sample for corresponding FS peptide; B. Positive rate distribution of each FS 
peptide was compared between cancer group and normal group of all FSPs, p-
value<0.0001.   
 
4.3.3 Anti-FS reactivity in different cancer types 
Out of the total 9 cancer types, 6 cancer types had 10 or more samples in the experiment 
(Table S4-1) and these 6 cancer types were used for the cancer type analysis. The positive 
rate distribution of all the FSPs was compared between different cancer types.  
Frameshift mutations in both MS and mis-splicing are depend on the level of RNA 
production. Therefore, the abundance of FSPs was hypothesized to be related to the gene 
expression level.  Therefore, we would assume that the anti-FS immune response of each 
cancer type was related to the expression profile of the origin of the cancer cells and that 
correlations between different cancer types should be relatively low.   
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It turned out that the positive rate correlations between cancer groups were relatively low 
(~0.3), which was consistent with our assumptions. However, common reactivity across 
3~4 cancer types was not rare (Fig4-3A), which indicated a broadly effective cancer 
vaccine would be feasible if we had included enough FSPs to cover different cancer 
types.  
In addition, lymphoma was clustered as a unique group and it had a specific anti-FSP 
profile which was totally different from the other 5 cancer types. The correlations of 
positive rate profile between lymphoma and other cancer types were the lowest and they 
range from 0.15~0.26 (Fig4-3B), which further validated our assumptions since the gene 
expression profile of lymphoma was most different from other 5 cancer types.  
Next step we would like to test whether common reactive FSPs and non-reactive FSPs 
could offer protection in mouse tumor models. 
A 
 
B 
Carcinoma
Fibrosarcoma
Hemangiosarcoma
Lymphoma
Mast Cell Tumor
Osteosarcoma
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Figure 4-3. Positive rate distribution across different cancer types. A. Two-way 
hierarchical clustering of positive rate of each FS peptide by each cancer type. 
Lymphoma was clustered to a unique group and the rest of the five cancer types as one 
group. B. Correlation matrix of positive rates by each cancer group (carcinoma).   
 
4.3.4 Only Reactive FSPs provided protection in mouse tumor models  
As mentioned previously, there was a group of 65 non-reactive FSPs which had 0% 
positive rate in the cancer group, while they had the same reactivity in the non-cancer 
group as other FSPs. At the same time, there were more than 400 FSPs which had more 
reactivity in cancer group than non-cancer group. We hypothesized that the reactive 
peptides in the cancer group should be good vaccine antigens.  There were two reasons 
behind this hypothesis: 1. Recent ICI clinical trials showed that ICIs were very effective 
for late stage microsatellite instability high (MSI-H) patients [66] and the FDA granted 
accelerated approval for using MSI-H as a biomarker for ICI treatments. ICI treatment 
boosted the anti-MS FSPs immune response for reactive FSPs but not for non-reactive 
FSPs in these patients, and the boosted anti-reactive FSPs immune response could kill 
tumor cells effectively; 2. The immunoediting process suppressed the anti-tumor immune 
response and was constantly removing highly immunogenic tumor cells.  The fact that a 
high anti-FSPs immune response could be detected at late stage indicated that it was 
Carcinoma Fibrosarcoma Hemangiosarcoma Lymphoma Mast Cell Tumor Osteosarcoma
Carcinoma 1.0000
Fibrosarcoma 0.2915 1.0000
Hemangiosarcoma 0.3352 0.2220 1.0000
Lymphoma 0.2664 0.2206 0.2603 1.0000
Mast Cell Tumor 0.3982 0.4694 0.3298 0.1528 1.0000
Osteosarcoma 0.3064 0.3337 0.3060 0.1912 0.3607 1.0000
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difficult for tumor cells to get rid of these FSPs.  However, it was not clear to us what the 
antigenic potential of the non-reactive FSPs would be.  
To test this hypothesis concerning the reactive FSPs and gain information on the non-
reactive FSPs, we tested these reactive and non-reactive FSPs in the mouse tumor 
models. Within these 65 non-reactive FSPs, we could find 5 highly conserved mouse 
homolog peptides, 2 mouse MS FSPs which had the same MS regions at the same 
location of the homolog genes, 3 mis-splicing FSPs included 2 peptides resulting from 
mis-splicing events in gene-fusions and 1 from mis-splicing events within the same gene.   
Most frameshift antigens included in the FS array had more than 34 amino acids and they 
were presented with 2 or more non-overlapping 17-mer peptides with a GSC linker.  The 
antibody response for different FSPs from the same FS antigen usually had different 
positive rates in the cancer group.  To make a direct comparison of reactive peptides and 
non-reactive peptides, we searched for reactive FSPs from the same 5 frameshift antigens 
which had one peptide in the non-reactive section. We could find one reactive peptide 
(RAGNFVTVEIQSLVPKK) from the C1S gene which had 7.7% positive rate in cancer 
group, the other FSP (SLPILFGSLRKQYMYSK) from the same antigen had no 
reactivity in cancer group at all (Fig4-4A & Table 4-1). 
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Table 4-1. List of non-reactive peptides and reactive peptide 
 
The mouse melanoma injectable model (B16F10 cell line) and breast cancer injectable 
model (4T1 cell line) were used for testing one reactive peptide and the 5 non-reactive 
peptide pool.  A pool of 13 previously tested frameshift antigens was used as a positive 
control (Table S4-3). All 4 groups received two rounds of genetic immunization with the 
gene gun on the ear and a peptide boost via sub-cutaneous injection. The reactive peptide 
vaccine group had significantly slower tumor growth in the melanoma model than the 
non-reactive FSPs pool group and control group (p-value <0.01). The same results were 
found in the 4T1 breast cancer model - the reactive FSPs offered tumor protection while 
non-reactive FSPs pool did not. The tumor volume between the non-reactive FSPs pool 
group and the control group was not significantly different.  The 13-frameshift antigen 
pool showed a similar level of protection as the reactive FSP group. These data indicated 
that reactive FSPs are better cancer neo-antigens in these two completely different mouse 
cancer models, and it is feasible to select cancer FS antigens for multiple cancer types 
based on the screening results of frameshift peptide array. 
Since these FSPs were first selected based on antibody response against FSPs in dog 
cancer serum samples, one interesting question would be whether we could see 
Gene Name Type Cancer PR Type of FS Dog (Array) Sequence Mouse homolog sequence
PCBP2 Non-reactive 0% MS HDAWQHRIQCRFGCICSGSC HDPWQHRIQCRFGCICS
C1S Non-reactive 0% MS SLPILFGSLRKQYMYSKGSC ALPILIGSPIRQNTCLKMW
FANCI Non-reactive 0% Mis-splicing VSPGVSELRRNSKKYGKGSC LSPGMSELQRNSKHCGK
CCDC13_HHATL Non-reactive 0% Mis-splicing PLVPAAAAWSLCGPLCGGSC PMVPAAAAWPLYGPLCG
DDIT3_MARS Non-reactive 0% Mis-splicing LPLGVSRGFPSAKASCFGSC LPLGVSMGFPSAKANCF
C1S   Reactive 7.76% MS RAGNFVTVEIQSLVPKKGSC RVGSFVTMEIPSPVLKK
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correlation between the antibody response level against the reactive FSP and tumor 
protection level. 
A 
 
B 
 
C 
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Figure 4-4. Reactive FSPs showed protection in the mouse melanoma and breast 
cancer models. A. Reactive and non-reactive FSPs from the same microsatellite 
frameshift antigen of C1S. B. 4 groups of mice were used: the control group was 
immunized with control plasmid, 13FS Pool was used as positive control, non-reactive 
FSPs pool and reactive FSP. All 4 groups received 2 rounds of genetic immunization 
with gene gun and peptide boost via subcutaneous injection. The B16F10 cell line was 
used for the melanoma model and the 4T1 cell line was used for breast cancer model. 
Each group had 10 mice. C. Reactive FSPs slowed tumor growth significantly compared 
to the non-reactive FSPs pool and the control group in the melanoma model (p-value 
<0.01). D. The Reactive FSPs offered tumor protection in mouse breast cancer model as 
well. The tumor volume was significantly lower than control group and non-reactive 
FSPs pool group (p-value<0.05). 
 
4.3.5 Tumor protection was linearly correlated to antibody response 
Reactive FSPs and non-reactive FSPs were selected based on the antibody response 
against the FSPs in dog cancer patients. We hypothesized that these antibody responses 
had anti-tumor activity or it was indirectly related to other anti-tumor mechanisms. To 
test the idea, the antibody response against vaccinated FSPs was measured in the mouse 
breast cancer model and correlated to tumor volume at the endpoint of the experiment. 
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Antibody responses were measured after PB2 (before tumor challenge) and at end point 
(after tumor challenge), both time points were included in the analysis since both 
timepoints could have impact on tumor protection. R-COMP peptide was encoded in a 
plasmid as an internal positive control for genetic immunization.  Antibody response 
against r-COMP was not correlated to tumor volume in any of the 13FS pool group, non-
reactive FSPs pool group or reactive FSP group, which indicated that anti-r-COMP 
immune response was not essential for tumor protection. However, the antibody response 
against 13FS pool and reactive FSP was significantly linearly correlated to tumor volume 
at the end point (p-value=0.03 for 13FS Pool, 0.0024 for Reactive FSP) , while antibody 
response against non-reactive FSPs pool did not correlate to tumor volume (p-
value=0.18). These data confirmed that tumor protection was linearly correlated to 
antibody response against selected reactive FSPs but not non-reactive FSPs, and the 
antibody response against reactive FSPs had tumor-killing activity or it was indirectly 
related to other tumor-killing activity mechanisms. 
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Figure 4-5. Tumor volume was linearly correlated to antibody response against 
vaccinated reactive FSPs in the 4T1 breast cancer model. Tumor volume at the end 
point was used for analysis. The antibody response was measured by ELISA after PB2 
and at the end point. r-COMP peptide was encoded in a plamsid and used as an internal 
control for genetic immunization. The p-value was calculated for linear fit of antibody 
response against tumor volume.  
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4.4 Discussion 
We first provided a platform for screening potential cancer frameshift antigens. Over 300 
frameshift antigens were represented in 830 FSPs on the frameshift peptide array and this 
platform could be easily expanded with more antigens and peptides. We had screened 
116 dog cancer serum samples representing 9 cancer types and 52 normal serum samples. 
Cancer-type specific and common anti-FSP immune responses were observed.  
Lymphoma was clustered as a unique group from the other cancer types. Then we 
selected non-reactive FSPs and corresponding reactive FSP based on the array data. We 
further validated that the selected reactive FSP could offer tumor protection in the mouse 
melanoma and breast cancer models while the non-reactive FSPs could not. We further 
showed that this tumor protection was linearly correlated to the antibody response against 
the immunized reactive FSPs but not the non-reactive FSPs. All these data suggest that 
using a frameshift peptide array for cancer FS antigen screening is feasible and efficient. 
With ~400K potential frameshift antigens at the mRNA level in cancer patients, we can 
only select a small proportion for developing cancer vaccines, usually only 20 candidates 
were included in a single vaccine. Using the frameshift peptide array to screen the B cell 
immune response in cancer patients could be a solution for selecting FS antigens. A 
potential criticism about using positive frameshift antigens discovered from late stage 
cancer patients is based on the logic that the antibody response did not stop the tumor 
progression in the first place.  However, the success of using immune checkpoint 
inhibitors in late stage MSI-H patients confirms that tumor can be killed by activating late 
stage anti-FS immune responses. In the meantime, unlimited rounds of an immunoediting 
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process could mean the surviving positive frameshift antigens are difficult for tumor to 
get rid of.  
Another interesting phenomenon was the group of 65 non-reactive FSPs.  These non-
reactive FSPs are not by chance based on statistical analysis, and most of these non-
reactive FSPs exist in the frameshift antigens which included a reactive FSP counterpart 
as well (Fig4-4A). We hypothesized that the immune reaction to these frameshift 
antigens was not unique to cancer.  It may also occur during acute virus or bacterial 
infections due to disrupted transcriptional and translational systems, but the presentation 
of these frameshift antigens was only transient in these infectious diseases and induced 
non-mature antibody response against these antigens which target the non-reactive FSP 
part of the frameshift antigen. However, when one patient developed a tumor, the 
immune system was constantly trained with these frameshift antigens and the antibody 
response matured towards targeting the reactive FSP in the same antigen.   This maturing 
antibody response had anti-tumor activity, and it could be detected in late stage cancer 
patient from the frameshift peptide array. The non-reactive FSP could not induce an 
effective anti-tumor immune response based on this hypothesis, but the reactive FSPs in 
the same antigen could, which was consistent with our findings (Figure S4-1). This 
hypothesis remains to be validated.  
In conclusion, these data demonstrated that the frameshift peptide array platform could be 
used for cancer neo-antigen screening and reactive FSPs selected from the screening can 
protect mice from tumor challenge while non-reactive FSPs could not. Besides the usage 
of this platform for broadly effective cancer antigen screening, the platform was also 
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expandable and it could be used widely in discovering cancer subtype specific neo-
antigens and personalized frameshift antigens in the future. The array may also have use 
in diagnosis of cancer.  
 
4.5 Materials and Methods 
4.5.1 Frameshift Peptide Array 
830 frameshift peptides were non-overlapping 17-mer peptides with GSC linker at the C-
terminus representing 377 frameshift antigens from mis-splicing events and indels in 
microsatellite regions. All the peptides were synthesized by ChinaPeptides Co. 
(Shanghai, China). The peptide array was printed as previously described by Applied 
Microarrays, Inc (Tempe, AZ) on NSB-9 amine slides from NSB Postech (Seoul, Korea). 
Serum samples were 1:200 diluted with 3% BSA in PBST and 200 µl diluted serum was 
incubated with the peptide array at R.T overnight. After washing with PBST for 3 times, 
the slide was incubated with secondary antibody for 1 hour at R.T. The slide was washed 
and then scanned with the Agilent C Scanner (Agilent Technologies, CA). Fluorescence 
intensity was analyzed with GenePix Pro 6.0 (Axon Instruments, CA). Each array was 
normalized to the median. The positive rate was calculated by setting a cutoff as average 
of normal the samples plus two standard deviation of this average. 
4.5.2 Dog Serum Samples 
116 dog cancer serum samples and 52 non-cancer dog serum samples were collected by 
CSU and detailed cancer type information is in Table S4-1. 
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4.5.3 Genetic Immunization 
The DNA fragments encoding the FS peptides were cloned as a C-terminal fusion into 
the genetic immunization vectors pCMVi-UB and pCMVi-LSrCOMPTT with the Bgl II 
and Hind III sites and mixed in a 1:1 ratio as the genetic vaccine plasmids. Three 
adjuvants were encoded by genetic immunization vectors. LTAB is an abbreviation of 
immunization with a 1:5 ratio by weight of two plasmids, pCMVi-LTA and pCMVi-
LTB, expressing the heat-labile enterotoxins LTA and LTB from Escherichia coli. 
Vectors pCMVi-UB, pCMVi-LSrCOMPTT, pCMVi-LTA (also called pCMVi-LS-LTA-
R192G) and pCMVi-LTB were available from the PSI:Biology-Materials Repository 
DNASU (dnasu.org) at Arizona State University. Additional adjuvants were the poly I:C 
single strand nucleotides from Sigma. The first genetic immunization was at week 7. 
Each mouse was immunized with two sets of bullets and each set included 1 µg plasmid, 
0.25µg LTA-LTB mix adjuvant and 2.5µg CpG. 4 weeks later, mice were vaccinated 
with the second genetic immunization with the same dosage. The control group was 
immunized with empty plasmid and the same dosage of adjuvants. Peptides were 
conjugated with KLH using Imject Maleimid-Activated mcKLH Spin Kit (Thermo Fisher 
Scientific, MA) using a standard protocol. In the peptide boost, mice in the vaccine group 
were immunized with 15 µg KLH-conjugated peptide pool and 15 µg CpG, and the 
control group was immunized with 15 µg KLH only and the same dosage of CpG. 
4.5.4 Gene Gun and Bullets  
The gene gun protocol and bullets for genetic vaccination was described in Chapter 3. 
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4.5.5 Mouse tumor models 
4T1 and B16F10 cell lines were purchased from ATCC and cultured with ATCC 
recommended protocols. Naïve C57BL/6 and BALB/c mice were purchased from 
Jackson Laboratory. 100,000 B16F10 cells were injected into C57BL/6 mice 2 weeks 
after the final peptide boost, and 5,000 4T1 cells were injected into BALB/c mice 2 
weeks after final PB as well. Each group had 10 mice. 
4.5.6 ELISA 
Mouse serum was collected after peptide boost and the antibody response was measured 
by ELISA. Briefly, serum samples were diluted 1:200, 96-well plates (Thermo Fisher 
Scientific, MA) were coated with 50ul 10 µg/ml peptide overnight at 4 ºC, then it was 
blocked with 3% BSA/PBST for 1hr at 37 ºC. After incubation with sera for 1hr at 37 ºC, 
wells were probed with HRP Anti-mouse goat IgG for 1hr at 37 ºC, then the plate was 
developed using TMB substrate solution and terminated with 0.5N HCl. Plates were 
assessed using SpectraMax 190 Molecular Devices at OD 450nm. 
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Supplemental Data 
 
 
Figure S4-1 A simple model to explain why non-reactive FS cannot offer protection 
in mouse tumor models. 
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Table S4-1 Description of Dog tumor samples 
 
Table S4-2 High positive rate peptides in the cancer group 
 
 
 
 
Cancer Type Number Collection Site
Mast Cell Tumor 22 CSU
Fibrosarcoma 20 CSU
Osteosarcoma 20 CSU
Hemangiosarcoma 17 CSU
Carcinoma 13 CSU
Lymphoma 10 CSU
Sarcoma 8 CSU
Malignant histiocytosis 4 CSU
Synovial cell sarcoma 2 CSU
Gene Type Peptide Cancer PR Normal PR
PLEKHM2 MS GSSAVAVGGPTPRIGPTGSC 19.83% 5.77%
DPH2 Mis-splicing LPCSSLTSYWEMLWLWLGSC 18.97% 1.92%
HGS MS KKSTTRIPMWPCTPWRSGSC 18.97% 3.85%
BAX MS HPSWPWTRCLRMRPPRSGSC 18.10% 5.77%
SEC62 MS KFFWMEMRYLCGSMTQFGSC 18.10% 1.92%
SEC62 MS QKKRKKKKDKVETQNRSGSC 17.24% 1.92%
OTUB2 MS QSPASGPGSLSLGWNGSGSC 16.38% 3.85%
CHST2 MS LLPPSGRPPPLQPPPPPGSC 16.38% 1.92%
WNT2B MS PLLPHSPRSSRTPLLPHGSC 16.38% 5.77%
ZNF282 MS RRSATRSRRCAGKWPREGSC 16.38% 1.92%
DCLK2 MS PVPWQAPEAGPPEAGLPGSC 16.38% 1.92%
FAM83H MS RPSRSAGPARCPPCPSAGSC 16.38% 5.77%
POU3F2 MS RLARSPCAPEAPGEPRAGSC 16.38% 5.77%
MSH3 MS LALWECSLPQARLCLIVGSC 15.52% 1.92%
EEF1A Mis-splicing GGHLCSSQRYNGSKICRGSC 15.52% 1.92%
KRT8 Mis-splicing SSMRSCRAWLGSTGMTCGSC 15.52% 1.92%
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Table S4-3 Components of 13 Frameshift Antigen Pool 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name TYPE mRNA Accession MS Type Frameshift Peptide
GM5464 MS NM_001034881.3 14_T VTAGYQEEEMEASACGAKGPGLAPWPPSWLALQDSLLCVVVALADLRRKSCC
SLC35F5 MS NM_028787.4 10_T LLCVVFGKFVIPRSTFRHTGCHSEYFVFNFWTFYFNPCSCISE
FAM71A MS NM_001109759.1 10_A RQKKIRPPKKKRSIQGQRQKPPRDHRCECDQLFCFFWWGGNP
CCDC112 MS NM_001160399.1 11_A RVYSKLENQKAAKEGGNTQVKRKGGHRASAFSKQSRR
NEMF MS NM_025441.3 11_A KAKEQAAAEAAEEQAAACRCGSQPVSLCQCQKIL
ANKRD45 MS NM_028664.1 18_T FGVNGARRNSRIGEFRKVTIFLTARV
RFC3 MS NM_027009.2 10_A LKSAPLQATTTLKLIPVMRGTATEL
CALR4 MS NM_001033226.4 13_T FFSLSLSFLHRWMDKTVGTI
MS255 MS YFSCDKRCIKHYAGNKSLLTFSGY
MS927 MS ICMSPPLLWATLQAPETTSAACKASYRPEGLYL
RBM Mis-splicing GRVIECDVVKGSCQDGEAVHWKSAPGGHRAGDPLTLRAVREGAGM
SLAIN2 (1-78) Mis-splicing IPRMQPQASANHCQLLKVMVA
SMC1A Mis-splicing TAIIGPNGSGCSGVYCHEEPQGEDSSV
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CHAPTER 5 
Safety Evaluation of a Frameshift Antigen Based Prophylactic Cancer Vaccine in 
Dog 
 
5.1 Summary 
5.1.1 Background 
Neoantigens are important for immune checkpoint inhibitor treatment and many ongoing 
clinical trials are testing combinational therapy of ICI and point mutation based on a 
personalized neoantigen cancer vaccine [14, 15]. The genetic vaccine (Oncept) which 
was designed to against tyrosinase was approved to treat dog melanoma [132] [16].  
However, here we propose that a broadly effective frameshift neoantigen based 
prophylactic cancer vaccine could be an alternative path for cancer therapy. This safety 
trial was conducted to evaluate the safety and immune response for a prophylactic cancer 
vaccine composed of 21 frameshift antigens.  
5.1.2 Methods 
Three healthy dogs were enrolled and they received two rounds of genetic immunization 
(300 µg antigen plasmid and 300 µg poly I:C) and a protein boost (300 µg antigen 
peptides and 300 µg poly I:C) intradermally. Blood was collected after each protein boost 
for antibody response assays, and extra blood was collected at week 0,2,4,6,9 for safety 
assessment.  PBMCs were extracted from the blood for T cell assays. 
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5.1.3 Results 
No adverse effects were detected from the vaccination. A strong antibody response was 
detected for all three dogs after the first protein boost but was then suppressed by third 
round of immunization. T cell responses were detected after the first round of 
immunization and then it was strongly boosted by the second immunization. No tumor 
has developed in these three dogs so far and they were still under monitoring. 
5.1.4 Conclusion 
The frameshift antigen based cancer vaccine had no adverse effect and they induced both 
B cell and T cell immune response successfully. 
 
5.2 Introduction 
Cancer vaccine development suffered decades of failures with the conventional self-
antigen based therapeutic vaccine [134,135]. With the success of immune checkpoint 
inhibitor treatments, neo-antigens are found to be the real target of the immune system 
and the number of neo-antigens (mutation load) is strongly correlated to better outcome 
of the ICI treatment [136]. Therefore, the idea of combining a neo-antigen based cancer 
vaccine and ICI treatment looks straightforward and promising [137,138]. 
However, most genomic mutations are patient specific point mutations, therefore, 
effectively making it impossible to develop a broadly effective neoantigen vaccine based 
on these genomic mutations. The personalized cancer vaccine idea was developed under 
these circumstances in response to this realization.  However, this approach would 
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involve tremendous cost and the long development cycle may scare away some patients 
from using this vaccine. 
We came up with a new idea of searching for frameshift neoantigens at the mRNA level 
instead of the genomic level.  This approach has the advantages of being more 
immunogenic, more error prone and much more abundant. Three sources of frameshift 
neoantigens are available: alternate splicing frameshift variants; gene fusion frameshift 
variants and microsatellite indel induced frameshift variants. Note that we use the term 
variants because these are not heritable mutations in the DNA. The feasibility of using 
such frameshift antigens was described in previous chapters. 
In this study, we selected 21 dog frameshift antigens from miss-splicing, trans-splicing 
and microsatellite regions. The vaccine was delivered intradermally with genetic 
immunization and protein boosts.  Blood was collected at multiple time points for 
immune response and safety assessments. 
 
5.3 Results 
5.3.1 Dog Prophylactic Cancer Vaccine Components 
Frameshift antigens from trans-splicing and miss-splicing were predicted from human 
tumor EST libraries.  Dog homologs of human frameshift antigens were used in the ‘dog 
version’ cancer vaccine. While microsatellite FS were directly predicted from dog homo-
polymer regions in coding sequences which had at least 7 homo-nucleotide repeats. Only 
FS antigens with human homologs were selected to provide for a human cancer vaccine 
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trial that could be conducted with highly conserved vaccine components if the dog 
efficacy vaccine trial was proved to be successful. Primers for most FS antigens were 
designed and FS antigens were validated by PCR in the dog tumor cDNA samples.  
A dog frameshift peptide array was made to screen for serum positive FS antigens in 7 
dog cancer types as described in chapter 4. Some FS antigens were then tested in the 
mouse tumor breast cancer (4T1) and melanoma (B16F10) injection models and showed 
protection. A detailed selection protocol is described in Fig5-1. 
21 frameshift antigens (Table5-1) were selected as the best vaccine candidates which met 
most criteria described in the protocol (Fig5-1). The vaccine included all three frameshift 
antigen sources and most frameshift candidates had a peptide length of 20 amino acids to 
100 amino acids. Because of their length, frameshift antigens are presumed to include 
multiple good MHC I and MHC II epitopes.   Unfortunately, MHC prediction was not 
used as criterion since there is not an MHC prediction algorithm for dogs. 
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Figure 5-1. Protocol for selecting frameshift antigens.  
Five criteria were used in selecting FS antigens for the dog cancer vaccine safety trial: 
these antigens were predicted from tumor EST libraries for mis-splicing antigens; the 
antigens had human homologs so the vaccine could be transformed into a human cancer 
vaccines; most frameshift antigens were confirmed by PCR; most FS antigens were 
positive in dog cancer serum samples from the frameshift peptide array screening; some 
FS antigens were tested in mouse models and they offered protection in injection tumor 
models. 
 
The vaccine schedule included two rounds of genetic immunization and protein boost 
delivered intradermally (Fig5-2). A pre-bleed was taken before immunization, 2nd bleed 
and 3rd bleeds were taken after each protein boost, extra bleeds at week 2, 4, 9 were taken 
for safety measurements.   
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Table 5-1 Summary of dog prophylactic cancer vaccine candidates. Sequence 
confirmed: for miss-splicing and trans-splicing candidates, the predicted FS transcripts 
were detected in dog tumor cDNA. For microsatellite candidates, the predicted MS were 
confirmed in the coding region of the dog genes. 
 
 
 
Figure 5-2. Immunization and blood collection schedule. GI: genetic immunization; 
PB: protein boost 
Sequence Positive on Protection in Human Dog Dog 
Name FS type FS peptide size comfirmed FS array mouse model Homolog Vaccine 1 Vaccine 2
SMC1A miss-splicing 27     
SLAIN2 miss-splicing 21     
RBM14-RBM4 trans-splicing 45    
ELAC1-SMAD4 trans-splicing 44    
CCDC13-HHATL trans-splicing 83    
C4H5orf22 microsatellite 30     
EFHC2 microsatellite 36     
OPHN1 microsatellite 80     
EIF2B3 microsatellite 56    
SLC44A4 microsatellite 77   
ZDHHC17 miss-splicing 21    
SLC35F5 microsatellite 23    
CHD2 microsatellite 12    
CEP290 microsatellite 25    
ARV1 microsatellite 28    
PLEKHM2 microsatellite 29    
SWAP70 minus microsatellite 30    
ZC3HAV1 microsatellite 47    
HNRNPH1 microsatellite 39    
GAP43 microsatellite 32    
SLITRK3 microsatellite 102   
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5.3.2 There were no adverse events from this dog cancer vaccine 
Blood tests were conducted at weeks 0, 2, 4, 6, 9 for assessing adverse effects of the 
cancer vaccine. Overall there were no adverse effects from the vaccination. No abnormal 
blood analyte concentration was detected at week 2 compared to week 0. At week 4, one 
dog showed only one percent higher red blood cells (56%) than normal range 
(40%~55%) and the percentage soon went back to normal level on week 6 and week 9 
(Table S5-2). Similar results were found in neutrophil counts, monocyte counts and 
magnesium concentration.  One dog had slightly higher or lower counts/concentration 
than the normal range in one time point. The counts/concentration then quickly went back 
to normal range (Table S5-1 to S5-3).  
Overall, the FS antigen based prophylactic cancer vaccine was proved to be very safe. 
Table 5-2 Vaccine-related abnormal blood analyte concentration in 3 dogs 
Analyte Week 2 Week 4 Week 6 Week 9 
Hb 0 0 0 0 
Hct 0 1 0 0 
RBC 0 0 0 0 
MCV 0 0 0 0 
RDW 0 0 0 0 
MCHC 0 0 0 0 
CHCM 0 0 0 0 
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Platelets 0 0 0 0 
MPV 0 0 0 0 
WBC 0 0 0 0 
Neutrophil 0 1 0 0 
Lymph 0 0 0 0 
Mono 0 0 0 1 
Eo 0 0 0 0 
Glucose 0 0 0 0 
BUN 0 0 0 0 
Creatinine 0 0 0 0 
Phosphorous 0 0 0 0 
Calcium 0 0 0 0 
Magnesium 0 0 0 1 
Total Protein 0 0 0 0 
Albumin 0 0 0 0 
Globulin 0 0 0 0 
A/G Ratio 0 0 0 0 
Cholesterol 0 0 0 0 
CK 0 0 0 0 
Bilirubin 0 0 0 0 
ALP 0 0 0 0 
ALT 0 0 0 0 
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AST 0 0 0 0 
GGT 0 0 0 0 
Sodium 0 0 0 0 
Potassium 0 0 0 0 
Chloride 0 0 0 0 
Bicarbonate 0 0 0 0 
Anion Gap 0 0 0 0 
Calc Osmolality 0 0 0 0 
PT 0 0 0 0 
PTT 0 0 0 0 
FDP 0 0 0 0 
 
5.3.3 Vaccinated dogs showed positive Antibody Response 
Blood was collected at week 0 (pre-bleed), week 6 (protein boost 1) and week 10 (protein 
boost 2) as shown in Figure 5-2 for antibody response assessment. Antibody response 
was measured for the 21-antigen pool and individual antigens in these three time points.  
Antibody response against 21-antigen pool was significantly higher after protein boost 1 
compared to pre-bleed (p value is 0.02 with one tail student t-test). However, the 
antibody response was then suppressed after protein boost 2 (Fig5-3A), which was 
possibly caused by over-immunization for certain candidates. 
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Antibody response against individual antigens was also assessed. Three categories of 
antigens were found from the antibody response pattern:  
Ab response against 4 antigens (SLAIN2, GAP43, SLC44A4, SMC1A) was significantly 
increased from pre-bleed to PB1, but was then suppressed by PB2 (Fig5-3B, same pattern 
as the 21-antigen pool Ab response);   
Ab response against another 4 antigens (CHD2, ZDHHC17, C4H5of22, ZC3HAV1) was 
not detected after PB1 but was then detected after PB2 (Fig5-3C), which indicated two 
rounds of immunization was necessary for these 4 antigens;  
Ab response against the rest of the 13 antigens was not significant different between pre-
bleed, PB1 and PB2, which indicated these antigens were outcompeted or they were not 
immunogenic at the antibody level. 
 
5.3.4 Each dog had a unique antibody response profile after each vaccination 
The immunosignature assay was also conducted to measure the antibody response in 
these three dogs. Serum of the three dogs with 4-time points was applied on the CIM 
330K non-natural random peptides array. Unsupervised hierarchal classification of the 12 
samples showed that pre-bleed, PB1, PB2 and endpoint of each dog were classified as its 
own group and not mixed with other sample sets, which indicates each dog had its unique 
immune signature regardless of the immunization (Fig5-4A).  
The analysis of 4-time points of each dog indicated that the antibody profile varied at 
each time point. Dog P had a large portion of the active antibody immune response after 
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PB1 (PVY3-2), but only a small percentage of the antibody response remained at high 
level after PB2 (PVY3-3). A totally different set of peptides showed positive response 
after PB2 (Fig5-4B).  These data showed that the antibody profile of each dog was not 
very stable and it varied a lot with each immunization. The same phenomenon was found 
in dog Q and dog U as well (Fig5-4C, D). The results were consistent with the ELISA 
analysis in Fig 5-3, which also showed that different antigens were activated or 
suppressed with the two rounds of protein boost. 
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Figure 5-3. Antibody Response analysis of the vaccine. A. Antibody response against 
the 21 antigen pools in naïve samples, samples after protein boost 1 and protein boost 2. 
B. Antibody response against 4 individual antigens was detected in protein boost 1 but 
suppressed in protein boost 2. C. Antibody against 4 individual antigens was detected 
after protein boost 2. 
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Figure 5-4. Immunosignature assay of the vaccine. A. Unsupervised hierarchal 
classification (Ward method) of the 3 dogs with 4-time points (1: pre-bleed; 2: PB1; 3: 
PB2; 4: End timepoint of the trial); B~D. Same analysis as in A was performed for 
individual Dog P, Dog Q and Dog U. 
 
5.3.5 Vaccinated dogs showed positive T cell immune responses 
PBMCs were extracted from blood collected at pre-bleed, PB1 and PB2. IFN γ ELISPOT 
assays and intracellular staining were used to measure the T cell response against the 
immunized antigens.  
Pre-bleed PBMCs had very low T cell responses with 48hr KLH stimulation or the 21-
antigen pool stimulation.  IFN γ secreting T cells could be rarely detected (Fig5-5A). 
With two rounds of immunization, IFN γ secreting T cells increased dramatically from 
pre-bleed to PB1 and from PB1 to PB2. Two immunizations were necessary for eliciting 
high T cell responses. Quantification of the results are summarized in Fig5-5B. PBMCs 
from PB1 and PB2 had significantly more IFN γ secreting T cells compared to pre-bleed 
(p-value <0.01). Interestingly, KLH stimulation or the 21-antigen pool stimulation 
induced about the same amount of IFN γ secreting T cells after PB1, but the 21-antigen 
pool stimulation induced significantly more active T cells than KLH after PB2, which 
indicated T cells were directed to target our vaccinated antigens after PB2 and not KLH. 
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Figure 5-5. T-cell response analysis of the vaccine. A. IFN γ releasing assay graph of 3 
dogs in the safety trial. B. Summary statistics of the IFN γ releasing spots.  
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A T cell intracellular staining assay was also conducted to measure the T cell response. 
PBMCs after PB2 were used for the assay. Since there was not a very clear lymphocytes 
population in the staining, all the PBMCs were used for the analysis (FigS5-1). As shown 
in Fig5-6A, all three dogs had more CD4+ IFN γ secreting T cells and more CD8+ IFN γ 
secreting T cells than unstimulated control when stimulated with the 21 antigen pools. 
Quantification of the results showed that there were slightly more active IFN γ secreting 
CD8+ cells (~10%) than CD4+ cells (7%~8%). KLH stimulation and 21 antigen pool 
stimulation had about the same percentage of active T cells, while positive control (PMA 
+ Ionomycin) induced more active T cells. 
A 
 
B                                                                C 
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Figure 5-6. IFN γ secreting T cell subtype analysis. A. IFN γ releasing CD4 and CD8 T 
cells with the 21-antigen pool stimulation. Unstimulated T cells were used as control. B. 
Quantification of CD4 and CD8 IFN γ secreting T cells with stimulation of the 21-
antigen pool, KLH and Positive control (PMA+Ionomycin). 
 
Both the ELISPOT assay and intracellular T cell staining assay showed there was a 
positive T cell response after two rounds of immunization, which indicates that the 
vaccine was not only safe but also could induce strong B cell and T cell responses. 
 
5.4 Discussion 
This safety trial of the 21-frameshift antigen pool, formulated for a dog prophylactic 
cancer vaccine, demonstrated that the vaccine was safe with no adverse effects and it 
could induce strong B cell and T cell response.  
The idea of using frameshift antigens as a broadly effective prophylactic cancer vaccine 
source could reduce the vaccine development cost significantly and may revolutionize the 
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cancer therapy field, but it has not been explored. Here we demonstrated that this 
approach was safe and applicable. 
We recognize that intradermal injection was not the optimal delivery method for the 
genetic vaccine. Vaccination with gene gun could induce stronger T cell response [139]. 
Furthermore, with the development of virus-based vaccination [141], RNA liposome 
vaccination [140] and other techniques [142], effective immune responses from the 
vaccine could be enhanced dramatically.  
In addition, the key step of developing a successful cancer vaccine was the antigen 
selection process. With our current strategy, antibody response against individual 
antigens in the 21 antigens pool showed that only a small portion of our antigens (8 out of 
21) induced B cell response successfully after PB1 and PB2. This could be due to antigen 
competition and over immunization problems. There is still huge space for improvement 
of the vaccine components and vaccination protocol. A second version of the dog cancer 
vaccine was developed and discussed in Appendix B. 
In summary, the data in this study suggested that a frameshift antigens pool based 
prophylactic cancer vaccine was very safe and it induced strong B cell and T cell 
response. 
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5.5 Methods and Materials 
5.5.1 Dogs enrolled in the safety trial 
Three dogs (Beagles) were purchased and used in the safety trial. There were named with 
Dog PVY3, QOD4, UYX3 in the paper. 
5.5.2 Vaccination Schedule 
GI: DNA fragments encoding each antigen were cloned into the plasmids (PCMVi-UB and 
PCMVi-LS-rCOM-TT) and the two plasmids were mixed equally as an antigen 
composition for the GI. Antigens were equally mixed according Table 5-1 for each 
candidate. One GI is composed by 300ug mixed antigens and 300ug Poly I:C in 500ul PBS. 
The vaccine was delivered intradermally.    
PI: Overlapped peptides were synthesized for each antigen. Synthesized peptides for the 
same antigen were equally mixed as a pool and conjugated with KLH 1:1 by weight as an 
antigen composition for the PI. Each peptide conjugated KLH were equally mixed 
according the Table 5-1 for each candidate. One PI was composed by 300ug mixed peptide-
KLH and 300ug Poly I:C in 500ul PBS. The vaccine was delivered intradermally. 
5.5.3 Analysis of antibody response by ELISA 
         ELISA was used to detect specific antibody response against immunized peptides. 
Multiple ELISA experiments in the paper were performed with the same protocol as in 
previous chapters. Briefly, 96-well plates (Thermo Fisher Scientific, Waltham, MA) were 
coated with 50ul 10 µg/ml peptide or KLH overnight at 4 ºC, then it was blocked with 
3% BSA/PBST for 1hr at 37 ºC. After incubation with sera for 1hr at 37 ºC, wells were 
probed with HRP Anti-dog IgG for 1hr at 37 ºC, then the plate was developed using TMB 
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substrate solution and terminated with 0.5N HCl. Plates were assessed using SpectraMax 
190 Molecular Devices at OD 450nm. 
5.5.4 Immunosignaturing Assay 
The CIM 330K peptide array was used for immunosignature assays. A detailed protocol 
has been published previously [82]. Basically, microarrays were pre-washed in 10% 
acetonitrile, 1% BSA to remove unbound peptides. Then the slide was blocked with 1*PBS, 
3%BSA, 0.05% Tween 20, 0.014% β-mercaptohexanol for 1hr at RT. After that the slide 
was loaded into multi-well array gasket, serum samples were diluted 1:5000 in 1*PBS, 
3%BSA, 0.05% Tween 20 (PBST) dilution buffer. Serum samples were incubated for 1hr 
at RT with BioTek 405TS plate washer. Anti-dog IgG secondary antibody with conjugated 
dye was added to serum samples at final concentration of 5 nM. Unbound secondary 
antibody was washed away with PBST and water. Arrays were then centrifuged, dried and 
scanned.  GenePix 8.0 (Molecular Devices, CA) was used for analyzing scanned picture. 
Each array was normalized to median and JMP Pro (SAS institute, CA) was used for non-
supervised clustering.   
5.5.5 IFN-gamma ELISPOT Assay 
          The ELISPOT assay was used to calculate frequency of cells releasing interferon 
gamma. A PVDF plate was pre-coated with canine anti-IFN γ monoclonal antibody 
overnight at 4 ºC, then the plate was blocked with blocking buffer (1%BSA, 5%Sucrose in 
PBS) for 2hr at room temperature. After that, 0.5 million dog PBMC cells were co-
incubated with 20ug/ml FS peptides or 1ug/ml Ionomycin and 50ng/ml PMA for 48hrs in 
a humidified 37 ºC CO2 incubator. The wells were then aspirated and washed with wash 
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buffer (0.05%Tween-20 in PBS), detection antibody was added to each well and incubated 
overnight at 4 ºC. After washing wells 3 times with wash buffer, Streptavidin-AP was 
added to each well and incubated for 2hr at room temperature, then plate was developed 
with substrate solution (BCIP/NBT) in dark. The plate was scanned and then positive spots 
were counted by software.  
5.5.6 T-cell in vitro staining Assay 
          Dog PBMCs were collected at weeks 0, 4 and 10 and stored in liquid nitrogen. Cells 
were recovered from liquid nitrogen and cultured in RMPI1640 complete media (1million 
cells/200µl) in 96 well plates.  Dog vaccinated peptides pool (20 µg/ml) were added to the 
media and PMA plus Ionomycin was used as positive control.  4 µl of BD Golgistop was 
added for every 6ml of media at the same time. After 7hr incubation, cells were washed 
and stained with anti-CD4 and anti-CD8 antibodies for 30 mins at 4°C, then cells were 
fixed in Fixation/Permeabilization solution for 20 mins at 4°C, after that, cells were washed 
and stained with anti- IFN γ antibody for 30 mins in the dark at 4°C. Cells were then 
suspended in staining buffer and analyzed in flow cytometer. 
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Supplemental Data  
 
Table S5-1. Blood work for dog PVY3 
Dog PVY3 
       
Analyte Normal 
Range 
Units Week 0 Week 2 Week 4 Week 6 Week 9 
Hb 13.0 - 
20.0 
g/dL 17.7 17.1 17.8 17.5 17.4 
Hct 40 - 55 % 52 49 51 51 51 
RBC 5.5 - 8.5 10^6/u
L 
8.01 7.72 7.95 7.91 7.92 
MCV 62 - 74 fL 65 64 64 65 65 
RDW 12.0 - 
15.0 
% 12.6 12.1 12.1 12.5 12.4 
MCHC 33 - 36 g/dL 34 35 35 34 34 
CHCM 33 - 36 g/dL 34 35 35 34 33 
Platelets 200 - 
500 
10^3/u
L 
366 352 382 366 340 
MPV 7.5 - 
14.6 
fL 8.7 8.8 8.7 8 8.6 
WBC 4.5 - 
15.0 
10^3/u
L 
11.9 10 14.8 10.7 9.2 
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Neutrophil 2.6 - 11 10^3/u
L 
6.8 6.4 11.4 7.5 6.1 
Lymph 1 - 4.8 10^3/u
L 
4.9 3 3.1 2.5 2.3 
Mono 0.2 - 1.0 10^3/u
L 
0.2 0.4 0.3 0.4 0.6 
Eo 0.1 - 1.2 10^3/u
L 
0 0.2 0 0.3 0.3 
        
Glucose 70 - 115 mg/dL 51 87 77 92 80 
BUN 7.0 - 30 mg/dL 24 11 22 11 14 
Creatinine 0.6 - 1.6 mg/dL 1 0.7 1.1 0.7 0.7 
Phosphoro
us 
2.5 - 6.0 mg/dL 5.2 3.5 4.9 3.7 4.3 
Calcium 9.0 - 
11.5 
mg/dL 10.5 10.5 10.3 10.4 9.9 
Magnesiu
m 
1.8 - 2.4 mg/dL 2 1.8 2 1.8 1.8 
Total 
Protein 
5.0 - 7.0 g/dL 6.1 6.3 6.1 6.2 6 
Albumin 3.0 - 4.3 g/dL 3.8 3.9 3.7 3.7 3.8 
Globulin 1.5 - 3.2 g/dL 2.3 2.4 2.4 2.5 2.2 
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A/G Ratio 0.9 - 2.4 RATI
O 
1.7 1.6 1.5 1.5 1.7 
Cholesterol 130 - 
300 
mg/dL 186 177 189 168 198 
CK 50 - 275 IU/L 324 189 260 176 239 
Bilirubin 0.0 - 0.2 mg/dL 0 0.1 0 0.1 0.1 
ALP 15 -140 IU/L 32 32 36 30 32 
ALT 10.0 - 
90 
IU/L 37 37 31 33 32 
AST 15 - 45 IU/L 33 29 30 31 30 
GGT 0.0 - 9 IU/L 1 3 0 3 3 
Sodium 142 - 
152 
mEq/L 147 147 146 148 148 
Potassium 3.9 -5.4 mEq/L 5.25 4.06 4.58 4.19 4.06 
Chloride 108 - 
118 
mEq/L 110 112 109.9 111.9 111.8 
Bicarbonat
e 
15 - 25 mEq/L 19.5 18.4 18.9 21 30.7 
Anion Gap 12.0 - 
23 
nmol/L 23 21 22 19 20 
Calc 
Osmolality 
260 - 
290 
mOsm/
kg 
295 290 292 292 292 
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PT 7.1 - 9.1 Sec 7.7 7.5 6.9 7.8 7.5 
PTT 9.4 - 
15.0 
Sec 10.3 11.1 10.8 10.2 10.9 
FDP 0 - 4 ug/mL NP NP Neg Neg Neg 
 
Table S5-2. Blood work for dog QOD4 
QDD4 
       
Analyte Normal 
Range 
Units Week 0 Week 2 Week 4 Week 6 Week 9 
Hb 13.0 - 
20.0 
g/dL 17.8 17.9 19.5 18.6 18.2 
Hct 40 - 55 % 50 50 56 54 53 
RBC 5.5 - 8.5 10^6/u
L 
7.18 7.24 7.99 8.07 7.62 
MCV 62 - 74 fL 70 69 70 67 69 
RDW 12.0 - 
15.0 
% 13 12.8 13.3 13.3 13.3 
MCHC 33 - 36 g/dL 35 36 35 34 34 
CHCM 33 - 36 g/dL 35 36 36 34 35 
Platelets 200 - 
500 
10^3/u
L 
254 232 284 312 242 
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MPV 7.5 - 
14.6 
fL 8.9 8.6 10.1 8.8 8.8 
WBC 4.5 - 
15.0 
10^3/u
L 
8.4 7.4 9.1 9 9.3 
Neutrophil 2.6 - 11 10^3/u
L 
5.4 4.8 6.6 5.9 6.5 
Lymph 1 - 4.8 10^3/u
L 
1.9 1.9 2 2.3 2.4 
Mono 0.2 - 1.0 10^3/u
L 
1.1 0.6 0.5 0.5 0.3 
Eo 0.1 - 1.2 10^3/u
L 
0 0.1 0 0.3 0.1 
        
Glucose 70 - 115 mg/dL 98 85 95 84 92 
BUN 7.0 - 30 mg/dL 23 14 21 15 20 
Creatinine 0.6 - 1.6 mg/dL 1 0.9 1.1 0.8 0.9 
Phosphoro
us 
2.5 - 6.0 mg/dL 5.3 3.9 5.7 4.3 4.4 
Calcium 9.0 - 
11.5 
mg/dL 10.1 10.3 10.1 10.5 9.6 
Magnesiu
m 
1.8 - 2.4 mg/dL 1.9 1.9 2 2.1 1.7 
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Total 
Protein 
5.0 - 7.0 g/dL 5.6 5.9 5.7 6 5.5 
Albumin 3.0 - 4.3 g/dL 3.6 3.7 3.7 3.9 3.4 
Globulin 1.5 - 3.2 g/dL 2 2.2 2 2.1 2.1 
A/G Ratio 0.9 - 2.4 RATI
O 
1.8 1.7 1.9 1.9 1.6 
Cholesterol 130 - 
300 
mg/dL 203 194 219 244 214 
CK 50 - 275 IU/L 188 190 175 101 204 
Bilirubin 0.0 - 0.2 mg/dL 0 0.1 0.1 0.1 0.1 
ALP 15 -140 IU/L 39 34 42 27 44 
ALT 10.0 - 
90 
IU/L 46 41 37 28 28 
AST 15 - 45 IU/L 25 27 28 26 29 
GGT 0.0 - 9 IU/L 0 0 0 3 1 
Sodium 142 - 
152 
mEq/L 146 146 147 148 146 
Potassium 3.9 -5.4 mEq/L 4.99 4.25 4.55 4.69 4.36 
Chloride 108 - 
118 
mEq/L 112.6 112.7 108.6 111.5 111.5 
Bicarbonat
e 
15 - 25 mEq/L 20.8 17.2 20 21.7 19.1 
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Anion Gap 12.0 - 
23 
nmol/L 18 20 23 19 20 
Calc 
Osmolality 
260 - 
290 
mOsm/
kg 
295 289 295 294 292 
        
PT 7.1 - 9.1 Sec 7.3 NA 7.4 7.9 NP 
PTT 9.4 - 
15.0 
Sec 10.7 NA 10.2 10.6 NP 
FDP 0 - 4 mg/dL NP NP Neg Neg NP 
 
Table S5-3. Blood work for dog UYX3 
UYX3 
       
Analyte Normal 
Range 
Units Week 0 Week 2 Week 4 Week 6 Week 9 
Hb 13.0 - 
20.0 
g/dL 18.2 17.8 18.8 NP 18.6 
Hct 40 - 55 % 52 51 64 NP 55 
RBC 5.5 - 8.5 10^6/u
L 
7.77 7.62 8.11 NP 8.27 
MCV 62 - 74 fL 67 67 66 NP 67 
RDW 12.0 - 
15.0 
% 13.1 13 12.9 NP 13.3 
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MCHC 33 - 36 g/dL 35 35 35 NP 34 
CHCM 33 - 36 g/dL 35 35 36 NP 34 
Platelets 200 - 
500 
10^3/u
L 
361 318 32 NP 317 
MPV 7.5 - 
14.6 
fL 9.5 9 9.9 NP 9.1 
WBC 4.5 - 
15.0 
10^3/u
L 
9.5 7.9 10.1 NP 8.4 
Neutrophil 2.6 - 11 10^3/u
L 
6.5 4.7 5.6 NP 5.8 
Lymph 1 - 4.8 10^3/u
L 
2.7 2.1 3.9 NP 2.5 
Mono 0.2 - 1.0 10^3/u
L 
0.2 0.9 0.6 NP 0.1 
Eo 0.1 - 1.2 10^3/u
L 
0.2 0.2 0 NP 0 
        
Glucose 70 - 115 mg/dL 72 90 82 NP 79 
BUN 7.0 - 30 mg/dL 23 22 27 NP 17 
Creatinine 0.6 - 1.6 mg/dL 1 0.9 1.1 NP 0.8 
Phosphoro
us 
2.5 - 6.0 mg/dL 4.7 5.6 5.6 NP 5 
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Calcium 9.0 - 
11.5 
mg/dL 10.4 10.4 10.3 NP 10 
Magnesiu
m 
1.8 - 2.4 mg/dL 2.1 2.1 2 NP 2 
Total 
Protein 
5.0 - 7.0 g/dL 6.1 6 5.9 NP 5.9 
Albumin 3.0 - 4.3 g/dL 3.9 3.8 3.8 NP 3.8 
Globulin 1.5 - 3.2 g/dL 2.2 2.2 2.1 NP 2.1 
A/G Ratio 0.9 - 2.4 RATI
O 
1.8 1.7 1.8 NP 1.8 
Cholesterol 130 - 
300 
mg/dL 237 234 254 NP 227 
CK 50 - 275 IU/L 130 114 122 NP 113 
Bilirubin 0.0 - 0.2 mg/dL 0.1 0.1 0.1 NP 0.1 
ALP 15 -140 IU/L 30 28 28 NP 28 
ALT 10.0 - 
90 
IU/L 30 29 289 NP 27 
AST 15 - 45 IU/L 28 26 23 NP 28 
GGT 0.0 - 9 IU/L 2 2 0 NP 3 
Sodium 142 - 
152 
mEq/L 147 145 147 NP 149 
Potassium 3.9 -5.4 mEq/L 5.14 4.57 4.99 NP 4.79 
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Chloride 108 - 
118 
mEq/L 110.8 113.3 110.9 NP 112.9 
Bicarbonat
e 
15 - 25 mEq/L 19.8 15.7 19.4 NP 18.9 
Anion Gap 12.0 - 
23 
nmol/L 22 21 22 NP 22 
Calc 
Osmolality 
260 - 
290 
mOsm/
kg 
295 291 297 NP 297 
        
PT 7.1 - 9.1 Sec 7.2 7.8 7.8 NP 7.8 
PTT 9.4 - 
15.0 
Sec 10.3 11 9.7 NP 10.5 
FDP 
  
NP NP Neg NP Neg 
                                                                          
 
Figure S5-1. Gating of T cells.  
132 
 
Since there was not a clear lymphocytes population, all cells were used for analysis. 
 
 
 
Figure S5-2. Positive Antibody Response coverage of the Dog Cancer Vaccine in 
Dog Cancer Samples.   
Total coverage is 84.5% in all the 116 dog cancer samples. 
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Table S5-4 Dog Cancer Vaccine Antibody Response Coverage by cancer type 
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Chapter 6 
Human Exon Junction Frameshift Peptide Database and its Applications 
 
6.1 Abstract 
Frameshift (FS) mutations from microsatellite regions and mis-splicing events were 
detected frequently in tumor mRNA. In addition, FS mutation load was also reported to 
be a better biomarker of beneficial immune checkpoint inhibitor treatment response than 
total mutation load [18].  However, FS peptides from mis-splicing have not been 
systematically investigated. Here I created a human an exon junction FS database which 
covered all possible FS peptides from human exon junctions (as well as MS FSs) and 
summarized the characteristics for the database. Furthermore, I provided an indirect 
method to find potential FS antigens from cancer immunosignature data with this FS 
database. In the meantime, a new platform to assay unbiasedly the anti-FS humoral 
immune response - the human 400K frameshift peptide array which covers all possible 
FS peptides was developed. 
6.2 Introduction  
Alternative splicing is a regulated process in mRNA maturation which uses different 
exons of the same gene to generate different functional proteins. It is reported that 95% of 
multi-exonic genes are alternatively spliced in humans [83]. Meanwhile, gene fusions are 
commonly detected in cancer patients due to chromosomal changes. Frameshift 
mutations within these two processes can create neo-antigens. Since the alternative 
splicing and chromosomal mutations are so frequent, it is likely that frameshift neo-
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antigens from mis-splicing are common as well with the high mutation rate of RNA 
spliceosome. However, these potential FS peptides from mis-splicing have not been 
systematically investigated or used in cancer vaccine development. In this chapter, I built 
the database for all potential FS peptides from mis-splicing in exon junctions and provide 
potential applications for using this database. 
One report in 2012 analyzed frequent frameshift mutations from mis-splicing events in 
human tumor EST libraries. 2,996 FS peptides from mis splicing within the same gene 
were found and 96 FS peptides were specific or highly enriched in tumor libraries. While 
321 FS peptides from mis-splicing in gene fusions were found [81]. However, with the 
limited number of tumor libraries and sequencing data, only a very small percentage of 
all possible FS mutations were detected. 
All possible FS peptides from human exon junctions were analyzed in this chapter and 
the basic characteristics are summarized. A large human breast cancer immunosignature 
dataset including different stages of breast cancer was used to predict putative FS 
antigens indirectly according to different patterns. An unbiased anti-FS screening 
platform is under development.  The human 400K peptide array was designed to cover all 
possible microsatellite frameshift peptides and mis-splicing FS peptides.  
6.3 Results 
6.3.1 Characteristics of the human exon junction FS database 
Frameshift peptides from microsatellite regions are not the sole source of potential 
frameshift antigens. To investigate unbiasedly potential frameshift antigens in human 
genes, all possible splicing frameshift peptides from alternate splicing within genes or 
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between genes (gene-fusions) need to be covered. To predict the frameshift peptide 
sequences from the second and third reading frames of every human exon, a total number 
of 41,930 mRNA sequences representing 19,270 genes were downloaded from NCBI 
RefSeq database [52] and coordinates of 421,337 exons were recorded. Then the second 
and third reading frames of each exon were translated into FS peptide sequences and 
stored in a human exon junction FS database. As shown in Figure 6-1, the ID of each 
frameshift candidate includes the mRNA accession number, exon number of this gene 
and its corresponding frame. 
Summary statistics of the database are shown in Table 6-1.  There are total 842,672 
output frameshift sequences with a minimum length of 0 and maximum length of 1082 
amino acids. The median FS length is 12 and the average length is 17 amino acids, and 
there are about 15 million FS amino acids in total.  
The distribution of the frameshift peptides length is summarized in Figure 6-2.  The 
number of frameshift candidates decreases exponentially as FS peptide length increases. 
The curve of actual FS length distribution is close to a random distribution (calculated by 
frequency of stop codons). The Pearson correlation between the two curves is 0.99. These 
data indicate frameshift peptide length is not under selection and they follow a random 
distribution. 
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Figure 6-1. The procedure for building the Human Exon Junction Frameshift 
Database. 
Table 6-1. Summary statistics of human exon junction FS database. 
Mean 17.66 
Standard Error 0.02 
Median 12.00 
Mode 0.00 
Standard Deviation 20.47 
Sample Variance 418.86 
Kurtosis 74.21 
Skewness 4.80 
Range 1082.00 
Minimum 0.00 
Maximum 1082.00 
Sum 14880663.00 
Count 842672.00 
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A 
 
B 
 
Figure 6-2. Random distribution of frameshift peptide length. A-B. Actual frameshift 
peptide counts of different frameshift peptide lengths (FS Length 0-80 was shown in A 
and above 80 was shown in B) and corresponding random frequency with different FS 
peptide length. Both distribution curves were similar to the random distribution and FS 
antigens with long FS length had higher similarity to the random distribution.  
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The characteristics of microsatellite frameshift peptides are summarized in previous 
chapters.  Here it is also interesting to find out whether the amino acid composition of the 
splicing frameshift peptides from exon junctions is like the microsatellite frameshift 
peptides. These two databases are both generated from human coding genes but with 
totally different selection criteria.  The MS FS database covers all MS regions in coding 
genes regardless of the microsatellite locations, while the exon junction FS database 
covers all frameshift peptides from the start location of every exon and it is 30 times 
bigger than the MS database.  
Detailed amino acid composition data is summarized in table 6-2 and a two-way 
clustering heatmap is shown in Figure 6-3.   The exon junction FS database has almost 
identical amino acid composition as the MS FS database with a correlation of 0.98. These 
two databases both have high correlation with the random frequency of 0.88 ~ 0.9, which 
indicates that the amino acid composition of frameshift peptides is not under high 
selection pressure. Alanine, Glycine, Proline, Cysteine, Histidine, Serine and Tryptophan 
are enriched in frameshift sequences.   It is unknown why some of these amino acids 
have higher percentage in frameshift sequences than the random frequency. 
 
 
 
Table 6-2. Amino acid composition of the human exon junction FS database and its 
comparison to random frequency, WT sequences and the human microsatellite FS 
database. 
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AA Random 
Frequency 
Human 
WT 
Human MS FS 
Database 
Exon Junction FS 
Database 
Ala A 6.25% 6.36% 6.53% 7.83% 
Arg R 9.38% 5.27% 8.91% 8.88% 
Asn N 3.13% 3.98% 2.72% 2.03% 
Asp D 3.13% 5.04% 2.08% 2.22% 
Cys C 3.13% 1.94% 4.04% 4.29% 
Glu E 3.13% 7.88% 3.68% 3.59% 
Gln Q 3.13% 5.00% 5.13% 4.82% 
Gly G 6.25% 5.85% 7.25% 8.30% 
His H 3.13% 2.54% 3.57% 3.71% 
Ile I 4.69% 4.60% 3.52% 2.80% 
Leu L 9.38% 9.55% 9.53% 9.49% 
Lys K 3.13% 6.81% 5.04% 3.53% 
Met M 1.56% 2.09% 1.95% 1.79% 
Phe F 3.13% 3.43% 3.18% 2.61% 
Pro P 6.25% 6.20% 8.06% 9.37% 
Ser S 9.38% 8.88% 10.01% 9.98% 
Thr T 6.25% 5.42% 5.85% 5.73% 
Trp W 1.56% 1.03% 3.04% 3.31% 
Tyr Y 3.13% 2.46% 1.83% 1.40% 
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A 
 
B 
 
Random 
Frequency 
Human 
WT 
Human MS FS 
Database 
Exon Junction FS 
Database 
Random 
Frequency 
1.00 
   
Human WT 0.71 1.00 
  
Human MS FS 
Database 
0.90 0.72 1.00 
 
Exon Junction 
FS Database 
0.88 0.66 0.98 1.00 
 
Val V 6.25% 5.67% 4.08% 4.31% 
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Figure 6-3. Compare amino acid composition of the human exon junction database 
to different databases A. Two-way clustering of the amino acid composition of the 
human exon junction database, human WT proteome, human MS FS database and 
random frequency. B. Correlation matrix of amino acid composition.  
 
6.3.2 Exon Frameshift peptide sequences in WT human proteome 
Frameshift peptide sequences of one gene can have partial identity to the wildtype protein 
sequence another gene-encoded protein, presumably by chance. Frameshift peptide 
sequences with identity to sequences of WT proteins are not ideal neo-antigens and need 
to be removed. 
To compare the frameshift peptides with WT sequences, human RefSeq protein 
sequences were used as WT sequences and compared to human exon junction frameshift 
peptides. BLAST (Basic Local Alignment Search Tool) was used to search for sequence 
matches. Output frameshift peptide matches with a minimum of 15 identical amino acids 
and minimum 98% similarity to WT protein sequences were classified into a group of 
frameshift peptides which contain WT peptide sequences.  
There is a total of 2,033 frameshift candidates with WT matches with these criteria, 
which represents less than 1% of the whole FS exon junction database. Since these 
matches indicate that WT protein sequences include partial matches of frameshift 
sequences, it is interesting to know whether these matches are enriched in a specific 
group of genes with certain motifs. Gene ontology enrichment analysis was used to 
analyze these 1,399 unique genes from the 2,033 FS genes with WT matches [84]. 
Results of both biological process and molecular function gene ontology analysis 
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indicated that these 1,399 unique genes were not highly enriched in one specific 
biological process or molecular function.  The most enriched biological process was 
protein complex subunit organization with 1.54-fold enrichment and only 134 FS 
containing genes, and the most enriched molecular function was identical protein binding 
with 1.5-fold enrichment and only 147 FS containing genes.  
Table 6-3 Biological process gene ontology analysis of FS genes with WT matches 
GO biological process FS genes 
with WT 
matches 
Expected 
gene 
number 
Fold 
Enrichment 
P-
value 
protein complex subunit 
organization (GO:0071822) 
134 86.93 1.54 6.22E-
03 
response to stress 
(GO:0006950) 
285 221.15 1.29 3.06E-
02 
metabolic process 
(GO:0008152) 
750 660.53 1.14 8.32E-
03 
biological_process 
(GO:0008150) 
1243 1156.2 1.08 5.57E-
07 
cellular process (GO:0009987) 1071 997.19 1.07 4.34E-
02 
 
Table 6-4 Molecular function gene ontology analysis of FS genes with WT matches 
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GO molecular function FS genes 
with WT 
matches 
Expected 
Number 
Fold 
Enrichme
nt 
P-
valu
e 
identical protein binding 
(GO:0042802) 
147 98.25 1.5 3.28
E-03 
catalytic activity (GO:0003824) 473 401.01 1.18 4.90
E-02 
protein binding (GO:0005515) 872 744.33 1.17 1.08
E-08 
binding (GO:0005488) 1068 974.54 1.1 4.99
E-05 
molecular_function (GO:0003674) 1239 1156.26 1.07 1.59
E-06 
 
Besides gene ontology analysis, it is also important to understand how these frameshift 
peptide sequence of one transcript can be transformed into wildtype protein sequence of 
another transcript. Within these 2,033 WT matches of FS candidates, 1,682 of these WT 
matches (83%) and corresponding frameshift peptide sequences were from different 
protein variants of the same gene. One example of this category was shown in Figure 6-4. 
Zinc finger protein 1 had 8 different isoforms. Frameshift peptide sequence of exon 4 in 
isoform 7 existed in wildtype protein sequences of isoform 1. It turned out that during 
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alternate splicing, exon 4 of isoform 1 was spliced into the third reading frame of isoform 
7, which changed the frameshift peptide sequence of isoform 7 into the wildtype 
sequences of isoform 1. Most the first category WT peptide matches were produced by 
the same mechanisms. While the rest of the 351 WT matches and corresponding FS 
peptides are from different genes with unknown mechanisms.  
 
Figure 6-4. ZFP1 as an example of WT matches of frameshift peptide sequences. 
Blue color represents untranslated regions (5’UTR and 3’UTR), green and red color 
represents translated sequences, red color of isoform 1 in exon 4 is in the 3rd reading 
frame of isoform 7. 
 
6.3.3 Frameshift Motifs in the120K Immunosignature Arrays 
Immunosignature is a peptide microarray-based technology which measures the activity 
of the humoral immune system [85, 86]. There are many versions of immunosignature 
peptide arrays and the current version is the CIM120K peptide array.  This peptide array 
includes ~120,000 12-mer random peptides and it is specifically designed to have high 
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coverage of random 5-mer peptide space for antibody recognition. Several studies 
indicated that the immunosignature technology could be used for cancer diagnosis in 
multiple cancer types [82], Alzheimer’s disease diagnosis [87] and valley fever diagnosis 
[88] etc.  
Besides the diagnosis potential of the immunosignature array, it is also interesting to 
‘decipher’ the peptide sequences of disease associated antigens from the antibody binding 
activities to random peptide sequences. One of our assumptions behind the idea of using 
frameshift antigens for a prophylactic cancer vaccine is that frameshift transcripts from 
microsatellite regions or mis-splicing events are more abundant in cancer patients due to 
generally higher expression levels of all the transcripts and potential dysfunctional 
quality control systems (i.e. NMD, proteasome associated degradation) in cancer cells. 
Therefore, humoral immune activities of cancer patients can potentially be driven by 
antibody responses against frameshift antigens and frameshift antigen peptide sequences 
(motifs) may be in part responsible for the cancer immunosignature. If true, it would 
imply that specific FS motifs can be found in the immunosignature of cancer patients.  
To map the frameshift peptide sequences to random peptide sequences of 
immunosignature arrays, the total 122,926 random 12-mer array peptides were Blasted 
against the human microsatellite FS database and exon junction FS database. FS-random 
peptide matches were recorded if they shared at least 5 identical amino acids. The e-value 
cutoff was set as 50 for this comparison.   
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Figure 6-5. Procedure of mapping FS motifs in CIM120K immunosignature peptide 
array. A. Mapping diagram, Blastp-short procedure was used for comparison. B. 
Examples of mapping output of array peptides mapped to frameshift antigen sequences.  
Out of these 122,926 12-mer CIM120K peptides, 102,916 random peptides (84%) have at 
least 1 FS match with the procedure in Fig6-5. There are total 267,448 FS matches from 
these random peptides, which indicates each array peptide has about 2.6 FS matches on 
average. Only 5.1% of these FS matches are from human MS FS database and the rest 
94.9% FS matches are from human exon junction database.  The ratio is about the same 
as the ratio between database sizes. The distribution of FS matches per array peptide is 
shown in Figure 6-6. 30% of the array peptides only have one FS match and 87.7% of 
these peptides have 1-4 FS matches, two array peptides have as many as 19 FS matches. 
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Most FS motifs (87%) appear only once in these array peptides and the number of FS 
motifs drops exponentially as the repeats number increase, some FS motifs have over 200 
repeats and they are summarized in Figure 6-6.   
With these FS motifs of array peptides available, it is possible to find the potential FS 
antigens behind the antibody-random peptide reactivity. The next step is to test human 
cancer patient serum samples on the CIM120K array and find any cancer specific array 
peptides and then decipher the antibody signals to the original FS antigens.  
A  
 
B                                                                                     C 
 
FS Motif # of repeats
SGALSG 591
LGVLSG 443
LSGVAL 434
LSGALS 292
ASGVAL 283
ALGVAL 267
LSVALG 265
LSGASG 205
LGALSG 204
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Figure 6-6. Distribution of FS matches of CIM120K array peptides and FS motifs. 
A. Distribution of FS matches per array peptide. B. Distribution of FS motif repeats. C. 
List of FS motifs which have over 200 repeats in Blast outputs.  
 
6.3.4 Anti-Frameshift Motif immune response in Breast Cancer Patients 
To characterize humoral immune activities of breast cancer patients, a cohort of 949 
samples were tested on CIM120K peptide arrays by the Peptide Array Core in CIM. 
These samples included 100 DCIS (ductal carcinoma in situ) samples from Abcodia, 399 
breast cancer Stage I samples from Abcodia and Duke University, 100 benign samples 
from Duke University and 350 healthy control samples from various source (Duke, 
Abcodia and ASU).  Benign breast tumors (lumps) are very common among women and 
it is a non-cancerous condition. In this chapter both benign and healthy control samples 
are treated as control group. DCIS is usually considered as the earliest stage of breast 
cancer and it is non-invasive [89].  
It is known that the host immune system can respond to a tumor and both adaptive and 
innate immune responses to tumor are detected [10]. The theory of immunoediting is 
proposed based on studies in mouse models.  It includes three phases of host-tumor 
interactions: host immune response kills highly immunogenic tumor cells in the 
elimination phase; if not, the tumor then becomes dormant and poorly immunogenic 
tumor cells replace highly immunogenic cells in equilibrium phase; finally, the tumor 
will overcome the host immune system by creating an immunosuppression 
microenvironment and consistently removing immunogenic tumor cells in the escape 
phase [90]. However, these studies only uncover the relation between cell mediated 
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immune responses and the tumor. The interaction between the humoral immune system 
and the tumor has not been investigated. And it is also not known which clinical stages 
are corresponding to these three phases. Therefore, it is interesting to know how the 
antibody profiles of cancer patients change during cancer progression and if the 
frameshift antigens are involved in the antibody response. 
Three stages of breast cancer were included in our dataset: Benign and healthy control; 
DCIS (Stage 0); Stage I. Antibody profiles against random peptides change over each 
stage.  How these antibody signals change in each stage and the potential frameshift 
antigens behind these signals are crucial for both tumor immunology and cancer vaccine 
antigen selection. Here my analysis was focused on three patterns of antibody response 
during the three stages.  Each pattern might uncover a unique process of tumor-host 
immune reaction:  
1. Antibody response increased in each stage: peptide signal went higher from healthy 
control to DCIS by 1.5-fold and from DCIS to Stage I by another 1.5-fold;  
2. Antibody response increased from healthy control to DCIS, and then decreased 
from DCIS to Stage I;  
3. Antibody response decreased from healthy control to DCIS and Stage I. 
 
Pattern 1: The first pattern was that antibody response against some array peptides 
increased during each stage, which indicated that the antibody response against a portion 
of antigens was boosted during each stage and it was not suppressed by the 
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immunoediting process. The average of normalized fluorescence intensity of all samples 
in each stage was calculated, and array peptides with an intensity which increased 1.5-
fold from healthy control to DCIS and another 1.5-fold from DCIS to Stage I were 
selected. A total 537 array peptides were selected with this pattern (Figure 6-7). 
Unsupervised hierarchical clustering results showed that almost all healthy and benign 
samples had low reactivity to these peptides, while the majority of Stage I samples and 
1/3 of the DCIS samples had high reactivity. Another 2/3 of the DCIS samples had low 
reactivity to these peptides. These results indicated that antibody response against these 
537 peptides was boosted in a portion of DCIS patients (30%) but it was further boosted 
in most of Stage I patients (80%).  20% of the Stage I patients did not have an antibody 
response against these peptides, which meant that 20% of the population might not 
present the antigens behind these 537 peptides and they would not benefit from the 
vaccine formulated by the FS antigens predicted with these 537 peptides. 
Even though the FS antigens behind these 537 peptides might not cover the whole 
population, it would be interesting to know which FS antigens could be related to these 
537 peptides. A portion of the related FS antigens with best E-value (high homology 
between array peptides and FS antigens) were summarized in Table 6-5.  
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Figure 6-7. The first pattern of antibody profile changes in breast cancer stages: 
antibody response increased 1.5-fold from healthy control to DCIS and 1.5-fold 
from DCIS to Stage I. A. The average of peptide signal in each stage was plotted against 
each stage. B. Hierarchical clustering with 537 selected peptides. 
 
Table 6-5 Best FS antigens from Pattern 1 by E-value 
 
 
Pattern 2: The second pattern referred to an antibody response which increased from 
healthy control to DCIS, but then decreased from DCIS to Stage I. This pattern might 
indicate that the antigens which induced this antibody response were selected against in 
Stage I and tumor cells presenting these antigens were removed by the immunoediting 
process. If this assumption is true, the potential FS antigens behind these array peptides 
are highly immunogenic and perfect vaccine antigens for early or prophylactic cancer 
vaccine development. Peptides which had 1.5-fold higher signal in DCIS group than 
healthy control group and Stage I group were selected for analysis. A total number of 
13,979 peptides passed the criteria and the peptide number increased 26-fold compared to 
pattern 1 which only had 537 peptides (Figure 6-8), which indicated a lot more antigens 
Array Peptide Array Motif FS Antigen Gene FS Motif E-Value
KEWNEQRWVLLS WNEQRW NM_003041.3_Exon14_3rd SLC5A2 WNEQRW 0.027
QSREREALFVAL REREALF NM_001098787.1_Exon4_3rd BET1L REREALF 0.15
DYEQWHVALGAL EQWHVAL NM_001300815.1_Exon7_3rd CIRBP EEWHVAL 0.25
SNDKRPVLVALG RPVLVALG NM_004386.2_Exon8_3rd NCAN RPVLVPLG 0.43
DGFQEYAQYVLG GFQEYAQYVL NM_001286721.1_Exon5_2nd ANKRD10 GFQECAQFLL 0.66
WVAKQEFKVLLG QEFK--VLLG NM_001042583.2_Exon6_3rd CD1E QEFKTSVLLG 0.72
DKEPPVLVALSG PVLVALSG NM_001282471.1_Exon3_3rd PRORY PVLIALSG 0.75
SEWPQRYHVLVL EWPQR-YH NM_133264.4_Exon6_3rd WIPF2 EWPQRFYH 0.82
DKVWLHVLGVAS WLHVLGVAS NM_001276254.2_Exon5_2nd IFNL4 WLHTLGLAS 0.94
DPSSRNHDVLVL RNHDVLVL NM_001290047.1_Exon17_2nd CECR2 RNHQVLVL 1
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might have gone through immunoediting from DCIS to Stage I. The result was consistent 
with other immunosignature studies with multiple cancer stages (unpublished data) – the 
humoral immune system was mostly suppressed in the early stages of breast cancer. The 
hierarchical clustering result showed that all DCIS samples had medium to high reactivity 
to these 13,979 peptides, a small portion of Stage I samples were mixed with DCIS 
samples and had high reactivity, while most of Stage I samples were suppressed and only 
had medium reactivity to these peptides. Healthy control samples and benign samples had 
much lower reactivity to these peptides than the other two groups. A group of Stage I 
samples had very low reactivity within Stage I samples (Figure 6-8B) and they were 
separated from other samples.  80% of these low reactivity samples were from Abcodia 
and the cause might be related with sample qualities or other unknown reasons. 
A 
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Figure 6-8. The second pattern of antibody profile changes in breast cancer stages: 
antibody response increased 1.5-fold from healthy control to DCIS and then 
decreased 1.5-fold from DCIS to Stage I. A. The average of peptide signal in each stage 
was plotted against each stage. B. Hierarchical clustering with 13,979 selected peptides. 
 
Potential FS antigens from the second pattern might be good vaccine antigens as 
mentioned previously.  Since the number of peptides was increased 26-fold compared to 
pattern 1, more corresponding frameshift antigens with conserved sequences could be 
found. Table 6-6 summarized a small portion of the potential FS antigens sorted with best 
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e-values.  The top FS antigens could have 8 to 9 exact amino acids matches to 12-mer 
array peptides. 
 
 
Table 6-6 Best FS antigens from Pattern 2 by E-value 
 
 
Array Peptide Array Motif FS Antigen FS Motif Gene E-value
LQSRYFNKASAL LQSRYFNKASAL NM_001282704.1_Exon10_2nd LQSRYFRKASLL PDIA6 0.007
YNQNRVLWALAG NQNRVLWAL NM_001135729.1_Exon6_2nd NQDRILWAL TOM1 0.018
GDGHLALSVALG GHLALSVALG NM_001303427.1_Exon1_2nd GHLGLSVALG LOC110117498-PIK3R3 0.019
VHDSVWDSGVLS SVWDSGVL NM_001852.3_Exon32_2nd SVWDSGVL COL9A2 0.021
QWKGRSYDVFSV QWKGRSYD CCDS6315.1|Hs104|chr8 QWKGRRYD CSMD3 0.026
PVWLVSFPNHDA VWLVSFP NM_001136.4_Exon3_2nd VWLVSFP AGER 0.035
KVSRREPWAYDS VS---RREPWAYDS NM_001080976.1_Exon2_3rd VSLHHRREPRSYDS DSE 0.04
NAAYDAFYWLSL DAFYWLS NM_003049.3_Exon3_3rd DAFYWLS SLC10A1 0.042
EEYVYENASVSG VYENASVSG NM_000712.3_Exon7_3rd VYENDSVSG BLVRA 0.05
SKQHFWALVLSG HFWALVL NM_001320373.1_Exon17_2nd HFWALVL VWA5B2 0.052
KAHKHSALSVLS HSALSVLS NM_001146032.1_Exon25_2nd HSALSVLS FCHO2 0.061
PASFNLFLQENL PA----SFNLFLQ NM_001197216.2_Exon8_2nd PARSHLSFNLFLQ ASGR1 0.062
RHFAFVGKASLG FVGKASLG NM_020817.1_Exon10_3rd FVGKASLG CCDC191 0.062
LWQKKSGVALSG WQKKSGVALSG NM_207361.5_Exon24_3rd WQKKCGVPFSG FREM2 0.068
ALNHPNQFASGS HPNQFASG NM_018190.3_Exon7_2nd HPNQYASG BBS7 0.083
KNAPFRALSALS NAPFRALSAL NM_001127715.2_Exon1_3rd NAPVRALSAL STXBP5 0.091
AVGFLEASGALG VGFLEASG NM_001206615.1_Exon3_2nd VGFLEASG EHF 0.092
NQHHYDALVLSG HHYDALVL NM_015496.4_Exon23_2nd HHYDPLVL VIRMA 0.093
NVLNWVFRNASG NVLNWVF NM_018656.2_Exon5_2nd NVLNWVF SLC35E3 0.095
SRQRWLNSVLSG SRQR---WLNSVL NM_015033.2_Exon17_3rd SRQRPPPWLGSVL FNBP1 0.098
LWRNYALSVLSG LWRNYALSVLSG NM_001167917.1_Exon4_2nd LWRSY-LCVLSG VEPH1 0.1
NRHVLLFPAVLG LLFPAVLG NM_001001670.2_Exon4_2nd LLFPAVLG SPATA31D1 0.1
ANSVDALSVALG SVDALSVAL NM_017509.3_Exon2_2nd SVDALTVAL KLK15 0.11
SRHRVFRAGVSG SRHRVFRAGVS NM_001145415.1_Exon15_2nd SRHRT-RAGVS SETDB1 0.12
QEPDVHLPWLFS QEPDVHLP NM_001142646.2_Exon9_2nd EEPDVHLP TPRA1 0.12
GKVWLKDSGVLG WLKDSGVLG NM_001280547.1_Exon5_3rd WLRDAGVLG PAX5 0.12
QFLLWLSREKGV FLLWLSREKG NM_181501.1_Exon17_3rd FFLWNSREKG ITGA1 0.12
AKFRLWAGVALG RLWAGVAL NM_001271765.1_Exon7_2nd RLWAGIAL SLC16A5 0.13
FPAQVFVPWDLS QVFVPWDL NM_001161580.1_Exon10_3rd QGFVPWDL POC1A 0.13
AKQKQYDASVAS KQKQYDASV NM_005422.2_Exon9_3rd KQKQYDSGV TECTA 0.13
PEARNGEYHAVL EARNGEY NM_017794.4_Exon22_3rd EARNGEY FOCAD 0.13
FAEQPYFWASVL EQPYFW NM_014289.3_Exon8_3rd EQPYFW CAPN6 0.14
KDLLGRAENASL LLGRAENA NM_015323.4_Exon14_2nd LLGRAENA UFL1 0.14
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Pattern 3: the third pattern was the dominant pattern and it referred to certain antibody 
responses which decreased dramatically with tumor initiation (decreased from healthy 
control to DCIS and Stage I). There were many potential causes for this phenomenon and 
two which I had thought of: 1. The immune system was suppressed at very early stages of 
tumor development (before DCIS) and this dominant pattern was due to non-specific 
immunosuppression; 2. Healthy people which had immune responses against these 
specific antigens would not develop a tumor because this specific immune response had 
strong anti-tumor effects. If it was caused by non-specific immunosuppression, then the 
array peptides from this pattern would not help with cancer vaccine development; 3. This 
pattern could be caused by the maturation process of anti-FS antibodies, the early forms 
of these antibodies could have low specificity but later they matured into highly specific 
antibodies targeting other FS peptides shown in pattern 1 or pattern 2. However, if it was 
caused by strong anti-tumor effect in healthy people, then the potential FS antigens from 
these peptides might be good source for a prophylactic cancer vaccine.  
Since a large portion of the whole 120K peptides were suppressed from healthy people to 
cancer patients, stricter selection criteria were applied in the analysis. Peptides with 
signals which had dropped 3-fold from healthy control to DCIS and Stage I were selected 
for further analysis. A total number of 20,322 peptides passed the criteria, the signals for 
these peptides dropped significantly from benign and control samples to DCIS, and then 
increased slightly from DCIS to Stage I which still had much lower signals than the 
control group (Figure 6-9). Potential FS antigens behind these peptides were listed in 
Table 6-6 which were sorted by e-values. 
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Frameshift antigens from the three patterns shared between each other due to repeat 
motifs in different array peptides. A Venn diagram in Figure 6-10 showed that more than 
60% of predicted FS antigens in pattern 1 were shared in pattern 2 or 3, which was 
mainly caused by certain repetitive FS motifs in many array peptides as shown in Figure 
6-6. 
A 
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Figure 6-9. The third pattern of antibody profile changes in breast cancer stages: 
antibody response decreased 3-fold from healthy control to DCIS and Stage I. A. 
The average of peptide signal in each stage was plotted against each stage. B. 
Hierarchical clustering with 20,322 selected peptides. 
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Table 6-6 Best FS antigens from Pattern 3 by E-value 
 
Array Peptide Array Motif FS Antigen FS Motif Gene E-value
LWQESESGVALS LWQESESGVAL NM_001321984.1_Exon17_3rd LWQQSEKGVAL ENTPD5 0.002
DAPSELHLSGSG PSELHLSGS NM_182584.2_Exon5_3rd PSELHLSGS C20orf203 0.014
WLRAEHALEHSV WLRAEHALEHS NM_001261442.1_Exon4_2nd WHRAEHALQRS EXTL2 0.028
AQYDPAPNHVAL AQYDPA-PNHVAL NM_001286643.1_Exon9_3rd AQYDPAKPNYISL MTERF3 0.031
WNYRHAPYKGVL WNYRHAP NM_001320458.1_Exon5_2nd WDYRHAP WNT9B 0.038
RSLQKWHLGVSG RSL-QKWHLGV CCDS6160.1|Hs104|chr8 RNLKQKWHLGI RP1 0.044
NSGLEARKHLSS LEARKHLSS NM_001105069.1_Exon5_2nd LEARKHLPS ACSM2B 0.048
YFPGHQPHDSAL GHQPHDSA NM_001317924.1_Exon30_3rd GHQPHDSA WDR19 0.051
FEWRDVLHGQKD EWRDVLHGQK NM_001160002.1_Exon5_3rd EWRGVLHGER NRG1 0.052
EQQGEKGVALSG QQGEKGVAL NM_001321984.1_Exon17_3rd QQSEKGVAL ENTPD5 0.06
RDAYRPLWHLVA RPLWHLV NM_001036.4_Exon36_2nd RPLWHLV RYR3 0.065
RYANFRHSNDLG NFRHSND NM_001004477.1_Exon1_3rd NFRHSND OR10X1 0.066
FGAARPVALGLS GAARPVALGL NM_001321831.1_Exon12_3rd GAARPVLLGL NFKBID 0.074
EFWNGFRKEDGS FWNGFR NM_001281765.2_Exon5_2nd FWNGFR EPHA5 0.09
FSLGFYGQNKHV FSLGFYG NM_031925.2_Exon12_3rd FSLGFYG TMEM120A 0.092
NLENGDALSRNA GDALSRNA NM_000350.2_Exon3_3rd GDALSRNA ABCA4 0.098
EDAPSKRWNSGS KRWNSGS NM_022470.3_Exon6_2nd KRWNSGS ZMAT3 0.1
DGFFPSQRDSAS FPSQRDS NM_005422.2_Exon13_3rd FPSQRDS TECTA 0.1
DKHQEHVRVASS DKHQEHVRVASS NM_012392.3_Exon2_2nd DKHQEPLRVATT PEF1 0.11
YRPSVEPYNDSG YRPSVEPYNDSG NM_023935.2_Exon2_2nd YRPSVEP---SG DDRGK1 0.11
LSPGEYAGFPHD LSPGEYAGF NM_024927.4_Exon1_2nd LSPGDYGGF PLEKHH3 0.11
YFHQRWKSNVSG YFHQRW NM_001277269.1_Exon25_3rd YFHQRW OTOG 0.11
FWFRYGESQEKV FRY-GESQEKV NM_001089.2_Exon33_3rd FRYSGESQGKV ABCA3 0.11
KAPHKVSEKSGS KAPHKVSEKSGS NM_001199692.1_Exon7_2nd KVPHRVAEKGGS SLC4A2 0.11
WGRVNLQLSGAS WGRVNLQLSG NM_001164473.2_Exon17_3rd WGRV-LELSG FNBP1L 0.12
161 
 
 
Figure 6-10. Venn Diagram of Predicted FS antigens from Pattern 1, 2 and 3. 
 
6.3.5 Human 400K Frameshift Peptide Array 
The method of finding FS motifs from immunosignature data was promising in predicting 
potential FS antigens potentially eliciting the antibody response. However, this method 
used only partial information (5-9 mer motifs) of the 12-mer random peptides in 
predicting the FS antigens and this prediction might not be accurate.   Further validation 
experiments need to be conducted to prove the anti-FS response. To measure direct anti-
FS humoral immune response in cancer patients, an unbiased frameshift peptide array 
which covers all possible microsatellite and exon junction FS peptides is needed.   
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It is possible to synthesize millions of peptides with in situ photolithographic synthesis 
technology. The 12-plex format slide has the capacity of including 392,000 15-mer 
peptides per array, which is sufficient to cover the whole human MS and exon junction 
FS peptides.  
The design of the human 400K frameshift peptide array includes all 14,588 human MS 
FS peptides, and all human exon junction frameshift peptides with peptide length ranges 
from 7-100aa. FS candidates with 100 amino acids or more are excluded from the array 
because they may be functional proteins.  
The design of human 400K frameshift peptide is completed and this array is currently 
under synthesis and analysis 
 
6.4 Discussion  
In this chapter, I created the human exon junction frameshift database which included all 
possible frameshift peptides from every human exon. The analysis of FS peptide length 
and amino acid composition indicated that exon junction FS peptides were not under high 
selection pressure and they were close to random distribution. A group of FS peptides 
had identical sequences in wildtype protein variants of the same gene which was caused 
by alternate splicing of the last exon. In addition, I established a method of searching for 
potential FS antigens from immunosignature arrays.  An immunosignature data set with 
different stages of breast cancer samples was used to find potential FS antigens against 
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three different patterns. Furthermore, a human 400K FS peptide array which covers all 
possible FS peptides from MS and exon junctions is under development. 
Frameshift antigens were rare in cancer patients at the genomic level, but recently we 
found microsatellite frameshift mutations and mis-splicing frameshift mutations from 
EST tumor libraries were very common in the mRNA of tumor tissues and tumor cell 
lines. It was difficult to detect frameshift peptides in tumor tissues by mass spectrometry, 
but the human humoral immune system could amplify signals of frameshift antigens if 
these FS antigens were expressed and presented.   Then we could detect antibodies 
against these FS antigens. The development of the human 400K FS peptide array was 
based on this idea and with this platform we can screen anti-FS immune responses across 
cancer patients unbiasedly.  Highly immunogenic FS antigens which have not yet been 
discovered might be revealed in this platform. 
The Immunosignature technology maximizes the capability of recognizing all kinds of 
antibodies by increasing the 5-mer diversity and this platform contains a huge number of 
motifs. It could successfully separate different kinds of cancer types and the tumor 
specific immune response might be caused by tumor specific FS neo-antigens. It was 
possible to transform the random peptide array data to anti-FS data since there were a 
large number of FS motifs in these random peptides. However, this method only used a 
portion of the 12-mer peptide sequences for the comparison.  The antibody might not 
recognize the FS motif per se when it is bound to the corresponding 12-mer peptide. So, 
there were a considerable number of false positives in the analysis and further validation 
experiments are needed.   
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In summary, the human exon junction FS peptides are potential source for cancer vaccine 
development and this human 400K FS array can be a great platform for cancer diagnosis, 
vaccine discovery  
6.5 Methods 
6.5.1 Human Exon Junction Frameshift Database 
Human mRNA sequences and exon coordinates were downloaded from NCBI Refseq 
Database [52]. mRNA sequences of each exon were calculated by exon coordinates, then 
the second frame and third frame of these mRNA sequences were translated into 
frameshift peptides.  
6.5.2 Database Characteristics Analysis 
Frameshift peptide length and amino acid compositions of the database were calculated 
by the FS peptides. Reference amino acid composition was calculated by WT human 
RefSeq proteome. Unsupervised two-way hierarchical clustering was conducted with 
JMP Pro 13 (Cary, NC).   
6.5.3 Human Breast Cancer Immunosignature Dataset 
A total of 949 samples with healthy control, benign breast tumor, DCIS and Stage I 
breast samples were collected from Duke, Abcodia and ASU.  Samples were tested on the 
CIM120K array and standard immunosignature assay protocols were used [82]. Data was 
normalized to the median of each array.   
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6.4.4 Find FS motifs in CIM120K Array and Breast Cancer IMS data analysis 
120K 12-mer random array peptides were compared to the FS database via BLAST [55]. 
The E-value cutoff was set as 50 and FS matches with 5 amino acids exact match or more 
were included. Samples in the breast cancer dataset were separated into three groups: 
healthy control/benign; DCIS; Stage I. JMP Pro 13 was used for two-way clustering.  
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CHAPTER 7 
Early Treatment of Breast Cancer with Checkpoint Inhibitors in the neuN 
Transgenic Mouse Model 
 
7.1 Abstract 
Immune checkpoint blockade was approved initially for treating late stage cancer patients 
when other treatments failed. Adverse events were common in these treatments and only 
a proportion of patients would benefit. Here we proposed the idea of early immune 
checkpoint inhibitor (ICI) treatment at early cancer diagnosis by immunosignatures. We 
tested this idea in the mouse FVB/N neuN transgenic mammary tumor model.  Results 
demonstrated that very early ICI treatments delayed tumor initiation significantly. 
Furthermore, timing was shown to be an important factor in ICI treatment as early 
treatment (8 weeks after the earliest detection time point) gave the best protection in this 
model. Additionally, immunosignatures were used to separate responders from non-
responders in the ICI treatments.  Remarkably, non-treatment mice presenting a 
responder signature also had delayed tumor initiation which indicates a pre-determined 
anti-tumor immune status could predict the tumor progression. With these results, a 
model for early immunotherapy was summarized to predict best ICI treatment timepoint.     
 
7.2 Introduction 
Immune checkpoint blockade (ICB) has gained great success in treating late stage cancer 
patients in multiple cancer types [91-93]. At least 6 monoclonal antibodies targeting 
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PD1/PDL-1/CTLA-4 have been approved by the FDA. However, large doses of immune 
checkpoint inhibitors cause a broad spectrum of toxicities in many patients and 
autoimmune diseases in a portion of patients.   Persistent immune related AEs and deaths 
have also been reported [94-96]. In the meantime, ICB treatment was not effective in all 
late stage patients. A durable objective response to immune checkpoint blockade ranges 
from 20% to 50% in different cancer types [93, 97-103]. To improve the current 
situation, we proposed the idea of treating cancer patients much earlier with less immune 
checkpoint inhibitors.  Less ICI could be used with less tumor burden at much earlier 
stages.  This approach could be more effective because immunosuppression was not so 
overwhelming in early cancer patients as in late stage patients.  This approach was only 
feasible with the Immunosignature technology which could diagnose cancer much earlier 
than current diagnostics.  The NeuN transgenic mouse breast cancer model was used to 
test this idea in this chapter. 
Immunosignature technology uses random peptide arrays to profile the humoral immune 
system of individuals. Details of this technology were reviewed in Chapter 6. 
Immunosignatures were also used for early cancer diagnosis in the FVB/N neuN 
transgenic mouse model.  The technology could diagnose early tumorigenesis as far as 12 
weeks before the first palpable tumor [104]. 
In the meantime, since only a proportion of patients respond to ICI treatment and the 
treatment cost is very high it would be beneficial to have a biomarker that could 
distinguish who would respond. Biomarkers to predict responders vs. non-responders are 
important for reducing the cost and improving the efficiency. There are three available 
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biomarkers: PDL1 expression in tumor tissues; tumor mutational load and CD8+ T cells 
tumor infiltration [105, 106]. These three biomarkers are functionally related to each 
other, and they cannot separate responders perfectly from non-responders. For example, 
the response rate was 48% in PDL1+ patients and 15% in PDL1- patients [107].  The 
difference is significant but not sufficient to be used as a biomarker in the clinic. The 
immunosignature platform may have advantages for biomarker discovery with 120,000 
peptide features that unbiasedly bind antibodies.   We are testing this platform in 
predicting responders vs. non-responders in this the FVB/N neuN mouse model.  
In this chapter, I compared three different treatment timepoints with the combination 
treatment of anti-PDL1 and anti-CTLA4 mAbs: very early treatment (16 weeks); early 
treatment (24-26 weeks); late treatment (first palpable tumor). Furthermore, 
immunosignatures were used for predicting responders vs. non-responders to ICI with 
serum samples prior to the treatment.    
 
7.3 Results 
7.3.1 FVB/N neuN Transgenic Mouse Breast Cancer Model and Breast Cancer 
Early detection 
The FVB/N neuN transgenic mouse model was established in 1992 by William Muller.  
The ERBB2 (also known as HER2) gene was overexpressed under the mouse mammary 
tumor virus promotor (MMTV) [108, 109]. Overexpression of HER2 gene induces 
mammary tumors and metastasis after a long latency. The tumor free curve within a 
group of 28 transgenic mice is shown in Figure 7-1.  The median age for the first palpable 
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tumor in this mouse model was 31.7 weeks, with 90% of these mice having the first 
palpable tumor before 40 weeks.  
 
Figure 7-1. Tumor free curve and median age for first palpable tumor in the FVB/N 
neuN transgenic mouse model. 
 
Though the first palpable tumor was detected at 31.7 weeks, the humoral immune system 
of these transgenic mice might have changed way before the palpable tumor was evident. 
Immunosignature arrays (CIM 10K version 2) were used previously for early detection of 
breast tumors in this model.  This report showed that transgenic mice could not be 
separated from the wildtype mice at 12 weeks, but these transgenic mice had significantly 
different immunosignatures compared to wildtype mice at 16 weeks, which indicated that 
the earliest detectable time point was between 12 to 16 weeks [104]. This time point was 
15 weeks on average before the first palpable tumor.  
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7.3.2 Very early ICI treatment delayed the first palpable tumor while early 
treatment boosted the tumor protection  
The earliest time point for cancer detection was at 16 weeks. To compare early treatment 
versus the current strategy (treatment at late stage for cancer patients), four groups of 
mice were included in the experiment: a very early treatment group in which mice were 
treated at the earliest detection time point (16 weeks); an early treatment group at 24 to 
26 weeks which allowed the early tumor to grow for several weeks; a late treatment 
group which were treated after the 1st palpable tumor and a non-treatment group with no 
treatments. The initial treatment date was different between groups but the treatment 
schedule was the same as shown in Figure 7-2.  
 
 
Figure 7-2. Three different ICI treatment regimens in the FVB/N neuN mouse 
model, 7 doses of ICI treatments were injected via IP. Each dose of ICI treatment 
included 100 µg anti-CTLA4 mAb and 200 µg anti-PDL1 mAb.   
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Tumor development was monitored weekly and tumor initiation age was recorded for 
each mouse. Treatment at the Very Early stage delayed the tumor initiation significantly 
compared to non-treatment group (p-value=0.032). The median age for first palpable 
tumor in the Very Early treatment group was 38 weeks compared to 32 weeks in non-
treatment group.  Treatment at the Early stage, to my surprise, further boosted the 
protection compared to Very Early treatment (p-value=0.029).  The median age for the 
first palpable tumor was 41 weeks and 4 mice were tumor-free till now. The median age 
will be at least 41 weeks over time. These data indicate that the Early treatment regimen 
provided the best protection in delaying tumor initiation, even more than Very Early 
treatment.    
A 
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Figure 7-3. Tumor initiation was significantly delayed by Very Early treatment and 
Early. Tumor free curve for Very Early treatment group (16 mice), Early treatment group 
(15 mice) and non-treatment group (28 mice). 
 
Tumor volumes for each mouse were recorded weekly after the first palpable tumor was 
detected. The summary of the tumor volume data is shown in Figure 7-4.  Tumor growth 
was not suppressed by any of these three regimens once it started. ICI treatment after the 
1st palpable tumor did not suppress the tumor growth compared to the non-treatment 
group.  This is consistent with other reports in which therapeutic ICI treatments did not 
protect mice from tumor challenge alone [110]. Average tumor volume decreased at 
some time points since the number of mice was reduced in these points because some 
mice were euthanized when the tumor volume reached the 2,000 mm3. The Very Early 
treatment and the Early treatment groups had slightly slower tumor growth but there was 
no significant difference.  These data support the idea that ICI is more effective at early 
stage with less tumor cells and less suppressive tumor microenvironment. Surprisingly, 
treatment at the Early stage was more effective than the Very Early stage.   
 
Group Comparison P-value Significance
Very Early Treatment vs. Early Treatment 0.029 *
Very Early Treatment vs. Non-treatment 0.0164 **
Early Treatment vs. Non-treatment 0.0001 ****
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Figure 7-4. Tumor growth curves between the 4 groups were not significant 
different. Tumor volumes were recorded weekly after the first palpable tumor was 
detected. 
7.3.3 Immunosignature technology can separate responders vs. non-responders 
prior to the treatment 
In the Very Early treatment group, 6 mice (37.5%, responder) developed the first 
palpable tumor after 41.5 weeks, while the tumor initiation age for another 7 mice (44%, 
non-responder) was less than 33.5 weeks which was close to the non-treatment group 
(Figure 7-5A). Similar percentages of responders and non-responders were seen in human 
ICI clinical trials.  PDL1 expression level and mutational load are currently being 
investigated as biomarkers to separate responders from non-responders. Here the 
immunosignature technology was used to attempt to classify the responders and non-
responders. 
Serum samples were collected before the treatment at week 16 and tested with the 
CIM120K immunosignature array. 2,700 peptides were selected by comparing the two 
groups with a student’s t-test (p-value <0.01).  Unsupervised two-way hierarchical 
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clustering separated the responders and non-responders with 100% accuracy (Figure 7-
5B). PCA analysis also separated these two groups with 100% accuracy. It was 
interesting that the antibody response against most of these 2,700 peptides was lower in 
responders than non-responders, while 30% of these peptides had much higher signals in 
responders. 
Besides using the immunosignature platform, the human frameshift peptide array which 
included 300 predicted frameshift antigens (reviewed in chapter 3) was also used for 
diagnosing responders with serum samples prior to the treatment. A similar approach was 
applied as with the immunosignatures and 33 peptides were selected by t-test (p-value 
<0.05). Responders and non-responders were separated with 100% accuracy (Figure 7-6). 
These data confirmed that it is possible to use immunosignatures or even frameshift 
peptide array to separate responders vs. non-responders before the treatment.   
A 
 
B 
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Figure 7-5. Immunosignatures can separate responders from non-responders in the 
ICI Very Early treatment group.  A. Tumor initiation ages for each mouse. B. Early 
tumor samples: non-responders; late tumor: responders. 2,700 peptides were selected by 
T-test. C. PCA analysis for these 13 mice, green dots were non-responders and red dots 
were responders.  
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Figure 7-6. The Human Frameshift Peptide Array can separate responders from 
non-responders in ICI early treatment group.  
Each column represented one frameshift peptide from the human frameshift peptide 
array, each row represented one mouse sample from responder group (late tumor) and 
non-responder group (early tumor). 
 
7.3.4 Transgenic mice with the responder immunosignature develop tumor later 
even without ICI treatment 
Whether patients would benefit from ICI treatment has been related to the conditions of 
patients before the treatment.  Three major predictors were tumor PDL1 expression, 
mutational load and the proportion of active CD8+ infiltrating lymphocytes. In summary, 
a pre-existing active immune response against tumor would boost the efficacy of ICI 
treatment. Under this hypothesis, patients with pre-existing active immune response 
against the tumor would be predicted to have better survival even without ICI treatment. 
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To test this idea, mice from non-treatment group were separated into a late tumor 
initiation group and an early tumor initiation group, and the responder immunosignature 
from the ICI treatment (the same 2,700 peptides as in Figure 7-5) was used to classify 
later tumor initiation events and early tumor initiation events. 
A total of 11 mice (Figure 7-7A) were included in the test. 6 mice developed the tumor 
very early (before 27.6 weeks) and 5 mice had late tumor initiation (after 39.6 weeks). 
Serum samples were also collected at week 16 and the CIM120K arrays were used.  
These 2,700 peptides were selected with student’s t-test by comparing responder vs. non-
responders in ICI Very Early treatment group. 10 mice were correctly predicted (91% 
accuracy), and there was only 1 mouse (NT3-3, marked with black arrow) in the late 
tumor initiation group was misclassified into the early tumor initiation group. The 
immunosignature pattern of these non-treatment mice was close to the responder vs. non-
responder mice in early ICI treatment group with weaker differences.  
One mouse was misclassified using the responder immunosignature. To investigate 
whether the misclassification was due to the responder immunosignature or not, late 
tumor events and early tumor events in non-treatment group were compared directly. 
1,509 peptides were selected with t-test (p-value<0.05). The same mouse (NT3-3) was 
still misclassified using these 1,509 peptides (Figure 7-8), which indicates that the 
responder immunosignature had the same classification power in separating early tumor 
events and late tumor events.  
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Since the responder immunosignature could predict which mice would grow tumor later 
without treatment, it was interesting to know whether the prediction could work in the 
reverse direction (use the late tumor immunosignature against the non-treatment group to 
predict which mice would be responders to ICI treatment). These same 1,509 peptides 
were used for classifying responders vs. non-responders in Very Early treatment group. 
These peptides could not separate responders from non-responders and samples were 
mixed together. A major difference between these 1,509 peptides (late tumor signature) 
and the previous 2,700 peptides (responder signature) was that most of these 1,509 
peptides had higher signals in late tumor samples which was the opposite in the responder 
signature.     
The responder signature (33 peptides in Figure 7-6) from the frameshift peptide array was 
tested with the same method. However, these 33 peptides could not separate early tumor 
events from late tumor events in the non-treatment group.  Early tumor samples were 
totally mixed with late tumor samples and there was not a clear signature (Figure 7-9).  
These results demonstrated that mice which could potentially benefit from ICI treatment 
(with responder immunosignature) would develop tumor later than mice with non-
responder immunosignature without any treatments. In other words, this data indicates 
that the hypothesis that mice with pre-existing active immune response against the tumor 
would develop tumor later with or without ICI treatments, and the immunosignature 
technology could be used for identifying this responder signature. The frameshift peptide 
array, using much fewer features, failed in predicting responders. 
179 
 
A 
 
B 
 
Figure 7-7. Responder immunosignature from ICI treatment could separate late 
tumor initiation mice from early tumor initiation mice without ICI treatment. A. 
List of 11 mice in non-treatment group. B. Unsupervised two-way hierarchical clustering 
of 11 mice in A, black arrow indicated one misclassified sample.  
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Figure 7-8. Using 1,509 peptides selected by comparing early tumor events and late 
tumor events for classification (p-value <0.05). A. same mice (NT3-3) was 
misclassified with these 1,509 peptides. B. These 1,509 peptides couldn’t separate 
responders vs. non-responders in early treatment group. 
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Figure 7-9. Responder signature from human frameshift peptide array could not 
separate early tumor events from late tumor events in the non-treatment group.  
Each column represented one frameshift peptide from the human frameshift peptide 
array, each row represented one mouse sample from late tumor events and early tumor 
events in the non-treatment group. 
 
7.3.5 A model for early immunotherapy cancer treatment  
Based on the results from these experiments, I propose a model to explain the response to 
checkpoint inhibitors treatment in cancer patients (Figure 7-10). It is known that three 
important factors are important in determining the treatment time: tumor burden, number 
of tumor neo-antigens and immunosuppression. When tumor burden is too high and there 
are billions of tumor cells, lymphocytes can be outnumbered and it is difficult for ICI 
treatment to be effective. Meanwhile, the number of tumor neoantigens grows as the 
tumor burden increases and more tumor neoantigens are related to a strong anti-tumor 
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immune response with ICI treatment. Immunosuppression is the third factor which 
increases as the tumor grows and this makes ICI treatment less effective.  Here we use 
the capacity of the immune system as the measure in the y-axis of the figure, which is the 
opposite of immunosuppression. Time A (week 16) represents the Very Early treatment 
in our previous mouse experiment.   There is no immunosuppression at Time A, but there 
are too few tumor neo-antigens with few tumor cells and ICI treatments are relatively 
ineffective with not enough neoantigens. Time B (week 24-26) represents the Early 
treatment, which is the perfect timepoint for ICI treatment with enough tumor 
neoantigens and low immunosuppression at the same time. Time C (treat at palpable 
tumor) does not work at all with high tumor burden and high immunosuppression, the 
immune system cannot deal with too many tumor cells with the high level of 
immunosuppression at the same time.  Although the number of the tumor neoantigens is 
large they are not effectively seen by the immune system due to suppression. 
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Figure 7-10. A simple Model for early ICI treatment in cancer patients.   
Tumor burden and tumor neoantigens increase exponentially as tumor grows, while the 
capacity of immune system does not change in the earliest time of tumor initiation, but 
then drops exponentially as tumor grows and immunosuppression increases. Time A 
represents the Very Early treatment (week 16) in our mouse model. There is no 
immunosuppression but not enough tumor neoantigens, which makes the treatment 
relatively ineffective. Time B is the best treatment time (week 24-26) with relatively low 
immunosuppression, low tumor burden and relatively high tumor neoantigens. Time C 
has the advantages of more tumor neoantigens, but with high tumor burden and high 
immunosuppression, the treatment could not work. 
 
7.4 Discussion 
In this study, we compared the idea of ‘early cancer detection, early ICI treatment’ and 
conventional therapeutic ICI treatment in the FVB/N neuN transgenic mouse model. 
Conventional therapeutic ICI treatment did not suppress the tumor growth at all in this 
model, while Very Early treatment and Early treatment delayed the first palpable tumor 
from 31.7 weeks to 38 weeks and 41 weeks correspondingly. Furthermore, the 
immunosignature technology was successfully used to separate responders from non-
responders and the responder immunosignature could predict late tumor initiation events 
even without ICI treatment. 
Therapeutic ICI treatment did not suppress tumor growth in this FVB/N neuN mouse 
model, which is consistent with some reports using ICI treatments [143]. Tumor cells 
from this mouse model had much lower PDL1 expression compared to other models 
[110], which made therapeutic ICI treatment less effective in this model. However, Very 
Early and Early ICI treatment could delay the tumor initiation significantly, which could 
be related to less tumor cells and less immune suppression in the early stages. More 
interestingly, Early treatment had significantly better protection than Very Early 
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treatment. ICI activates the immune system by turning off the brakes, but cancer cells 
have to present enough neo-antigens for the immune system to produce CD8+ killing T 
cells. Higher number of mutations and immunogenic neo-antigens correlated to better 
response for ICI treatment [18].  Probably 16 weeks was too early for the ICI treatment in 
this mouse model even though the immunosignature could distinguish the difference 
compared to WT mice. These results indicate that timing may be crucial for effective ICI 
treatment. 
Mutational load and PDL1 expression are commonly used for predicting responders in 
ICI treatment.  Immunosignatures have the advantage of being a simple and fast test. 
However, immunosignatures assess the humoral immune system which is usually 
considered not important and has received less attention in cancer research. Our results 
show that immunosignature arrays can predict responders for ICI treatment accurately 
prior to the treatment in this mouse model, and this responder immunosignature could 
further predict which mice would have late tumor initiation without ICI treatment. The 
immune system is important in battling against cancer. Even for mice with the same 
breeding, different mice had different immune responses against the tumor initiation and 
mice with responder the immunosignature had more active anti-tumor immune responses. 
These mice developed tumor late naturally without treatment and could also be boosted 
by ICI treatment.  
We noticed that the responder immunosignature could predict late tumor initation events 
in the non-treatment group, but the late tumor immunosignature could not predict 
responders in ICI treatment group. The responder immunosignature was mostly anti-
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tumor immune response because the anti-tumor response was boosted by ICI treatment. 
While the late tumor immunosignature in the non-treatment group was not only 
composed of anti-tumor immune response, but also included other unknown components 
which might related to late tumor initiation. Since the anti-tumor immune response was 
the key for predicting responders or late tumor events, it is easy to understand why the 
reverse direction wouldn’t work. 
There were only 800 frameshift peptides (of 200,000 possible for mis-splicing and mis-
transcription through MSs) in the human FS array.  This platform could separate 
responders vs. non-responders from the ICI treatment but could not be used for predicting 
late tumor initiation events. This is presumably primarily due to the fewer number of 
features (800 vs 120,000) compared to the immunosignature arrays. 
In summary, our results demonstrated that the idea of early diagnosis and early treatment 
was feasible with the immunosignature technology, and this approach delayed tumor 
initiation significantly in the FVB/N neuN model while conventional therapeutic ICI 
treatment did not suppress tumor growth at all. Immunosignature technology could also 
be used as biomarker to predict responders vs. non-responders in ICI treatments. Other 
early treatments include chemotherapy and vaccination are possible with this technology 
and remain to be investigated. 
7.5 Methods 
7.5.1 Mice and sera collection 
        Transgenic FVB/N neuN mice were kindly gifted by Dr. Chella David at Mayo, 
Rochester. Blood samples were collected from week 16 and every 4 weeks after that. 
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Serum was separated with serum separating Microcontainer (BD Biosciences, CA) and 
stored in -20C.   
7.5.2 Binding serum samples to CIM120K peptide array and human frameshift 
peptide array 
       Serum samples were collected at week 16 prior to treatment and tested on the 
CIM120K peptide array and human frameshift peptide array. CIM120K array was 
reviewed in Chapter 6 and the protocol for running samples on the CIM120K array was 
summarized in the Chapter 5 Methods.  
      The human frameshift peptide array included 800 FS peptides from human coding 
genes (predicted microsatellite FS peptides and mis-splicing FS peptides from tumor EST 
libraries). These 800 peptides were printed on the NSB9 surface. The protocol for 
running samples on the human FS arrays was identical to the immunosignature assay. 
      Fluorescence intensities were normalized to median per array and analyzed with JMP 
Pro 13. 
7.5.3 Immune checkpoint inhibitor treatments 
     Mice in treatment groups were treated with 7 doses of ICI as shown in Figure 7-2. 
Each dose of ICI treatment included 200 µg anti-PDL1 mAb (10F.9G2) from BioXcell 
and 100 µg anti-CTLA4 mAb (UC10-4F10-11) from BioXcell as well. ICI treatment was 
administered via IP.  
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CHAPTER 8 
CONCLUSION 
 
           Tumor FS neo-antigens at the mRNA level are abundant resources for cancer 
diagnosis and both preventive and therapeutic cancer vaccine development. However, 
this area is fairly neglected by the scientific world. In this thesis, I demonstrated the 
feasibility of using FS neo-antigens for cancer vaccine development. Moreover, I pushed 
the idea of “early detection early treatment” forward with the Immunosignature 
technology as a diagnostic and immune checkpoint blockade as treatment.   
           I first built the microsatellite frameshift database for human, dog and mouse. 
Besides being as resources for vaccine development, these microsatellites and frameshift 
peptides from these regions showed interesting patterns and positive/negative selection 
pressures were seen in different subgroups. Very long FS peptides were enriched in the 
microsatellite regions and they had very unique amino acid composition and codon usage 
patterns which were not similar to the short FS or the WT proteome. The functions of 
these very long FS peptides were still unknown. Clearly MS FS candidates are better 
tumor antigens with high immunogenicity, high abundance and low chance to cause 
autoimmune diseases compared to antigens from genomic point mutations. The presence 
of microsatellite frameshift mutations was detected in both tumor cDNA samples and cell 
lines. Surprisingly, the mutation rate was very high in an 11A homopolymer region and 
mutation rates correlated with repeat length. A pool of 9 MS candidates showed 
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protection in mouse breast tumor model and they were simply selected based on 
informatics (repeat length, peptide length and MHC prediction).  
            Next, I designed the human and dog frameshift peptide array with 800 FS 
peptides representing 300 FS antigens from ~200K possible FS antigens. We screened 
hundreds of dog tumor samples on our FS array and selected positive and negative FS 
peptides in the cancer group from the array. It turned out positive FS peptides could offer 
protection in both mouse breast tumor and melanoma models while negative FS peptides 
could not. This phenomenon was further validated by another independent experiment 
with a similar approach from our group (unpublished data). These results showed that 
frameshift peptide arrays could be a good platform for FS antigen selection. It was 
puzzling that this group of negative FS peptides had 0 positive sample in the cancer 
group while there were positive samples in the normal control group, I had a preliminary 
explanation in the discussion but it could not explain this phenomenon very well and 
further investigation is needed. 
            The first version of dog cancer vaccine was developed with dog frameshift array 
and safety trial was conducted to evaluate the vaccine. The results demonstrated that this 
FS antigens based vaccine was safe with no adverse effect and it could induce strong B/T 
cell immune responses. 
            Meanwhile, I built the human exon junction FS database and the dog version 
database to cover all possible mis-splicing FS antigens. I provided a method to extract 
anti-FS immune from large immunosignature datasets. The results showed three 
interesting patterns of antibody response in different stages of breast cancer which might 
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provide insights in cancer development and vaccine design. Besides, our group designed 
the human/dog 400K frameshift peptide arrays which included all possible microsatellite 
FS antigens and mis-splicing antigens. It is currently under production. 
            And last, I tested the idea of “early cancer detection, early treatment” in mouse 
transgenic breast cancer model with current immune checkpoint blockade treatments. 
Immunosignature technology could detect cancer at very early stage in this mouse model. 
Results showed that the timing of immune checkpoint inhibitor treatment was crucial to 
maximize the treatment benefits. Treating at Early stage but not Very Early provided the 
best outcome which might indicate a minimum number of tumor antigens was required 
for ICIs to be effective. In the same time, treating at late stage (palpable tumor) did not 
offer any protection in this mouse model which meant that early treatment was necessary.  
           Based our hypothesis, frameshift neo-antigens are generated due to the abnormal 
transcriptional system and dysfunctional quality control system. The future of my 
research includes three areas: 1) explore the possibility of using human/dog 400K FS 
array for cancer diagnostics, antigen selection; 2) explore the anti-FS immune response in 
other chronic/acute diseases and the potential of using FS based vaccines to treat other 
diseases including aging; 3) explore the idea of “early detection early treatment” with 
new cancer treatments and combinational cancer treatments. 
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APPENDIX A 
GENOMIC MUTATIONS FROM MICROSATELLITE REGIONS 
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Table A.1 Top 5 frequent Genomic Mutations for 40 cancer driver genes with 
Microsatellite regions 
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Mutation information for these 40 cancer driver genes was acquired from the COSMIC 
database [111].   Mutation frequency, mutation type and detailed mutation are 
summarized for the top 5 most frequent mutations of each gene. It was interesting that 
frameshift mutations were the most frequent mutation type in these 40 genes and both 
insertions and deletions were found in most of these. Mutation frequency represents the 
frequency of this specific mutation in all the patients who carried any kinds of mutations 
in this gene. 
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Table A.2 Distribution of mutation types in genomic mutations of cancer driver 
genes  
 
Genomic mutations for all human cancer driver genes (total 591) were downloaded from 
COSMIC. Overall distribution of mutation types was summarized in the table, missense 
point mutations were the most dominant mutation type with 67% of all genomic 
mutations, while frameshift INDELs only accounted for 6% of all mutations. 
 
 
 
 
 
 
 
 
 
 
Mutation Type Total Mutations % of this Mutation Type
Substitution - Missense 352619 67.26%
Unknown 41887 7.99%
Substitution - coding silent 35475 6.77%
Substitution - Nonsense 22433 4.28%
Deletion - Frameshift 18026 3.44%
Deletion - In frame 17050 3.25%
Insertion - In frame 16021 3.06%
Insertion - Frameshift 13036 2.49%
Whole gene deletion 2303 0.44%
Complex - deletion inframe 2257 0.43%
Frameshift 1604 0.31%
Complex - frameshift 772 0.15%
Complex - insertion inframe 429 0.08%
Complex - compound substitution 165 0.03%
Complex 102 0.02%
Nonstop extension 98 0.02%
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APPENDIX B 
THE NEXT VERSION OF DOG CANCER VACCINE 
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Introduction 
The first dog cancer vaccine was described in Chapter 5 and the selection criteria did not 
include gene type information. It is known that if a gene is a cancer driver gene, the gene 
is more frequently mutated in cancer patients. And if a gene has high expression level in 
the earliest tumor initiation stage, it is going to make more errors at the transcription and 
RNA splicing level and thus more frameshift antigens. In addition, a frameshift antigen 
will be more difficult for cancer cells to get rid of if it is from an essential gene.  
Therefore, in the second version of dog cancer vaccine, I added three more criteria: 
cancer driver genes, essential genes and highly expressed genes.  
A list of cancer driver genes was adapted from the COSMIC (catalogue of somatic 
mutations in cancer) cancer consensus genes [112]. The list of essential genes was 
acquired from 5 studies of human essential genes and genes were included if they were 
found in 3 studies or more. The list of highly expressed genes was acquired from the 
RNA-Seq Atlas [113].  Gene expression from all the normal tissues was averaged and 
standard deviations were calculated. The gene expression values of normal tissues were 
used since cancer initiates from normal tissues and the earliest form of tumor should have 
similar expression values as normal tissues. 
Three tables were summarized for the second version dog cancer vaccine.  Table B.1 
summarizes microsatellite candidates from genes that meet all three criteria: cancer driver 
gene, essential gene and highly expressed gene. Table B.2 summarizes the list of 
microsatellite candidates which have long MS regions and meet any one criteria of the 
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three. Table B.3 summarizes the list of MS candidates which have high antibody 
responses in 116 dog cancer samples from 9 types of dog cancers as discussed in Chapter 
5. 
The second version of dog cancer vaccine included 21 candidates with microsatellite 
candidates from these three tables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
209 
 
Table B.1 List of Microsatellite Candidates from genes which meets all three 
criteria: cancer driver genes, essential genes and high expression genes 
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Table B.2 List of MS candidates with long microsatellite regions and meets one 
criteria 
Expression Average
Expression Standard deviation
m
RN
A Position
10.47
3.92
4.78%
19.11
8.34
62.67%
12.43
2.94
88.13%
19.11
8.34
88.89%
19.11
8.34
32.57%
19.11
8.34
88.89%
9.62
2.61
27.66%
41.29
12.53
57.55%
9.47
4.03
34.63%
12.43
2.94
3.72%
12.43
2.94
3.72%
10.47
3.92
0.13%
7.30
3.03
6.57%
7.30
3.03
15.46%
7.90
3.55
17.96%
22.60
14.74
7.46%
7.87
4.01
36.62%
19.11
8.34
51.54%
19.11
8.34
41.18%
9.62
2.61
27.66%
12.48
9.62
17.79%
9.06
3.24
84.64%
17.34
6.76
56.87%
17.34
6.76
12.10%
7.62
3.07
68.14%
7.62
3.07
68.43%
8.66
2.65
3.72%
13.80
6.10
90.14%
9.47
4.03
64.07%
9.47
4.03
9.82%
12.43
2.94
3.72%
12.43
2.94
3.72%
10.47
3.92
0.13%
10.47
3.92
34.88%
7.30
3.03
6.57%
24.01
6.94
36.58%
5.53
2.24
77.42%
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G
EN
E N
AM
E
PRO
TEIN
 N
AM
E
M
S Type
M
S Length
IN
S/DEL
FS LEN
G
TH
Essential
Driver
High Exp
M
O
RF4L1
 m
ortality factor 4-like protein 1
TTTTTTTTTTTTTTTTTTTTTTTTT
25
Del
21
Y
M
ED13
 m
ediator of RN
A polym
erase II transcription subunit 13
TTTTTTTTTTTTTTTT
16
Ins
31
Y
G
O
SR2
 G
olgi SN
AP receptor com
plex m
em
ber 2 isoform
 X3
CCCCCCCCCCCCCCCC
16
Del
23
Y
PLD1
 phospholipase D1
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
15
Del
36
Y
PLD1
 phospholipase D1
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
15
Ins
77
Y
IRF4
 interferon regulatory factor 4
CCCCCCCCCCCCCCC
15
Ins
46
Y
IRF4
 interferon regulatory factor 4
CCCCCCCCCCCCCCC
15
Del
64
Y
IN
TS3
 integrator com
plex subunit 3
CCCCCCCCCCCCCC
14
Del
56
Y
Y
PW
W
P2A
 PW
W
P dom
ain-containing protein 2A
G
G
G
G
G
G
G
G
G
G
G
G
G
G
14
Ins
21
Y
N
SM
CE4A
 non-structural m
aintenance of chrom
osom
es elem
ent 4 hom
olog A
CCCCCCCCCCCCCC
14
Del
48
Y
U
BR1
 E3 ubiquitin-protein ligase U
BR1 isoform
 X4
AAAAAAAAAAAAA
13
Ins
30
Y
RBP1
 retinol-binding protein 1
CCCCCCCCCCCCC
13
Del
44
Y
RBM
10
 RN
A-binding protein 10
CCCCCCCCCCCCC
13
Ins
38
Y
Y
RBM
10
 RN
A-binding protein 10
CCCCCCCCCCCCC
13
Del
58
Y
Y
N
SM
CE4A
 non-structural m
aintenance of chrom
osom
es elem
ent 4 hom
olog A
TTTTTTTTTTTTT
13
Ins
19
Y
XRN
1
 5'-3' exoribonuclease 1 isoform
 X5
AAAAAAAAAAAA
12
Ins
17
Y
Y
XRN
1
 5'-3' exoribonuclease 1 isoform
 X6
AAAAAAAAAAAA
12
Ins
19
Y
Y
EIF4G
2
 eukaryotic translation initiation factor 4 gam
m
a 2
G
G
G
G
G
G
G
G
G
G
G
G
12
Del
169
Y
Y
SBN
O
1
 protein straw
berry notch hom
olog 1 isoform
 X3
AAAAAAAAAAA
11
Ins
23
Y
Y
SO
S1
 son of sevenless hom
olog 1
G
G
G
G
G
G
G
G
G
G
G
11
Del
42
Y
Y
SEC62
 translocation protein SEC62
AAAAAAAAAAA
11
Del
58
Y
Y
ZCCHC6
 term
inal uridylyltransferase 7 isoform
 X4
AAAAAAAAAAA
11
Ins
24
Y
M
ARCKS
 m
yristoylated alanine-rich C-kinase substrate
AAAAAAAAAAA
11
Ins
88
Y
M
TA3
 m
etastasis-associated protein M
TA3
CCCCCCCCCCC
11
Del
83
Y
TSPYL1
 testis-specific Y-encoded-like protein 1
CCCCCCCCCCC
11
Del
98
Y
ARID2
 AT-rich interactive dom
ain-containing protein 2 isoform
 X1
CCCCCCCCCCC
11
Del
37
Y
E2F3
 transcription factor E2F3 isoform
 X2
AAAAAAAAAAA
11
Del
18
Y
DTYM
K
 thym
idylate kinase
G
G
G
G
G
G
G
G
G
G
G
11
Ins
78
Y
DTYM
K
 thym
idylate kinase
G
G
G
G
G
G
G
G
G
G
G
11
Del
81
Y
DDX24
 ATP-dependent RN
A helicase DDX24
AAAAAAAAAA
10
Ins
20
Y
Y
DDX24
 ATP-dependent RN
A helicase DDX24
AAAAAAAAAA
10
Del
29
Y
Y
M
BN
L1
 m
uscleblind-like protein 1 isoform
 X9
TTTTTTTTTT
10
Ins
41
Y
Y
ACTB
 actin, cytoplasm
ic 1 isoform
 X1
CCCCCCCCCC
10
Del
36
Y
Y
AN
KRD12
 ankyrin repeat dom
ain-containing protein 12 isoform
 X3
AAAAAAAAAA
10
Del
24
Y
ECHDC1
 ethylm
alonyl-CoA decarboxylase isoform
 X2
AAAAAAAAAA
10
Del
23
Y
SLC35F5
 solute carrier fam
ily 35 m
em
ber F5 isoform
 X2
TTTTTTTTTT
10
Del
22
Y
SLC35F5
 solute carrier fam
ily 35 m
em
ber F5 isoform
 X2
TTTTTTTTTT
10
Ins
23
Y
HK1
 hexokinase-1 isoform
 X3
AAAAAAAAAA
10
Del
21
Y
HK1
 hexokinase-1 isoform
 X3
AAAAAAAAAA
10
Ins
33
Y
TCF7L2
 transcription factor 7-like 2
CCCCCCCCCC
10
Del
17
Y
TTF1
 transcription term
ination factor 1 isoform
 X2
AAAAAAAAAA
10
Ins
18
Y
EIF2B3
 translation initiation factor eIF-2B subunit gam
m
a isoform
 X2
AAAAAAAAAA
10
Del
57
Y
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G
ene Expression Average
Standard deviation
m
RN
A Position
40.43
14.79
31.49%
5.71
1.68
2.41%
4.21%
5.48
4.49
83.26%
5.48
4.49
83.26%
19.95%
19.95%
7.42
2.60
17.00%
24.94%
3.85%
5.59
2.00
4.12%
17.12
31.18
10.91%
24.31%
24.31%
17.00%
5.19
2.12
97.63%
5.19
2.12
97.63%
50.26
13.51
0.48%
7.19
5.23
56.52%
5.46
2.39
2.31%
12.08
5.61
34.92%
8.48
4.33
3.37%
6.48
4.24
44.91%
5.62
3.76
9.26%
9.36
6.77
19.47%
0.94%
12.54%
53.66%
53.66%
25.49
13.26
18.41%
25.49
13.26
18.41%
14.17
7.88
14.58%
83.43
45.89
67.49%
10.45
4.75
35.93%
11.70
6.77
12.25%
6.66
3.83
46.73%
6.66
3.83
46.73%
12.25
10.25
15.18%
12.25
10.25
15.18%
77.39%
8.22%
33.18%
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Table B.3 List of MS candidates with high antibody response in dog cancer samples 
and meets one criteria 
 
 
 
 
 
 
Positive Rate Positive Rate
Normal Cancer Overall
Candidate Gene Driver Essential High Exp 52 116
345803468_ins RAB12 Y 9.62% 24.14%
345790242_del PDS5B Y 13.46% 23.28%
345801690_del SETD1A Y 7.69% 23.28%
50979053_ins TCOF1 Y 13.46% 22.41%
94962361_del TCOF1 Y 11.54% 22.41%
359319099_del SPEN Y Y Y 11.54% 21.55%
345796542_del SEC62 Y Y 9.62% 19.83%
345796190_ins CCDC80 Y 11.54% 19.83%
50979053_del TCOF1 Y 11.54% 19.83%
359320226_del HGS Y 3.85% 18.97%
345777441_del RUFY1 Y 11.54% 18.10%
345794707_del PRDM2 Y 5.77% 17.24%
73957532_del TCOF1 Y 11.54% 17.24%
345797019_del SP3 Y 7.69% 16.38%
345790842_ins DTYMK Y 9.62% 16.38%
359320226_ins HGS Y 9.62% 15.52%
73977514_ins TCOF1 Y 1.92% 15.52%
345798736_ins RHOBTB3 Y 7.69% 14.66%
345797019_ins SP3 Y 5.77% 14.66%
345787800_del SWAP70 Y 3.85% 14.66%
CDC7_9a_de CDC7 Y 9.62% 14.66%
359320691_del HNRNPH1 Y Y 7.69% 13.79%
TGFβR II TGFBR2 Y Y 15.38% 13.79%
345803468_del RAB12 Y 11.54% 13.79%
345803795_del SERPINA3 Y 9.62% 13.79%
345781087_ins TMPO Y 7.69% 13.79%
73992592_del TCOF1 Y 3.85% 13.79%
345798777_ins RHOBTB3 Y 1.92% 12.93%
345804985_del NSRP1 Y 3.85% 12.93%
16605494_del TCOF1 Y 5.77% 12.93%
73996466_del TCOF1 Y 3.85% 12.93%
345796984_del IRF4 Y 3.85% 12.93%
345803795_ins SERPINA3 Y 5.77% 12.07%
345794468_ins MFN2 Y 9.62% 12.07%
345796987_del PRPF4B Y Y 11.54% 11.21%
345787800_ins SWAP70 Y 7.69% 11.21%
345797136_ins ZAK Y 5.77% 11.21%
345794365_del ZCCHC17 Y 7.69% 11.21%
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APPENDIX C 
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) APPROVAL 
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